var title_f35_26_36256="Biologic debridement with larvae";
var content_f35_26_36256=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1086px;\">",
"  <div class=\"videoplayer\" h264=\"./images/SURG/70202/Bio_debridment_larvae_movie.mp4?title=Biologic+debridement+with+larvae\" style=\"width:496px;height:384px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Biologic debridement with larvae",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 325px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. David G Armstrong/SALSA. For more information, visit www.toeandflow.com.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_26_36256=[""].join("\n");
var outline_f35_26_36256=null;
var title_f35_26_36257="Resisted thumb adduction";
var content_f35_26_36257=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F65820&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F65820&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Resisted thumb adduction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 273px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_26_36257=[""].join("\n");
var outline_f35_26_36257=null;
var title_f35_26_36258="Inflammatory acne";
var content_f35_26_36258=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F70809&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F70809&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Inflammatory acne",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erythematous papules and pustules are present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_26_36258=[""].join("\n");
var outline_f35_26_36258=null;
var title_f35_26_36259="Diabetes mellitus type 1: Overview";
var content_f35_26_36259=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Diabetes mellitus type 1: Overview (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?35/26/36259/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/26/36259/contributors\" id=\"au5149\">",
"       David K McCulloch, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?35/26/36259/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/26/36259/contributors\" id=\"se6384\">",
"       David M Nathan, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?35/26/36259/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/26/36259/contributors\" id=\"de1470\">",
"       Jean E Mulder, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"mobipreview.htm?35/26/36259?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      TYPE 1 DIABETES OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Type 1 diabetes mellitus is a chronic medical condition that occurs when the pancreas, an organ in the abdomen, produces very little or no insulin (",
"     <a class=\"graphic graphic_figure graphicRef53979 \" href=\"mobipreview.htm?12/2/12325\">",
"      figure 1",
"     </a>",
"     ). Insulin is a hormone that helps the body to absorb and use glucose and other nutrients from food, store fat, and build up protein. Without insulin, blood glucose (sugar) levels become higher than normal.",
"    </p>",
"    <p>",
"     Type 1 diabetes requires regular blood sugar monitoring and treatment with insulin. Treatment, lifestyle adjustments, and self-care can control blood sugar levels and minimize the risk of disease-related complications.",
"    </p>",
"    <p>",
"     Type 1 diabetes usually begins in childhood or young adulthood, but can develop at any age. In the United States, Canada, and Europe, type 1 diabetes accounts for 5 to 10 percent of all cases of diabetes.",
"    </p>",
"    <p>",
"     Other topics that discuss type 1 diabetes are available.",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       (See",
"       <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/31/35317?source=see_link\">",
"        \"Patient information: Diabetes mellitus type 1: Insulin treatment (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       (See",
"       <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/43/39603?source=see_link\">",
"        \"Patient information: Self-blood glucose monitoring in diabetes mellitus (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       (See",
"       <a class=\"medical medical_patient\" href=\"mobipreview.htm?3/20/3397?source=see_link\">",
"        \"Patient information: Type 1 diabetes mellitus and diet (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       (See",
"       <a class=\"medical medical_patient\" href=\"mobipreview.htm?3/63/4083?source=see_link\">",
"        \"Patient information: Hypoglycemia (low blood sugar) in diabetes mellitus (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       (See",
"       <a class=\"medical medical_patient\" href=\"mobipreview.htm?10/45/10966?source=see_link\">",
"        \"Patient information: Care during pregnancy for women with type 1 or 2 diabetes mellitus (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      THE IMPACT OF TYPE 1 DIABETES",
"     </span>",
"    </p>",
"    <p>",
"     Being diagnosed with type 1 diabetes can be a frightening and overwhelming experience, and it is common to have questions about why it developed, what it means for long-term health, and how it will affect everyday life.",
"    </p>",
"    <p>",
"     For most patients, the first few months after being diagnosed are filled with emotional highs and lows. You and your family can use this time to learn as much as possible so that diabetes-related care (eg, self-blood sugar testing, medical appointments, daily insulin) becomes a \"normal\" part of your routine. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/43/39603?source=see_link\">",
"      \"Patient information: Self-blood glucose monitoring in diabetes mellitus (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     In addition, you should talk with your doctor or nurse about resources that are available for medical as well as psychological support. This might include group classes, meetings with a nutritionist, social worker, or nurse educator, and other educational resources such as books, web sites, or magazines. Several of these resources are listed below (see",
"     <a class=\"local\" href=\"#H11\">",
"      'Where to get more information'",
"     </a>",
"     below).",
"    </p>",
"    <p>",
"     Despite the risks associated with type 1 diabetes, most people can lead active lives and continue to enjoy the foods and activities they enjoyed before being diagnosed with diabetes. Diabetes does not mean an end to special occasion foods like birthday cake. With a little advanced planning, most people with diabetes can enjoy exercise in almost any form.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      TYPE 1 DIABETES CAUSES",
"     </span>",
"    </p>",
"    <p>",
"     Type 1 diabetes usually develops when the immune system destroys the insulin-producing cells (called the beta cells) in the pancreas. This is called an autoimmune response. The cause of this abnormal immune response is being studied.",
"    </p>",
"    <p>",
"     This process occurs over many months or years, and there may be no symptoms of diabetes. High blood sugar and its associated symptoms (frequent urination, thirst) do not usually occur until more than 90 percent of the cells that make insulin have been destroyed.",
"    </p>",
"    <p>",
"     Type 1 diabetes can develop in people with a family history of type 1 diabetes, but it also develops in people with no family history of diabetes. In either case, people who develop diabetes have one or more genes that make them susceptible to the disease. Environmental factors, such as exposure to certain viruses and foods early in life, might trigger the autoimmune response.",
"    </p>",
"    <p>",
"     Close relatives (children, siblings) of a person with type 1 diabetes have an increased risk of developing type 1 diabetes, compared to a person with no family history (5 to 6 percent versus 0.4 percent, respectively).",
"    </p>",
"    <p>",
"     Genetic testing can help to determine if a family member is at risk of developing diabetes. However, these tests are currently only available to people who participate in a clinical research trial.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      TYPE 1 DIABETES DIAGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     The diagnosis of diabetes is based on your symptoms and blood tests.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Symptoms",
"     </span>",
"     &nbsp;&mdash;&nbsp;Most people with type 1 diabetes have symptoms of high blood sugar levels (hyperglycemia). This includes:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Excessive thirst",
"      </li>",
"      <li>",
"       Feeling tired",
"      </li>",
"      <li>",
"       Needing to urinate frequently",
"      </li>",
"      <li>",
"       Losing weight",
"      </li>",
"      <li>",
"       Blurred vision",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Less commonly, there are symptoms of a problem called diabetic ketoacidosis (DKA). People with DKA have symptoms of high blood sugar (see above), as well as nausea and vomiting, belly pain, breathing rapidly, feeling sluggish, having trouble paying attention, and sometimes coma. DKA is a medical emergency and must be treated promptly.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Blood tests",
"     </span>",
"     &nbsp;&mdash;&nbsp;Several blood tests are used to measure blood sugar levels. Having a higher than normal blood sugar, as well as the symptoms described above, usually means that you have diabetes.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Type 1 versus type 2 diabetes",
"     </span>",
"     &nbsp;&mdash;&nbsp;It is usually easy to tell if you have type 1 or type 2 diabetes. However, there are situations where it is not clear if a person has type 1 or 2 diabetes. In this situation, your doctor or nurse will treat you as if you have type 1 while waiting on the results of further blood tests.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H8\">",
"     <span class=\"h1\">",
"      TYPE 1 DIABETES TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     Treatment of diabetes requires a team approach, including you and your family and healthcare providers (doctor, nurse, diabetes educator, dietitian), and sometimes other clinicians (exercise physiologist, podiatrist, etc). The treatment of type 1 diabetes is discussed separately. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/31/35317?source=see_link\">",
"      \"Patient information: Diabetes mellitus type 1: Insulin treatment (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H9\">",
"     <span class=\"h1\">",
"      COMPLICATIONS OF TYPE 1 DIABETES",
"     </span>",
"    </p>",
"    <p>",
"     Keeping your blood sugar near-normal can reduce your risk of long-term complications. This means that you will need to check your blood sugar several times per day, give insulin shots or use an insulin pump, monitor what you eat, and see your doctor or nurse on a regular basis.",
"    </p>",
"    <p>",
"     People with type 1 diabetes are at increased risk of cardiovascular disease, which can cause heart attack, chest pain, stroke, and even death. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?40/1/40980?source=see_link\">",
"      \"Patient information: Preventing complications in diabetes mellitus (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     However, you can substantially lower your risk of cardiovascular disease by:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Not smoking (see",
"       <a class=\"medical medical_patient\" href=\"mobipreview.htm?19/13/19670?source=see_link\">",
"        \"Patient information: Quitting smoking (Beyond the Basics)\"",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       Taking a low-dose aspirin every day if indicated (for adults only) (see",
"       <a class=\"medical medical_patient\" href=\"mobipreview.htm?39/54/40803?source=see_link\">",
"        \"Patient information: Aspirin and cardiovascular disease (Beyond the Basics)\"",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       Managing high blood pressure and high cholesterol with diet, exercise, and medications (see",
"       <a class=\"medical medical_patient\" href=\"mobipreview.htm?6/4/6212?source=see_link\">",
"        \"Patient information: High cholesterol and lipids (hyperlipidemia) (Beyond the Basics)\"",
"       </a>",
"       and",
"       <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/32/37380?source=see_link\">",
"        \"Patient information: High blood pressure treatment in adults (Beyond the Basics)\"",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       Keeping your A1C at 7 percent or lower",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H10\">",
"     <span class=\"h1\">",
"      PREGNANCY AND TYPE 1 DIABETES",
"     </span>",
"    </p>",
"    <p>",
"     Women with type 1 diabetes are usually able to become pregnant and have a healthy baby. However, it is important to tightly control blood sugar levels before and during pregnancy to minimize the risk of complications. A full discussion of this topic is available separately. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?10/45/10966?source=see_link\">",
"      \"Patient information: Care during pregnancy for women with type 1 or 2 diabetes mellitus (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H11\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1804364055\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14371092\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?0/43/692?source=see_link\">",
"      Patient information: Type 1 diabetes (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?0/14/227?source=see_link\">",
"      Patient information: Hemoglobin A1C tests (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?14/47/15091?source=see_link\">",
"      Patient information: Preparing for pregnancy when you have diabetes (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?36/2/36898?source=see_link\">",
"      Patient information: Diabetic ketoacidosis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?3/57/3986?source=see_link\">",
"      Patient information: Friedreich ataxia (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?19/52/20292?source=see_link\">",
"      Patient information: Diabetes and infections (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14371178\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/31/35317?source=see_link\">",
"      Patient information: Diabetes mellitus type 1: Insulin treatment (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/43/39603?source=see_link\">",
"      Patient information: Self-blood glucose monitoring in diabetes mellitus (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?3/20/3397?source=see_link\">",
"      Patient information: Type 1 diabetes mellitus and diet (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?3/63/4083?source=see_link\">",
"      Patient information: Hypoglycemia (low blood sugar) in diabetes mellitus (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?10/45/10966?source=see_link\">",
"      Patient information: Care during pregnancy for women with type 1 or 2 diabetes mellitus (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?40/1/40980?source=see_link\">",
"      Patient information: Preventing complications in diabetes mellitus (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?19/13/19670?source=see_link\">",
"      Patient information: Quitting smoking (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?39/54/40803?source=see_link\">",
"      Patient information: Aspirin and cardiovascular disease (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?6/4/6212?source=see_link\">",
"      Patient information: High cholesterol and lipids (hyperlipidemia) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/32/37380?source=see_link\">",
"      Patient information: High blood pressure treatment in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/23/15734?source=see_link\">",
"      Amylin analogs for the treatment of diabetes mellitus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/60/29641?source=see_link\">",
"      Blood glucose self-monitoring in management of adults with diabetes mellitus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/33/14874?source=see_link\">",
"      Classification of diabetes mellitus and genetic diabetic syndromes",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/54/38758?source=see_link\">",
"      Diagnosis of diabetes mellitus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/50/20265?source=see_link\">",
"      Effects of exercise in diabetes mellitus in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/45/11993?source=see_link\">",
"      Estimation of blood glucose control in diabetes mellitus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/55/15225?source=see_link\">",
"      General principles of insulin therapy in diabetes mellitus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/34/11817?source=see_link\">",
"      Glycemic control and vascular complications in type 1 diabetes mellitus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/19/20794?source=see_link\">",
"      Medical management of type 1 and type 2 diabetes mellitus in pregnant women",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/46/41702?source=see_link\">",
"      Insulin secretion and pancreatic beta-cell function",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/20/24906?source=see_link\">",
"      Insulin therapy in adults with type 1 diabetes mellitus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/63/27641?source=see_link\">",
"      Management of hypoglycemia during treatment of diabetes mellitus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/49/42777?source=see_link\">",
"      Microalbuminuria in type 1 diabetes mellitus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/2/25641?source=see_link\">",
"      Nutritional considerations in type 1 diabetes mellitus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/63/30714?source=see_link\">",
"      Overview of diabetic nephropathy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/38/36458?source=see_link\">",
"      Overview of medical care in adults with diabetes mellitus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/63/7162?source=see_link\">",
"      Pancreas and islet transplantation in diabetes mellitus",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Institute of Diabetes and Digestive and Kidney Diseases",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.niddk.nih.gov/\">",
"      www.niddk.nih.gov",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Diabetes Association (ADA)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(800)-DIABETES (800-342-2383)",
"     <br/>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.diabetes.org/\">",
"      www.diabetes.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The Endocrine Society",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.endo-society.org/\">",
"      www.endo-society.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The Hormone Foundation",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp; (",
"     <a class=\"external\" href=\"file://www.hormone.org/public/diabetes.cfm\">",
"      www.hormone.org/public/diabetes.cfm",
"     </a>",
"     , available in English and Spanish)",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"mobipreview.htm?35/26/36259/abstract/1-6\">",
"      1-6",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 21, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"mobipreview.htm?35/26/36259?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36259/abstract/1\">",
"      The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36259/abstract/2\">",
"      Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36259/abstract/3\">",
"      Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997; 20:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36259/abstract/4\">",
"      Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353:2643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36259/abstract/5\">",
"      Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. N Engl J Med 2000; 342:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36259/abstract/6\">",
"      LaGasse JM, Brantley MS, Leech NJ, et al. Successful prospective prediction of type 1 diabetes in schoolchildren through multiple defined autoantibodies: an 8-year follow-up of the Washington State Diabetes Prediction Study. Diabetes Care 2002; 25:505.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f35_26_36259=[""].join("\n");
var outline_f35_26_36259=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           TYPE 1 DIABETES OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           THE IMPACT OF TYPE 1 DIABETES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           TYPE 1 DIABETES CAUSES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           TYPE 1 DIABETES DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H8\">",
"           TYPE 1 DIABETES TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H9\">",
"           COMPLICATIONS OF TYPE 1 DIABETES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H10\">",
"           PREGNANCY AND TYPE 1 DIABETES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H11\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?12/2/12325\" title=\"figure 1\">",
"           Pancreas anatomy",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f35_26_36260="Meth mouth";
var content_f35_26_36260=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F80482&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F80482&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Meth mouth",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 321px; height: 453px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    These photographs demonstrate the extensive tooth decay (\"meth-mouth\") common in chronic methamphetamine abuse due to bruxism, decreased saliva production, and poor dental hygiene.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Stephen Wagner DDS Albuquerque, NM.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_26_36260=[""].join("\n");
var outline_f35_26_36260=null;
var title_f35_26_36261="Letrozole: Drug information";
var content_f35_26_36261=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Letrozole: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?14/18/14629?source=see_link\">",
"    see \"Letrozole: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F187285\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Femara&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F187286\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Femara&reg;;",
"     </li>",
"     <li>",
"      JAMP-Letrozole;",
"     </li>",
"     <li>",
"      Letrozole Tablets, USP;",
"     </li>",
"     <li>",
"      MED-Letrozole;",
"     </li>",
"     <li>",
"      Myl-Letrozole;",
"     </li>",
"     <li>",
"      PMS-Letrozole;",
"     </li>",
"     <li>",
"      Sandoz-Letrozole",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F187319\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Aromatase Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F187288\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Females: Postmenopausal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Breast cancer, advanced (first- or second-line treatment):",
"     </b>",
"     Oral: 2.5 mg once daily; continue until tumor progression",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Breast cancer, early (adjuvant treatment):",
"     </b>",
"     Oral: 2.5 mg once daily; optimal duration unknown, duration in clinical trial is 5 years; discontinue at relapse",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Breast cancer, early (extended adjuvant treatment):",
"     </b>",
"     Oral: 2.5 mg once daily; optimal duration unknown, duration in clinical trials is 5 years (after 5 years of tamoxifen); discontinue at relapse",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ovarian (epithelial) cancer (unlabeled use):",
"     </b>",
"     Oral: 2.5 mg once daily; continue until disease progression  (Ramirez, 2008)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F187289\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F187290\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment is required in patients with renal impairment if Cl",
"     <sub>",
"      cr",
"     </sub>",
"     is &ge;10 mL/minute.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F187291\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Mild-to-moderate impairment (Child-Pugh class A or B): No adjustment recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Severe impairment (Child-Pugh class C) and cirrhosis: 2.5 mg every other day.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F187263\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 2.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Femara&reg;: 2.5 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F187248\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F6743706\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer with or without food.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F187264\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For use in postmenopausal women in the adjuvant treatment of hormone receptor positive early breast cancer, extended adjuvant treatment of early breast cancer after 5 years of tamoxifen, advanced breast cancer with disease progression following antiestrogen therapy, hormone receptor positive or hormone receptor unknown, locally-advanced, or first-line (or second-line) treatment of advanced or metastatic breast cancer",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F6743705\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of ovarian (epithelial) cancer, endometrial cancer",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F187326\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Femara&reg; may be confused with Famvir&reg;, femhrt&reg;, Provera&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Letrozole may be confused with anastrozole",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F187317\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Edema (7% to 18%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (4% to 20%), dizziness (3% to 14%), fatigue (8% to 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypercholesterolemia (3% to 52%), hot flashes (6% to 50%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (9% to 17%), weight gain (2% to 13%), constipation (2% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (4% to 34%), arthralgia (8% to 25%), arthritis (7% to 25%), bone pain (5% to 22%), back pain (5% to 18%), bone mineral density decreased/osteoporosis (5% to 15%), bone fracture (10% to 14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Dyspnea (6% to 18%), cough (6% to 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis (&le;24%), night sweats (15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Chest pain (6% to 8%), hypertension (5% to 8%), chest wall pain (6%), peripheral edema (5%); cerebrovascular accident including hemorrhagic stroke, thrombotic stroke (2% to 3%); thromboembolic event including venous thrombosis, thrombophlebitis, portal vein thrombosis, pulmonary embolism (2% to 3%); MI (1% to 2%), angina (1% to 2%), transient ischemic attack",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Insomnia (6% to 7%), pain (5%), anxiety (&lt;5%), depression (&lt;5%), vertigo (&lt;5%), somnolence (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (5%), alopecia (3% to 5%), pruritus (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Breast pain (2% to 7%), hypercalcemia (&lt;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (5% to 8%), vomiting (3% to 7%), weight loss (6% to 7%), abdominal pain (6%), anorexia (1% to 5%), dyspepsia (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary tract infection (6%), vaginal bleeding (5%), vaginal dryness (5%), vaginal hemorrhage (5%), vaginal irritation (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Limb pain (4% to 10%), myalgia (7% to 9%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Cataract (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Renal disorder (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Pleural effusion (&lt;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Infection (7%), influenza (6%), viral infection (6%), secondary malignancy (2% to 4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1%, postmarketing, and/or case reports (Limited to important or life-threatening): Anaphylactic reaction, angioedema, arterial thrombosis, cardiac failure, carpal tunnel syndrome, endometrial cancer, endometrial hyperplasia, endometrial proliferation, erythema multiforme, hepatitis, leukopenia, memory impairment, stomatitis, tachycardia, thrombocytopenia, toxic epidermal necrolysis, trigger finger",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F187268\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use in women who are or may become pregnant",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling: Additional contraindications (not in U.S. labeling): Hypersensitivity to letrozole, other aromatase inhibitors, or any component of the formulation; use in patients &lt;18 years of age; breast-feeding",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F187252\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause dizziness, fatigue, and somnolence; patients should be cautioned before performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Decreased bone mineral density: May cause decreases in bone mineral density (BMD).  A decrease in hip BMD by 3.8% from baseline in letrozole-treated patients vs 2% in placebo at 2 years has been demonstrated; however, there was no statistical difference in changes to the lumbar spine BMD scores. Monitor BMD.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Increased cholesterol: May increase total serum cholesterol. In patients treated with adjuvant therapy and cholesterol levels within normal limits, an increase of &gt;1.5 x ULN in total cholesterol  has been demonstrated in 8.2% of letrozole-treated patients (25% requiring lipid-lowering medications) vs 3.2% of tamoxifen-treated patients (16% requiring medications). Monitor cholesterol panel; may require antihyperlipidemics.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; dose adjustment recommended in patients with cirrhosis or severe hepatic dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F187313\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2A6 (minor), CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2A6 (strong), CYP2C19 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F187257\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2A6 Substrates: CYP2A6 Inhibitors (Strong) may decrease the metabolism of CYP2A6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamoxifen: May decrease the serum concentration of Letrozole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F187259\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F187271\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Letrozole may cause fetal harm when administered to pregnant women. Animal studies have demonstrated embryotoxicity and fetotoxicity. There are no adequate and well-controlled studies in pregnant women. If used in pregnancy, or if patient becomes pregnant during treatment, the patient should be apprised of potential hazard to the fetus. Letrozole is FDA indicated for postmenopausal women only (no clinical benefit for breast cancer has been demonstrated in premenopausal women). Women who are perimenopausal or recently postmenopausal should use adequate contraception until postmenopausal status is fully established.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F187295\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F187272\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken without regard to meals. Calcium and vitamin D supplementation are recommended.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F187270\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Femara Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5 mg (30): $604.49",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Letrozole Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5 mg (30): $543.44",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F187261\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor periodically during therapy: Complete blood counts, thyroid function tests; serum electrolytes, cholesterol, transaminases, and creatinine; blood pressure; bone density",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F187273\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Antif (PE);",
"     </li>",
"     <li>",
"      Bretra (KP);",
"     </li>",
"     <li>",
"      Femar (NO);",
"     </li>",
"     <li>",
"      Femara (AE, AR, AT, AU, BD, BE, BG, BH, BO, BR, CH, CL, CN, CO, CR, CY, CZ, DE, DK, DO, EC, EE, EG, ES, FI, FR, GB, GR, GT, HK, HN, HU, ID, IE, IL, IQ, IR, IT, JO, JP, KW, LB, LY, MX, MY, NI, NL, NZ, OM, PA, PE, PH, PK, PL, PR, PT, PY, QA, RU, SA, SE, SG, SV, SY, TH, TR, TW, UY, VE, YE);",
"     </li>",
"     <li>",
"      Femgard (CO);",
"     </li>",
"     <li>",
"      Hentrozole (PH);",
"     </li>",
"     <li>",
"      Lenara (KP);",
"     </li>",
"     <li>",
"      Letara (NZ);",
"     </li>",
"     <li>",
"      Letoripe (PH);",
"     </li>",
"     <li>",
"      Letzol (IN);",
"     </li>",
"     <li>",
"      Lezol (PH);",
"     </li>",
"     <li>",
"      Trozet (PH, TH, TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F187251\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Nonsteroidal competitive inhibitor of the aromatase enzyme system which binds to the heme group of aromatase, a cytochrome P450 enzyme which catalyzes conversion of androgens to estrogens (specifically, androstenedione to estrone and testosterone to estradiol). This leads to inhibition of the enzyme and a significant reduction in plasma estrogen (estrone, estradiol and estrone sulfate) levels. Does not affect synthesis of adrenal or thyroid hormones, aldosterone, or androgens.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F187267\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid and well absorbed; not affected by food",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : ~1.9 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding, plasma: Weak",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via CYP3A4 and 2A6 to an inactive carbinol metabolite",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Terminal: ~2 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to steady state, plasma: 2-6 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (90%; 6% as unchanged drug, 75% as glucuronide carbinol metabolite, 9% as unidentified metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Burstein HJ, Prestrud AA, Seidenfeld J, et al, &ldquo;American Society of Clinical Oncology Clinical Practice Guideline: Update on Adjuvant Endocrine Therapy for Women with Hormone Receptor-Positive Breast Cancer,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2010, 28(23):3784-96.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/26/36261/abstract-text/20625130/pubmed\" id=\"20625130\" target=\"_blank\">",
"        20625130",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Buzdar AU, Robertson JF, Eiermann W, et al, &ldquo;An Overview of the Pharmacology and Pharmacokinetics of the Newer Generation Aromatase Inhibitors Anastrozole, Letrozole, and Exemestane,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 2002, 95(9):2006-16.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/26/36261/abstract-text/12404296/pubmed\" id=\"12404296\" target=\"_blank\">",
"        12404296",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Coates AS, Keshaviah A, Thurlimann B, et al, &ldquo;Five Years of Letrozole Compared With Tamoxifen as Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2007, 25(5):486-92.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/26/36261/abstract-text/17200148/pubmed\" id=\"17200148\" target=\"_blank\">",
"        17200148",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Clinical Practice Guidelines in Oncology&trade;: Breast Cancer,&rdquo; Version 3.2010. Available at file://www.nccn.org/professionals/physician_gls/PDF/breast.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Clinical Practice Guidelines in Oncology&trade;: Ovarian Cancer,&rdquo; Version 1.2011. Available at file://www.nccn.org/professionals/physician_gls/PDF/ovarian.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Clinical Practice Guidelines in Oncology&trade;: Uterine Neoplasms,&rdquo; Version 1.2011. Available at file://www.nccn.org/professionals/physician_gls/PDF/uterine.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ramirez PT, Schmeler EM, Milam MR, et al, &ldquo;Efficacy of Letrozole in the Treatment of Recurrent Platinum- and Taxane-Resistant High-Grade Cancer of the Ovary or Peritoneum,&rdquo;",
"      <i>",
"       Gynecol Oncol",
"      </i>",
"      , 2008, 110(1):56-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/26/36261/abstract-text/18457865/pubmed\" id=\"18457865\" target=\"_blank\">",
"        18457865",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Simpson D, Curran MP, and Perry CM, \"Letrozole: A Review of Its Use in Postmenopausal Women With Breast Cancer,\"",
"      <i>",
"       Drugs",
"      </i>",
"      , 2004, 64(11):1213-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/26/36261/abstract-text/15161328/pubmed\" id=\"15161328\" target=\"_blank\">",
"        15161328",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smith IE and Dowsett M, \"Aromatase Inhibitors in Breast Cancer,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2003, 348(24):2431-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/26/36261/abstract-text/12802030/pubmed\" id=\"12802030\" target=\"_blank\">",
"        12802030",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Thurlimann B, Keshaviah A, Coates AS, et al, \"A Comparison of Letrozole and Tamoxifen in Postmenopausal Women with Early Breast Cancer,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2005, 353(26):2747-57.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/26/36261/abstract-text/16382061/pubmed\" id=\"16382061\" target=\"_blank\">",
"        16382061",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Winer EP, Hudis C, Burstein HJ, et al, \"American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors as Adjuvant Therapy for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Status Report 2004,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2005, 23(3):619-29.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/26/36261/abstract-text/15545664/pubmed\" id=\"15545664\" target=\"_blank\">",
"        15545664",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10064 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.66.252.144-6720EAAD2F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_26_36261=[""].join("\n");
var outline_f35_26_36261=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187285\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187286\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187319\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187288\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187289\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187290\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187291\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187263\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187248\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6743706\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187264\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6743705\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187326\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187317\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187268\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187252\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187313\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187257\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187259\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187271\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187295\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187272\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187270\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187261\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187273\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187251\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187267\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10064\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10064|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?14/18/14629?source=related_link\">",
"      Letrozole: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_26_36262="Thoracic vertebrae";
var content_f35_26_36262=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F54473&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F54473&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 623px\">",
"   <div class=\"ttl\">",
"    Thoracic vertebrae",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 603px; height: 342px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) T1 has a vertebral foramen and body similar to a cervical vertebra.",
"    <br>",
"     (B) T5-T9 vertebrae have typical characteristics of thoracic vertebrae.",
"     <br>",
"      (C) T12 has bony processes and a body size similar to a lumbar vertebra. The planes of the articular facets of thoracic vertebrae define an arc (red arrows) that centers on an axis traversing the vertebral bodies vertically.",
"      <br>",
"       (D) Superior and inferior costal facets (demifacets) on the vertebral body, costal facets on the transverse processes, and long sloping spinous processes are characteristic of thoracic vertebrae.",
"       <div class=\"footnotes\">",
"       </div>",
"       <div class=\"reference\">",
"        Reproduced with permission from: Moore KL, Dalley AF. Clinically Oriented Anatomy, 5th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"       </div>",
"       <div class=\"contractual\">",
"        <br/>",
"        <a href=\"file://www.lww.com\">",
"         file://www.lww.com",
"        </a>",
"       </div>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_26_36262=[""].join("\n");
var outline_f35_26_36262=null;
var title_f35_26_36263="Loiasis (Loa loa infection)";
var content_f35_26_36263=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Loiasis (Loa loa infection)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/26/36263/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/26/36263/contributors\">",
"     Amy D Klion, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/26/36263/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/26/36263/contributors\">",
"     Peter F Weller, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/26/36263/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/26/36263/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/26/36263/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Loiasis, also known as African eye worm, is caused by the filarial nematode Loa loa. Loiasis is transmitted by the bite of the Chrysops fly; west and central Africa are endemic regions. Manifestations of infection include transient localized subcutaneous swellings (known as Calabar swellings) and migration of the adult worm across the subconjunctiva of the eye.",
"   </p>",
"   <p>",
"    The epidemiology, clinical features, diagnosis, and treatment of L. loa will be reviewed here. Other filarial infections, including onchocerciasis, lymphatic filariasis, and Mansonella infection are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/30/20970?source=see_link\">",
"     \"Onchocerciasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/25/13719?source=see_link\">",
"     \"Epidemiology, pathogenesis, and clinical manifestations of lymphatic filariasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/56/15241?source=see_link\">",
"     \"Diagnosis, treatment, and prevention of lymphatic filariasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     LOA LOA",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Loiasis is transmitted by biting deerflies (Chrysops), which breed in the high-canopied rain forest of west and central Africa, including the coastal plains of northern Angola, southeastern Benin, Cameroon, Central African Republic, Chad, Republic of the Congo, Equatorial Guinea, Gabon, Nigeria, Sudan, and the Democratic Republic of Congo. Rare cases have been reported in the region from Ghana to Guinea and in Uganda, Mali, Zambia, and Ethiopia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36263/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is estimated that between 3 and 13 million people are infected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36263/abstract/1\">",
"     1",
"    </a>",
"    ]. Infection is occult in a large proportion of patients; therefore, in many areas, the epidemiology of loiasis has not been clearly defined. In endemic regions, the probability of infection increases with age; the proportion of infected individuals varies depending on vector abundance.",
"   </p>",
"   <p>",
"    Large scale mapping of loiasis in 11 potentially endemic countries has been developed using a Rapid Assessment Procedure for Loiasis (RAPLOA), based on community questionnaires documenting the prevalence of a history of eye worm. RAPLOA surveys have helped identify specific regions in 10 African countries where loiasis is endemic, including regions where the prevalence of infection exceeds 40 percent (",
"    <a class=\"graphic graphic_figure graphicRef83532 \" href=\"mobipreview.htm?8/43/8889\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36263/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. This is important given potential complications arising from",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/13/32976?source=see_link\">",
"     ivermectin",
"    </a>",
"    treatment of onchocerciasis in those with concomitant loiasis.",
"   </p>",
"   <p>",
"    Infection occurs most commonly in residents of endemic areas, but travelers to these regions can also be infected. Usually months to years of exposure are required for infection. However, cases have been reported after as little as four days of exposure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36263/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. It is unclear whether naturally acquired immunity develops after prolonged periods.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Life cycle",
"    </span>",
"    &nbsp;&mdash;&nbsp;L. loa is spread via the bite of the female Chrysops fly, also known as the tabanid fly (horse fly or deer fly). This vector breeds in the canopy of rain forests and lays eggs in muddy swamps. The flies are attracted to movement and tend to bite humans during the daytime (",
"    <a class=\"graphic graphic_figure graphicRef82917 \" href=\"mobipreview.htm?18/56/19335\">",
"     figure 2",
"    </a>",
"    ). During a blood meal, an infected fly introduces third-stage filarial larvae onto the skin of the human host, where they penetrate into the bite wound. These larvae mature into adult worms over a period of three months. The adult worms cause clinical disease; they live in the subcutaneous tissue and can migrate to any area of the body, including the subconjunctival tissue of the eye.",
"   </p>",
"   <p>",
"    After a period of 6 to 12 months from the time of initial infection (the prepatent period), the adult worms begin to produce thousands of larval microfilariae that are released into the bloodstream. Microfilariae can be detected on blood smears or Nuclepore filtered blood. Microfilariae do not cause pathology in untreated loiasis, but can contribute to complications following treatment. Microfilariae are responsible for transmission of infection since they are taken up during the blood meal of female flies. L. loa microfilariae exhibit greater numbers in the blood by day (diurnal periodicity) in accord with the daytime biting habits of the Chrysops vectors. The life cycle is completed following maturation of microfilariae into infective third stage larvae within the fly, which occurs over a period of 10 to 12 days.",
"   </p>",
"   <p>",
"    Adult worms can live for more than 20 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36263/abstract/6\">",
"     6",
"    </a>",
"    ] but do not replicate within the human host. Therefore, once an individual is no longer exposed to infective larvae (ie, after leaving an endemic region), the microfilarial burden can increase but the adult worm burden cannot increase.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most individuals with L. loa infection are asymptomatic. The two cardinal clinical manifestations of loiasis are transient localized subcutaneous swellings (known as Calabar swellings), and migration of the adult worm across the subconjunctiva of the eye (",
"    <a class=\"graphic graphic_picture graphicRef82918 \" href=\"mobipreview.htm?9/41/9878\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Nonimmune individuals who travel to endemic regions and acquire L. loa infection are more prone to broader allergic-type symptoms than local residents, including urticaria, pruritus, Calabar swellings, and occasionally asthma. Clinical manifestations can persist for prolonged periods even after the individual has left the endemic area because adult worms can live for more than 20 years. However, microfilariae are rarely detectable in blood smears of these individuals because there is usually a relatively low burden of infection. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Calabar swellings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transient localized subcutaneous swellings (known as Calabar swellings) are a form of angioedema potentially due to hypersensitivity reactions to migrating adult parasite",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    released microfilariae [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36263/abstract/1\">",
"     1",
"    </a>",
"    ]. The swellings can occur anywhere on the body but are most frequently observed on the face and extremities; they are generally preceded by local pain or itching (",
"    <a class=\"graphic graphic_picture graphicRef83533 \" href=\"mobipreview.htm?9/44/9922\">",
"     picture 2",
"    </a>",
"    ). Typical Calabar swellings are non erythematous and measure 5 to 20 cm in diameter. Swelling can extend into nearby joints or compress peripheral nerves. Calabar swellings usually resolve spontaneously after two to four days, but they occasionally last for several weeks. Recurrent episodes can develop at the same site or elsewhere.",
"   </p>",
"   <p>",
"    Calabar swellings are most frequently observed in nonimmune visitors to endemic regions with extended exposure. In one study in west Africa, Calabar swellings were observed in 95 percent of expatriates and 16 percent of native patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36263/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5118751\">",
"    <span class=\"h3\">",
"     Eye symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The adult worm migrates to the eye and crawls beneath the conjunctiva, causing transient inflammation and edema. The adult worm usually measures 3 to 7 cm by 0.3 to 0.5 mm and typically migrates at the rate of 1 cm per minute. The worm may be visualized directly as it crosses the conjunctiva, which usually takes 10 to 20 minutes. Symptoms resolve spontaneously after the worm has left the eye, and usually there are no sequelae. Eye symptoms can occur in both endemic and nonimmune individuals. Rarely, adult worms invade the eye causing pain and intraocular inflammation.",
"   </p>",
"   <p>",
"    Eye symptoms of loiasis should not be confused with intraocular microfilariae that characteristically develop with onchocerciasis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/30/20970?source=see_link\">",
"     \"Onchocerciasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Other complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional manifestations of loiasis in immune or nonimmune hosts include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Encephalitis &mdash; Encephalitis can occur in patients with loiasis, generally, but not always in the setting of treatment with diethylcarbamazine (DEC) or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/13/32976?source=see_link\">",
"       ivermectin",
"      </a>",
"      . Symptoms can include headache, insomnia, or coma; death can result. Although most cases of encephalitis have been reported in patients with more than 30,000",
"      <span class=\"nowrap\">",
"       microfilariae/mL",
"      </span>",
"      of blood [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/26/36263/abstract/8\">",
"       8",
"      </a>",
"      ], neurologic symptoms can occur in patients with lower microfilarial levels [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/26/36263/abstract/9\">",
"       9",
"      </a>",
"      ]. The mechanism of post-treatment neurologic complications in Loa loa infection is unknown; however, microfilariae have been described in the CSF in a number of cases, suggesting that inflammation caused by dying microfilariae may play a role.",
"     </li>",
"     <li>",
"      Cardiomyopathy &mdash; Endomyocardial fibrosis leading to a secondary cardiomyopathy can develop in loiasis patients with a substantial eosinophilia.",
"     </li>",
"     <li>",
"      Nephropathy &mdash; Renal involvement leading to hematuria or proteinuria may occur in up to one-third of infected individuals and may be transiently exacerbated during treatment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/26/36263/abstract/7,10\">",
"       7,10",
"      </a>",
"      ]. The exact mechanism of renal involvement is unclear; immune complexes are believed to play a role in some cases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/26/36263/abstract/4\">",
"       4",
"      </a>",
"      ]. Progression of nephropathy to renal failure is uncommon but has been reported.",
"     </li>",
"     <li>",
"      Other &mdash; L. loa adult worms can migrate to any subcutaneous site, occasionally resulting in arthritis or lymphadenitis. Entrapment neuropathy related to inflammation and angioedema involving peripheral nerves may also be observed [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/26/36263/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5118872\">",
"    <span class=\"h3\">",
"     Laboratory abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonspecific but characteristic laboratory abnormalities include a high eosinophil count, often",
"    <span class=\"nowrap\">",
"     &gt;3000/microL",
"    </span>",
"    (normal",
"    <span class=\"nowrap\">",
"     &lt;500/microL).",
"    </span>",
"    Hypergammaglobulinemia and a high level of IgE are often present. These findings are more common in symptomatic nonimmune individuals than in residents of endemic areas. In one study in west Africa, the eosinophil count was elevated in 100 percent of nonendemic patients (mean",
"    <span class=\"nowrap\">",
"     3026/microL)",
"    </span>",
"    and 50 percent of endemic patients (mean",
"    <span class=\"nowrap\">",
"     &lt;500/microL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36263/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Loiasis should be suspected in an individual with an appropriate epidemiologic exposure, consistent clinical findings, and supportive laboratory findings. The definitive diagnosis is established by identifying the adult worm or microfilariae in the blood. Serology may also be useful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Visualizing organisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of loiasis can be definitively established by identifying a migrating adult worm in the subcutaneous tissue or conjunctiva (",
"    <a class=\"graphic graphic_picture graphicRef82918 \" href=\"mobipreview.htm?9/41/9878\">",
"     picture 1",
"    </a>",
"    ) or by detecting microfilariae in a blood smear (",
"    <a class=\"graphic graphic_picture graphicRef82919 \" href=\"mobipreview.htm?25/4/25666\">",
"     picture 3",
"    </a>",
"    ). Microscopy sensitivity is increased with a variety of concentration techniques, including Knott&rsquo;s concentration and Nuclepore filtration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36263/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adult worms range in length from 2.0 to 3.5 cm for males and 5 to 7 cm for females. Both are no more than 0.5 mm wide. Microfilariae of L. loa are sheathed and measure 230 to 250 mcm long in stained blood smears. The tail is tapered and nuclei extend to the tip of the tail (",
"    <a class=\"graphic graphic_picture graphicRef82919 \" href=\"mobipreview.htm?25/4/25666\">",
"     picture 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    L. loa typically has diurnal periodicity, meaning that the microfilariae are more abundant in the bloodstream during the daytime (between 10AM and 2PM) than at night. This coincides with the feeding pattern of the vector, thereby potentiating transmission of infection. This diurnal periodicity differentiates microfilariae in loiasis from Bancroftian and Brugian filariasis; microfilariae in the latter infections are more abundant at night than during the daytime. Microfilariae of Mansonella perstans, another human filarial parasite that overlaps in geographic distribution with L. loa, are not periodic but can be distinguished from L. loa microfilariae on the basis of their small size and the absence of a sheath. &nbsp;",
"   </p>",
"   <p>",
"    Microfilaremia is observed more frequently among residents of endemic areas than in travelers and expatriates. In one study in west Africa, microfilaremia was observed in &gt;90 percent of residents and 10 percent of nonimmune travelers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36263/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Serology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serologic tests are most useful for diagnosis of loiasis among travelers and expatriates. In endemic populations, serology is generally not useful since antibodies remain positive for prolonged periods following infection and thus cannot distinguish between active or prior infections or quantitate microfilaremia. However, a negative result can exclude the possibility of L. loa infection.",
"   </p>",
"   <p>",
"    Most antibody tests use crude antigen extracts from related animal filarial species. They have relatively good sensitivity but poor specificity, since they cross-react both with other filarial infections and with other nonfilarial helminthic parasites. Newer techniques, which measure specific IgG4 antibodies rather than total IgG, have been developed and are thought to be more specific for active infection with loiasis. However, these tests are not widely available.",
"   </p>",
"   <p>",
"    One study evaluated an IgG4 antibody-based ELISA using a crude extract of L. loa microfilariae and found that, in patients with microfilaremia, this method had a sensitivity and specificity of 80 and 78 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36263/abstract/12\">",
"     12",
"    </a>",
"    ]. Among patients with no detectable microfilariae on blood smear, 55 percent had significant levels of specific-IgG4 antibodies against L. loa, suggesting they carried occult loiasis. The authors concluded that, despite the limited sensitivity and specificity of the test, IgG4-ELISA could be useful for estimating the real prevalence of loiasis in epidemiologic surveys and could help to confirm the diagnosis of L. loa in amicrofilaremic subjects with suggestive clinical signs.",
"   </p>",
"   <p>",
"    Another study examined IgG4 in three groups: amicrofilaremic individuals with verified ocular passage of adult worms of L. loa, microfilaremic patients, and unexposed individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36263/abstract/13\">",
"     13",
"    </a>",
"    ]. The study showed that there was no significant difference in the level of parasite-specific IgG4 between amicrofilaremic individuals with occult infection and microfilaremic individuals. It also showed excellent specificity because there was no reactivity among unexposed individuals or among individuals exposed to filarial infections other than loiasis.",
"   </p>",
"   <p>",
"    Serologic assays using recombinant L. loa antigens have been developed, including a sensitive and specific rapid assay that uses a luciferase immunoprecipitation system to detect antibodies to the recombinant L. loa antigen LLSXP-1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36263/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Other tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tests that detect circulating L. loa antigens are in development. A real-time polymerase chain reaction (PCR) assay has been developed at the Laboratory of Parasitic Diseases, National Institutes of Health that can detect and quantitate L. loa microfilaremia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36263/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Assistance with serologic and other diagnostic tests is available from the Laboratory of Parasitic Diseases, National Institutes of Health (301-496-5398).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15717704\">",
"    <span class=\"h3\">",
"     Clinical approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of choice for loiasis is diethylcarbamazine (DEC), which has activity against both L. loa microfilariae and macrofilariae (adult worms). Since the incidence and severity of treatment side effects increase with increasing blood microfilarial counts, quantification of blood microfilariae is essential before initiating treatment. This can be done by counting microfilariae on blood smears made from defined volumes of blood (eg, 50 microL) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36263/abstract/3\">",
"     3",
"    </a>",
"    ] or from larger volumes of blood (eg, 1 mL) concentrated through Nuclepore filters or using formalin (Knott&rsquo;s concentration) or saponin lysis. Quantification should be performed between 10 AM and 2 PM to capture the peak number of microfilariae circulating in the blood. In patients within two weeks of travel from a different time zone, the time of the blood draw should be adjusted accordingly.",
"   </p>",
"   <p>",
"    Serious side effects of treatment are uncommon in patients with low numbers of microfilariae in the blood (2500",
"    <span class=\"nowrap\">",
"     microfilariae/mL",
"    </span>",
"    has been suggested as a threshold, although supporting data is lacking). In general, patients with any detectable microfilariae should be monitored in a hospital setting during the first three days of treatment. Antihistamines",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    corticosteroids have been used to limit post-treatment reactions, including Calabar swellings and urticaria, but do not prevent serious side effects, including encephalopathy.",
"   </p>",
"   <p>",
"    In patients with high levels of microfilariae, the risks and benefits of treatment need to be considered. In general, treatment should be reserved for symptomatic patients, patients with marked elevations in the peripheral eosinophil count,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    patients with concomitant onchocerciasis or lymphatic filariasis (who require therapy to prevent morbidity and mortality due to these infections).",
"   </p>",
"   <p>",
"    An attempt should be made to lower blood microfilarial counts prior to DEC treatment. This can be accomplished using apheresis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36263/abstract/16\">",
"     16",
"    </a>",
"    ]. Treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/6/24678?source=see_link\">",
"     albendazole",
"    </a>",
"    , a benzimidazole with good oral bioavailability, has been shown to significantly decrease Loa microfilarial levels in controlled trial (dosed 200 mg twice daily for three weeks) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36263/abstract/17\">",
"     17",
"    </a>",
"    ]. Adverse effects were not observed, even in individuals with &gt;50,000",
"    <span class=\"nowrap\">",
"     microfilariae/mL",
"    </span>",
"    blood. Shorter higher dose regimens have not been effective. The gradual decrease in blood microfilarial levels over the course of several months suggests that albendazole may have preferential effects on adult parasites, explaining the lack of adverse effects associated with acute microfilarial clearance. Pretreatment with albendazole may provide an alternative to apheresis in patients with high level microfilaremias.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/13/32976?source=see_link\">",
"     Ivermectin",
"    </a>",
"    has L. loa microfilaricidal activity and, similar to DEC, can precipitate adverse events in patients with high levels of circulating microfilariae. Unlike DEC, however, ivermectin has no effect on adult worms and is not curative in Loa loa infection.",
"   </p>",
"   <p>",
"    Endosymbiotic Wolbachia have not been identified in L. loa by light or electron microscopy or by PCR [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36263/abstract/18\">",
"     18",
"    </a>",
"    ], (in contrast to other filariae that infect humans such as Wuchereria bancrofti, Brugia malayi, and Onchocerca volvulus) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36263/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h4\">",
"     Diethylcarbamazine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of choice for loiasis is diethylcarbamazine (DEC), a piperazine derivative. DEC has activity against both L. loa microfilariae and adult worms, so a sustained decrease in microfilarial intensity occurs following treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36263/abstract/20-23\">",
"     20-23",
"    </a>",
"    ]. In one study, DEC (8 to 10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day for 21 days) lowered microfilaremia to 2 to 12 percent of the initial level for up to six months, killed 30 percent of adult worms, and eradicated infection in 50 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36263/abstract/24\">",
"     24",
"    </a>",
"    ]. However, a single course of treatment is curative in only 40 to 50 percent of patients. Relapsed infection can also occur.",
"   </p>",
"   <p>",
"    Adverse events following treatment with DEC are due to rapid killing of the microfilariae and are most severe in patients with high levels of circulating microfilariae, although adverse effects can occur even in amicrofilaremic patients. Reactions are common, though serious reactions (encephalitis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    shock) are relatively uncommon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36263/abstract/9\">",
"     9",
"    </a>",
"    ]. Therefore, asymptomatic patients with high levels of circulating microfilariae should not receive treatment. Symptomatic patients with high levels of circulating microfilariae should undergo apheresis prior to therapy to remove part of their microfilarial burden or receive",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/6/24678?source=see_link\">",
"     albendazole",
"    </a>",
"    first as noted above. (See",
"    <a class=\"local\" href=\"#H15717704\">",
"     'Clinical approach'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Treatment for patients without evidence of microfilaremia consists of DEC 9",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    orally in three divided doses for 21 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36263/abstract/25\">",
"     25",
"    </a>",
"    ]. Treatment for patients with microfilaremia consists of a graded dosing schedule for DEC, as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Day 1: 50 mg (1",
"      <span class=\"nowrap\">",
"       mg/kg)",
"      </span>",
"     </li>",
"     <li>",
"      Day 2: 50 mg (1",
"      <span class=\"nowrap\">",
"       mg/kg)",
"      </span>",
"      three times a day",
"     </li>",
"     <li>",
"      Day 3: 100 mg (1 to 2",
"      <span class=\"nowrap\">",
"       mg/kg)",
"      </span>",
"      three times a day",
"     </li>",
"     <li>",
"      Day 4 to 21: 9",
"      <span class=\"nowrap\">",
"       mg/kg/day",
"      </span>",
"      in three divided doses",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A single 21-day course of DEC is curative in approximately 50 percent of patients. There are no data available on shorter course therapy. Long-term follow-up is needed after therapy, and retreatment should be considered if symptoms recur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36263/abstract/26\">",
"     26",
"    </a>",
"    ]. DEC should be avoided in pregnancy.",
"   </p>",
"   <p>",
"    DEC is not licensed for use in the United States, but it can be obtained from the Centers for Disease Control and Prevention (CDC) for compassionate use. (Centers for Disease Control and Prevention Drug Service, Atlanta, GA 30333; telephone 404-639-2888.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h4\">",
"     Albendazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/6/24678?source=see_link\">",
"     Albendazole",
"    </a>",
"    is an alternative agent for treatment of loiasis. Albendazole has macrofilaricidal activity, causing sterilization or death of adult L. loa worms. Unlike DEC, albendazole does not have significant microfilaricidal activity. Consequently, fewer adverse effects are observed with albendazole compared with DEC, since there is no massive antigen release associated with dying microfilariae [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36263/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/6/24678?source=see_link\">",
"     albendazole",
"    </a>",
"    against the adult worm leads to a gradual decline in microfilariae levels over several months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36263/abstract/17,27,28\">",
"     17,27,28",
"    </a>",
"    ]. Although cure rates following albendazole treatment of loiasis have not been studied directly, the fact that microfilariae are not completely eliminated in most patients suggests that albendazole is less effective than DEC as initial therapy.",
"   </p>",
"   <p>",
"    In individuals with high levels of circulating microfilariae loads, treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/6/24678?source=see_link\">",
"     albendazole",
"    </a>",
"    may be useful for reduction of microfilaremia prior to treatment with DEC. Albendazole has also been used as an alternative agent in individuals with L. loa infection that is refractory to multiple courses of DEC; repeat courses of therapy may be needed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36263/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. A dose of 200 to 400 mg twice daily for three weeks has been used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h4\">",
"     Ivermectin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/13/32976?source=see_link\">",
"     Ivermectin",
"    </a>",
"    is not a preferred therapeutic agent for treatment of loiasis. It has microfilaricidal activity against L. loa but is not active against adult worms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36263/abstract/31-34\">",
"     31-34",
"    </a>",
"    ]. As with DEC, the rapid microfilaricidal effect of ivermectin can result in severe adverse events (encephalitis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    shock), particularly in individuals with high-level microfilaremic infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36263/abstract/8,35\">",
"     8,35",
"    </a>",
"    ]. As discussed above, ivermectin pre-treatment is indicated in patients with concomitant onchocerciasis and loiasis. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H254240\">",
"    <span class=\"h3\">",
"     Onchocerciasis coinfection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coinfection with loiasis and onchocerciasis warrants special attention, since DEC is contraindicated in onchocerciasis and can provoke severe inflammatory responses in the skin and eyes (Mazzotti reaction).",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/6/24678?source=see_link\">",
"     Albendazole",
"    </a>",
"    has been shown to be effective in a small study of patients with loiasis refractory to multiple courses of DEC. If the burden of Loa loa microfilariae is low, pretreatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/13/32976?source=see_link\">",
"     ivermectin",
"    </a>",
"    can be administered prior to DEC. The optimal length of time between ivermectin and DEC treatment is unknown, but based on microfilarial clearance data it is likely to be between two and four weeks. If the burden of Loa loa microfilariae is high, the risks and benefits of treatment need to be weighed as discussed above, and apheresis or albendazole should be considered prior to sequential treatment with ivermectin and DEC. (See",
"    <a class=\"local\" href=\"#H15717704\">",
"     'Clinical approach'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical removal of worms from the eye or the skin can be performed for diagnostic purposes. This is generally not a practical method for cure of infection, however, particularly in endemic areas where large worm burdens are common. Surgical removal of subconjunctival worms is not required for therapeutic management since migration of the worm does not result in ocular damage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no vaccine against L. loa infection. Personal protection measures to avoid fly bites may have some utility in individual travelers, but large scale vector control has not been shown to be feasible in endemic areas.",
"   </p>",
"   <p>",
"    A weekly 300 mg dose of DEC can be given for prophylaxis against loiasis for individual travelers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36263/abstract/25\">",
"     25",
"    </a>",
"    ]. This should be considered for workers with longer-term exposures (eg, Peace Corps personnel) but is not necessary for most short-term travelers to endemic areas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36263/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15717989\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Loiasis, also known as African eye worm, is caused by the filarial nematode Loa loa. Loiasis is transmitted by the bite of Chrysops flies (",
"      <a class=\"graphic graphic_figure graphicRef82917 \" href=\"mobipreview.htm?18/56/19335\">",
"       figure 2",
"      </a>",
"      ); west and central Africa are endemic regions for infection. Infection is occult in a large proportion of patients; therefore in many areas the epidemiology of loiasis has not been clearly defined. Infection occurs most commonly in residents of endemic areas, but travelers to these regions can also be infected. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most individuals with L. loa infection are asymptomatic. The clinical manifestations include transient localized subcutaneous swellings (known as Calabar swellings) and migration of the adult worm across the subconjunctiva of the eye (",
"      <a class=\"graphic graphic_picture graphicRef82918 \" href=\"mobipreview.htm?9/41/9878\">",
"       picture 1",
"      </a>",
"      ). Nonimmune individuals who travel to endemic regions and acquire L. loa infection are generally more prone to hypersensitivity reactions to microfilariae",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      migrating adult worms than local residents. Eosinophilia",
"      <span class=\"nowrap\">",
"       (&gt;3000/microL)",
"      </span>",
"      is more common in nonimmune individuals. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of loiasis can be definitively established by identifying a migrating adult worm in the subcutaneous tissue or conjunctiva (",
"      <a class=\"graphic graphic_picture graphicRef82918 \" href=\"mobipreview.htm?9/41/9878\">",
"       picture 1",
"      </a>",
"      ), or by detecting microfilariae in a blood smear (",
"      <a class=\"graphic graphic_picture graphicRef82919 \" href=\"mobipreview.htm?25/4/25666\">",
"       picture 3",
"      </a>",
"      ). Serologic tests have been developed and are most useful for diagnosis of loiasis among travelers and expatriates. New polymerase chain reaction techniques are sensitive and quantitative assays of infection and levels of microfilaremia. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest diethylcarbamazine for treatment of patients with loiasis and &lt;2500 microfilariae per mL of blood (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Use of diethylcarbamazine can lead to adverse events (encephalitis",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      shock) in patients with high levels of circulating microfilariae due to rapid microfilariae killing. Therefore, management of patients with symptomatic loiasis and &gt;2500 microfilariae per mL of blood should consist of one of the following: apheresis prior to diethylcarbamazine administration or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/6/24678?source=see_link\">",
"       albendazole",
"      </a>",
"      administration for gradual reduction of microfilaremia prior to administration of diethylcarbamazine. Patients with concomitant loiasis and onchocerciasis should receive",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/13/32976?source=see_link\">",
"       ivermectin",
"      </a>",
"      treatment prior to definitive therapy with DEC or a regimen that does not contain DEC. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is no vaccine against L. loa infection. Personal protection measures to avoid fly bites may have some utility in individual travelers, but large scale vector control has not been shown to be feasible in endemic areas. There are no mass community chemotherapy programs in place for loiasis. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H177323013\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editorial staff at UpToDate, Inc. would like to acknowledge Drs. Karin Leder and Peter Weller, who contributed to an earlier version of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Klion A, Nutman TB. Loiasis and Mansonella Infections. In: Tropical Infectious Diseases: Principles, Pathogens and Practice, Guerrant R, Walker DH, Weller PF.  (Eds), Churchill Livingstone, Philadelphia 2011. Vol 3, p.735.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36263/abstract/2\">",
"      Zour&eacute; HG, Wanji S, Noma M, et al. The geographic distribution of Loa loa in Africa: results of large-scale implementation of the Rapid Assessment Procedure for Loiasis (RAPLOA). PLoS Negl Trop Dis 2011; 5:e1210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36263/abstract/3\">",
"      Wanji S, Akotshi DO, Mutro MN, et al. Validation of the rapid assessment procedure for loiasis (RAPLOA) in the democratic republic of Congo. Parasit Vectors 2012; 5:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36263/abstract/4\">",
"      Nutman TB, Miller KD, Mulligan M, Ottesen EA. Loa loa infection in temporary residents of endemic regions: recognition of a hyperresponsive syndrome with characteristic clinical manifestations. J Infect Dis 1986; 154:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36263/abstract/5\">",
"      Rakita RM, White AC Jr, Kielhofner MA. Loa loa infection as a cause of migratory angioedema: report of three cases from the Texas Medical Center. Clin Infect Dis 1993; 17:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36263/abstract/6\">",
"      Richardson ET, Luo R, Fink DL, et al. Transient facial swellings in a patient with a remote African travel history. J Travel Med 2012; 19:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36263/abstract/7\">",
"      Klion AD, Massougbodji A, Sadeler BC, et al. Loiasis in endemic and nonendemic populations: immunologically mediated differences in clinical presentation. J Infect Dis 1991; 163:1318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36263/abstract/8\">",
"      Gardon J, Gardon-Wendel N, Kamgno J, et al. Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection. Lancet 1997; 350:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36263/abstract/9\">",
"      Carme B, Boulesteix J, Boutes H, Puruehnce MF. Five cases of encephalitis during treatment of loiasis with diethylcarbamazine. Am J Trop Med Hyg 1991; 44:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36263/abstract/10\">",
"      Pillay VK, Kirch E, Kurtzman NA. Glomerulopathy associated with filarial loiasis. JAMA 1973; 225:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36263/abstract/11\">",
"      Dennis DT, Kean BH. Isolation of microfilariae: report of a new method. J Parasitol 1971; 57:1146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36263/abstract/12\">",
"      Tour&eacute; FS, Egwang TG, Millet P, et al. IgG4 serology of loiasis in three villages in an endemic area of south-eastern Gabon. Trop Med Int Health 1998; 3:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36263/abstract/13\">",
"      Akue JP, Egwang TG, Devaney E. High levels of parasite-specific IgG4 in the absence of microfilaremia in Loa loa infection. Trop Med Parasitol 1994; 45:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36263/abstract/14\">",
"      Burbelo PD, Ramanathan R, Klion AD, et al. Rapid, novel, specific, high-throughput assay for diagnosis of Loa loa infection. J Clin Microbiol 2008; 46:2298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36263/abstract/15\">",
"      Fink DL, Kamgno J, Nutman TB. Rapid molecular assays for specific detection and quantitation of Loa loa microfilaremia. PLoS Negl Trop Dis 2011; 5:e1299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36263/abstract/16\">",
"      Gardner A, Hardy L, Bell SK. Eosinophilia in a returned traveler. Clin Infect Dis 2010; 50:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36263/abstract/17\">",
"      Klion AD, Massougbodji A, Horton J, et al. Albendazole in human loiasis: results of a double-blind, placebo-controlled trial. J Infect Dis 1993; 168:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36263/abstract/18\">",
"      Grobusch MP, Kombila M, Autenrieth I, et al. No evidence of Wolbachia endosymbiosis with Loa loa and Mansonella perstans. Parasitol Res 2003; 90:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36263/abstract/19\">",
"      Brouqui P, Fournier PE, Raoult D. Doxycycline and eradication of microfilaremia in patients with loiasis. Emerg Infect Dis 2001; 7:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36263/abstract/20\">",
"      Nor&otilde;es J, Dreyer G, Santos A, et al. Assessment of the efficacy of diethylcarbamazine on adult Wuchereria bancrofti in vivo. Trans R Soc Trop Med Hyg 1997; 91:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36263/abstract/21\">",
"      Bockarie MJ, Alexander ND, Hyun P, et al. Randomised community-based trial of annual single-dose diethylcarbamazine with or without ivermectin against Wuchereria bancrofti infection in human beings and mosquitoes. Lancet 1998; 351:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36263/abstract/22\">",
"      Nicolas L, Plichart C, Nguyen LN, Moulia-Pelat JP. Reduction of Wuchereria bancrofti adult worm circulating antigen after annual treatments of diethylcarbamazine combined with ivermectin in French Polynesia. J Infect Dis 1997; 175:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36263/abstract/23\">",
"      Ottesen EA. Efficacy of diethylcarbamazine in eradicating infection with lymphatic-dwelling filariae in humans. Rev Infect Dis 1985; 7:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36263/abstract/24\">",
"      Wahl G, Georges AJ. Current knowledge on the epidemiology, diagnosis, immunology, and treatment of loiasis. Trop Med Parasitol 1995; 46:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36263/abstract/25\">",
"      Drugs for parasitic infections. Med Lett Drugs Ther 2010; 8:e20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36263/abstract/26\">",
"      Klion AD, Ottesen EA, Nutman TB. Effectiveness of diethylcarbamazine in treating loiasis acquired by expatriate visitors to endemic regions: long-term follow-up. J Infect Dis 1994; 169:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36263/abstract/27\">",
"      Awadzi K, Hero M, Opoku O, et al. The chemotherapy of onchocerciasis. XV. Studies with albendazole. Trop Med Parasitol 1991; 42:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36263/abstract/28\">",
"      Kamgno J, Boussinesq M. Effect of a single dose (600 mg) of albendazole on Loa loa microfilaraemia. Parasite 2002; 9:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36263/abstract/29\">",
"      Klion AD, Horton J, Nutman TB. Albendazole therapy for loiasis refractory to diethylcarbamazine treatment. Clin Infect Dis 1999; 29:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36263/abstract/30\">",
"      Tabi TE, Befidi-Mengue R, Nutman TB, et al. Human loiasis in a Cameroonian village: a double-blind, placebo-controlled, crossover clinical trial of a three-day albendazole regimen. Am J Trop Med Hyg 2004; 71:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36263/abstract/31\">",
"      Martin-Prevel Y, Cosnefroy JY, Ngari P, Pinder M. Reduction of microfilaraemia with single high-dose of ivermectin in loiasis. Lancet 1993; 342:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36263/abstract/32\">",
"      Martin-Prevel Y, Cosnefroy JY, Tshipamba P, et al. Tolerance and efficacy of single high-dose ivermectin for the treatment of loiasis. Am J Trop Med Hyg 1993; 48:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36263/abstract/33\">",
"      Chippaux JP, Bouchit&eacute; B, Boussinesq M, et al. Impact of repeated large scale ivermectin treatments on the transmission of Loa loa. Trans R Soc Trop Med Hyg 1998; 92:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36263/abstract/34\">",
"      Kombila M, Duong TH, Ferrer A, et al. Short- and long-term action of multiple doses of ivermectin on loiasis microfilaremia. Am J Trop Med Hyg 1998; 58:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36263/abstract/35\">",
"      Boussinesq M, Gardon J, Gardon-Wendel N, et al. Three probable cases of Loa loa encephalopathy following ivermectin treatment for onchocerciasis. Am J Trop Med Hyg 1998; 58:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36263/abstract/36\">",
"      Nutman TB, Miller KD, Mulligan M, et al. Diethylcarbamazine prophylaxis for human loiasis. Results of a double-blind study. N Engl J Med 1988; 319:752.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5684 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.65.66-BC5B390E05-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_26_36263=[""].join("\n");
var outline_f35_26_36263=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15717989\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      LOA LOA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Life cycle",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Calabar swellings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5118751\">",
"      - Eye symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Other complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5118872\">",
"      - Laboratory abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Visualizing organisms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Serology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Other tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15717704\">",
"      - Clinical approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Diethylcarbamazine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Albendazole",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Ivermectin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H254240\">",
"      - Onchocerciasis coinfection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15717989\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H177323013\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/5684\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5684|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?8/43/8889\" title=\"figure 1\">",
"      Loiasis prevalence map",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?18/56/19335\" title=\"figure 2\">",
"      Loa loa life cycle",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5684|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?9/41/9878\" title=\"picture 1\">",
"      Loa loa eye worm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?9/44/9922\" title=\"picture 2\">",
"      Calabar swelling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?25/4/25666\" title=\"picture 3\">",
"      Loa loa blood smear",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/56/15241?source=related_link\">",
"      Diagnosis, treatment, and prevention of lymphatic filariasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/25/13719?source=related_link\">",
"      Epidemiology, pathogenesis, and clinical manifestations of lymphatic filariasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/30/20970?source=related_link\">",
"      Onchocerciasis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_26_36264="Tardive dyskinesia: Etiology and epidemiology";
var content_f35_26_36264=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Tardive dyskinesia: Etiology and epidemiology",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/26/36264/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/26/36264/contributors\">",
"     Daniel Tarsy, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/26/36264/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/26/36264/contributors\">",
"     Howard I Hurtig, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/26/36264/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/26/36264/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/26/36264/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tardive dyskinesia (TD) is a hyperkinetic movement disorder that appears with a delayed onset after prolonged use of dopamine receptor blocking agents, mainly the antipsychotic drugs (also called neuroleptics) and the antiemetic drug,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36264/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    TD has numerous clinical manifestations that include chorea, athetosis, dystonia, akathisia, stereotyped behaviors, and rarely tremor. The term \"tardive\" differentiates these dyskinesias from acute dyskinesia, parkinsonism, and akathisia, which appear very soon after exposure to antipsychotic drugs.",
"   </p>",
"   <p>",
"    This topic will review the etiology and epidemiology of TD. Other aspects of this condition are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/40/27269?source=see_link\">",
"     \"Tardive dyskinesia: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/8/34952?source=see_link\">",
"     \"Tardive dyskinesia: Prevention and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tardive dyskinesia (TD) is a unique complication of antipsychotic drugs and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    ; convincing cases have not occurred after the chronic use of antidepressants or anti-anxiety medications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36264/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Pathophysiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prolonged and often irreversible course of TD suggests that structural cellular alterations in the brain are responsible for the disorder. However, pathologic studies in laboratory animals and humans have failed to demonstrate consistent findings following chronic exposure to antipsychotic drugs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36264/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The uniform capacity of antipsychotic drugs to block postsynaptic dopamine receptors seems a likely mechanism for the development of both antipsychotic drug-induced extrapyramidal reactions and TD. In animal models, repeated treatment with antipsychotic drugs leads to dopamine receptor supersensitivity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36264/abstract/1,4\">",
"     1,4",
"    </a>",
"    ]. In humans, there is evidence for upregulation of striatal dopamine receptors following chronic antipsychotic drug exposure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36264/abstract/5\">",
"     5",
"    </a>",
"    ], but correlation with clinical evidence of TD is uncertain. In addition, dopamine supersensitivity in animal models is a universal and rapidly appearing pharmacologic phenomenon that lasts for only several weeks. This raises some doubt about its relevance to TD in humans, where it is possible that more lasting structural changes in neurons or receptors may have taken place.",
"   </p>",
"   <p>",
"    An updated version of the dopamine hypothesis suggests that an imbalance between D1 and D2 receptor-mediated effects in the basal ganglia may be responsible for TD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36264/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. According to this theory, traditional antipsychotic drugs preferentially block D2 receptors, resulting in excessive activity of D1-mediated striatopallidal output, altered firing patterns in medial globus pallidus, and eventual evolution of the clinical features of TD. This model explains the low tendency of the second-generation antipsychotic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    to cause TD, since clozapine produces relatively less D2 and relatively more D1 blockade.",
"   </p>",
"   <p>",
"    The development of TD may also involve changes in other basal ganglia neuronal systems. TD could result from loss of striatal interneurons that exert a feedback influence on nigrostriatal dopamine neurons and also form part of an efferent output pathway from the basal ganglia. Such interneurons may utilize gamma-aminobutyric acid (GABA), acetylcholine, or peptides as their neurotransmitter.",
"   </p>",
"   <p>",
"    Of these possibilities, the GABA hypothesis has been given the most consideration. Chronic treatment of monkeys with antipsychotic drugs over a period of several years has produced persistent dyskinesia and reduced GABA and glutamic acid decarboxylase levels in several regions of the basal ganglia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36264/abstract/8\">",
"     8",
"    </a>",
"    ]. An excitotoxic mechanism may account for this selective destruction of a localized population of basal ganglia neurons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36264/abstract/9\">",
"     9",
"    </a>",
"    ]. According to this hypothesis, chronic blockade of D2 receptors may lead to increased release of glutamate within the striatum, thereby causing excitotoxic destruction of striatopallidal GABA and peptide-containing neurons.",
"   </p>",
"   <p>",
"    There are two potential mechanisms by which this might occur: First, interference with the inhibitory action of dopamine on corticostriatal terminal D2 receptors could cause excessive release of glutamate in the striatum, leading to degeneration of striatopallidal GABA and peptide neurons; second, blockade of nigrostriatal dopamine activity could, as in Parkinson disease, lead to increased firing of glutamate-mediated subthalamic neurons causing excitotoxic degeneration of globus pallidus neurons. A possible role of free radicals generated by increased neuronal dopamine turnover caused by antipsychotic drugs has also been considered [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36264/abstract/10\">",
"     10",
"    </a>",
"    ]. The major flaw in this hypothetical excitotoxic cascade is the lack of supporting pathologic evidence from animal and human brain tissue.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prevalence estimates of TD at a specific time have several limitations when used to establish risks in different patient populations or in those with different treatment exposures. Antipsychotic drugs cause TD but can also mask its manifestations by their hypokinetic effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36264/abstract/11\">",
"     11",
"    </a>",
"    ]. The severity of TD often fluctuates with behavioral and emotional arousal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36264/abstract/12\">",
"     12",
"    </a>",
"    ], and differences in population age, gender, treatment duration, and type and dose of antipsychotic drugs add complexity to the ascertainment process [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36264/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Misclassification of spontaneous dyskinesia (ie, dyskinesia occurring independent of antipsychotic drug treatment) may inflate prevalence estimates of TD. Spontaneous orofacial dyskinesia are common in persons older than age 65 even without exposure to antipsychotic drugs; point-prevalence estimates have ranged from 3 to 77 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36264/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence of new cases of TD appearing in a population during a specified period of exposure is a better measure of risk than cross-sectional estimates of prevalence at a particular observation point. However, incidence data are much more difficult to acquire since they require repeated observations over time.",
"   </p>",
"   <p>",
"    The prevalence and incidence data for TD associated with first-generation (conventional) antipsychotic drugs and second-generation antipsychotic drugs are reviewed in the following sections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     FIRST-GENERATION ANTIPSYCHOTIC DRUGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;When first described in the 1960s, the frequency of TD was widely regarded to be low. This misperception was due to a failure of patients with chronic psychosis to complain of dyskinesia, and to the limited familiarity of movement disorders among psychiatric clinicians [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36264/abstract/12,16\">",
"     12,16",
"    </a>",
"    ]. By the late 1970s, it became apparent that the prevalence of TD was substantial, ranging from 5 to 45 percent in patients with psychiatric disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36264/abstract/11,17\">",
"     11,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An influential report from 1982 analyzed 56 studies involving nearly 35,000 patients treated with antipsychotic drugs and estimated the overall prevalence of TD to be 20 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36264/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. In 19 studies involving 11,000 patients not exposed to antipsychotic drugs, the prevalence of spontaneous dyskinesia was approximately 5 percent, suggesting a best-estimate, corrected rate for antipsychotic drug-associated TD of about 15 percent (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/24/7562?source=see_link\">",
"     \"First-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\"",
"    </a>",
"    .).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Incidence of tardive dyskinesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most prospective studies of patients treated with conventional antipsychotics suggest the annual incidence of TD is between 3 and 8 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36264/abstract/19-22\">",
"     19-22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beginning in 1977, the Hillside study enrolled 908 consecutive patients (19 to 40 years old) who were admitted to a single psychiatric hospital in New York [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/26/36264/abstract/20,21\">",
"       20,21",
"      </a>",
"      ]. These patients were followed for up to 20 years, and monitored for the presence of dyskinesia. Most subjects had only several months of exposure to antipsychotic drugs at study entry. Psychiatric diagnoses included schizophrenia, affective disorder, schizoaffective disorder, and other conditions. Fifty-one patients (5.6 percent) met diagnostic criteria for TD at initial evaluation or had a prior diagnosis of probable TD. All patients were treated with conventional and predominantly high-potency antipsychotic agents, such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/50/32553?source=see_link\">",
"       haloperidol",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/10/38055?source=see_link\">",
"       fluphenazine",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The cumulative incidence of TD after antipsychotic drug exposure of 1, 5, and 10 years was 5, 27 and 43 percent, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/26/36264/abstract/23\">",
"       23",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      The cumulative incidence of persistent TD lasting for at least three months at 1, 5, and 10 years was 3, 20 and 34 percent, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/26/36264/abstract/23\">",
"       23",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These rates suggest an overall annual TD incidence of approximately 5 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36264/abstract/23\">",
"     23",
"    </a>",
"    ]. For TD persisting for at least three months, they suggest an annual incidence of approximately 3 percent, and an early spontaneous annual remission rate of approximately 2 percent.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Yale study obtained similar results in 362 patients treated with antipsychotic drugs, most of whom had chronic schizophrenia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/26/36264/abstract/24,25\">",
"       24,25",
"      </a>",
"      ]. Although previous antipsychotic drug exposure (mean 8 years) was 14 times longer than in the Hillside study, and age was greater (median 41 versus 30 years old), none was considered to have TD at study entry. For TD persisting at least six months, the cumulative five-year incidence was 25 percent, remarkably similar to the incidence of persistent TD in the Hillside study [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/26/36264/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Incidence in the elderly",
"    </span>",
"    &nbsp;&mdash;&nbsp;Older patients appear to have a higher incidence of TD than younger patients.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Hillside group prospectively analyzed 261 patients older than 55 years who were naive to antipsychotic drugs, of whom 63 percent had dementia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/26/36264/abstract/26\">",
"       26",
"      </a>",
"      ]. After beginning treatment with antipsychotic drugs, they were examined quarterly for 2.2 years, during which time TD developed in 23 percent. TD persisted for at least six months in two-thirds of those who developed TD.",
"     </li>",
"     <li>",
"      Another prospective study followed 266 patients (mean age 65 years) with psychiatric disorders but without dyskinesia at study entry who had relatively brief prior exposure to antipsychotic drug treatment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/26/36264/abstract/27\">",
"       27",
"      </a>",
"      ]. The cumulative incidence of TD at one and three years was 26 and 60 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These data suggest that the annual incidence of TD among older patients, during continuous exposure to a variety of potent antipsychotic drugs, is approximately 10 to 20 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     SECOND-GENERATION ANTIPSYCHOTIC DRUGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The introduction of second-generation antipsychotic drugs, also known as atypical neuroleptics, anticipated a lower risk of acute extrapyramidal reactions and TD because of the weaker affinity of these drugs for blocking the dopamine receptor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36264/abstract/13,28-30\">",
"     13,28-30",
"    </a>",
"    ]. The common term \"atypical\" emphasizes the relative freedom of second-generation antipsychotic drugs from risks of acute extrapyramidal reactions \"typical\" of older conventional antipsychotic drugs. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/10/15530?source=see_link\">",
"     \"Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Second-generation antipsychotic drugs approved for general clinical use in the United States include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/11/43193?source=see_link\">",
"     aripiprazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/39/4728?source=see_link\">",
"     ziprasidone",
"    </a>",
"    . It is commonly stated that these drugs have lower risks of causing acute dystonia and parkinsonism than the conventional antipsychotic drugs, and produce less cataleptic and other motor-inhibitory effects in laboratory animals. However, evidence from large prospective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36264/abstract/31\">",
"     31",
"    </a>",
"    ] and retrospective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36264/abstract/32\">",
"     32",
"    </a>",
"    ] studies comparing first and second generation antipsychotic drugs indicate that any difference between these medication classes in the incidence of acute extrapyramidal side effects may be less than originally thought, or even negligible.",
"   </p>",
"   <p>",
"    Pharmacologically, second-generation antipsychotic drugs are characterized by relatively low affinity for, or rapid dissociation from, dopamine D2 receptors, thereby limiting antagonistic actions at these receptors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36264/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. In addition, these agents often have potent antagonism at serotonin 5HT2A receptors.",
"   </p>",
"   <p>",
"    Nevertheless, some second-generation antipsychotic drugs, including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/11/43193?source=see_link\">",
"     aripiprazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/39/4728?source=see_link\">",
"     ziprasidone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    , particularly at relatively high doses, have risks of acute extrapyramidal reactions that overlap those of the conventional antipsychotic drugs of moderate or low potency. In addition, all antipsychotic drugs appear to have some risk of akathisia. Antipsychotic drugs have also been associated with rare instances of neuroleptic malignant syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Risk of tardive dyskinesia among second-generation antipsychotic drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among second-generation antipsychotic drugs,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    has an unusually low risk for acute extrapyramidal reactions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36264/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. Reports of TD attributable to clozapine have been rare and unconvincing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36264/abstract/23,37\">",
"     23,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the prospective Hillside study, 28 patients with psychosis and an average of six years of previous antipsychotic drug exposure at baseline, but no definite preexisting TD, were treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    and followed for one year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36264/abstract/37\">",
"     37",
"    </a>",
"    ]. Two patients (7.1 percent) developed TD that persisted for at least five years. Although neither patient met criteria for definite TD at study entry, both had evidence of some abnormal involuntary movements, raising suspicion that the later dyskinesia was attributable to prior antipsychotic drug use and not to clozapine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36264/abstract/3\">",
"     3",
"    </a>",
"    ]. In any case, clozapine treatment was associated with a significantly lower cumulative incidence of TD when compared with conventional antipsychotic drug treatment in another group of patients from the same clinic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36264/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among patients never previously exposed to conventional antipsychotic drugs, a review published in 2006 identified 13 reports of TD that developed in patients treated exclusively with second-generation antipsychotic drugs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36264/abstract/23\">",
"     23",
"    </a>",
"    ], including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/39/4728?source=see_link\">",
"     ziprasidone",
"    </a>",
"    . Risperidone was the drug used in 10 of these 13 cases.",
"   </p>",
"   <p>",
"    The same study identified 39 reports of patients with previous exposure to conventional antipsychotic drugs who developed new TD during long-term treatment with second-generation antipsychotic drugs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36264/abstract/23\">",
"     23",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/33/11802?source=see_link\">",
"     Risperidone",
"    </a>",
"    , which has been in clinical use longer than any second-generation antipsychotic drug other than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    , was implicated in 22 of these 39 TD cases (56 percent). The remaining drugs associated with TD were",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    (n = 6),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/39/4728?source=see_link\">",
"     ziprasidone",
"    </a>",
"    (n = 5), clozapine (n = 4), and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    (n = 2). Emergence of TD after withdrawal of previous conventional antipsychotic drugs probably account for at least some of these cases.",
"   </p>",
"   <p>",
"    Compared with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    , later introduction into the market and less clinical use may account for the small numbers of TD cases associated with other second-generation antipsychotic drugs such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/39/4728?source=see_link\">",
"     ziprasidone",
"    </a>",
"    . However, this reasoning does not explain the rarity of TD cases associated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    , which has been in use for several decades.",
"   </p>",
"   <p>",
"    Despite severe limitations, these case reports suggest that most second-generation antipsychotic drugs, other than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    , carry some risk for TD, and that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    and perhaps",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    may have a greater risk of TD than other second-generation antipsychotic drugs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36264/abstract/23\">",
"     23",
"    </a>",
"    ]. Nevertheless, second-generation antipsychotic drugs vary markedly in their neuropharmacologic properties and risks of acute extrapyramidal reactions, making it unwise to assume that all are equivalent in risks for TD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36264/abstract/34,36,38\">",
"     34,36,38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Is the rate of tardive dyskinesia declining?",
"    </span>",
"    &nbsp;&mdash;&nbsp;With increased use of second-generation antipsychotic drugs, the prevalence of TD was expected to decline, but data are conflicting.",
"   </p>",
"   <p>",
"    Several studies published from 1996 to 2002 reported TD prevalence rates of 16 to 43 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36264/abstract/39-42\">",
"     39-42",
"    </a>",
"    ], suggesting that risk of TD was similar to that found in earlier studies with the use of conventional antipsychotic drugs. However, these studies did not separate patients who received only second-generation antipsychotic drugs from those who received prior or concurrent conventional antipsychotic drug treatment.",
"   </p>",
"   <p>",
"    In contrast, a systematic review that evaluated four cross-sectional studies published or presented from 2004 through 2007 found that the prevalence of TD was significantly lower in adult patients taking second-generation antipsychotic drugs than in those taking conventional antipsychotics (13 percent [95% CI 11.1-15.2] versus 32.4 percent [95% CI 29.0 to 35.9]) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36264/abstract/43\">",
"     43",
"    </a>",
"    ]. Furthermore, in 57 patients treated with second-generation antipsychotic drugs who had no prior antipsychotic drug exposure, the prevalence of TD was 5.3 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SECOND- VERSUS FIRST-GENERATION ANTIPSYCHOTIC DRUGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of TD is probably lower with second-generation than with conventional (first-generation) antipsychotic drugs. However, there is mounting evidence that the incidence of TD associated with second-generation agents is higher than first reported. The following reports illustrate this issue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36264/abstract/43,44\">",
"     43,44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A systematic review published in 2004 analyzed 11 studies of at least one year duration that examined second-generation antipsychotic drug treatment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/26/36264/abstract/44\">",
"       44",
"      </a>",
"      ]. The studies included a total of 2769 subjects (average age 45 years); schizophrenia was the diagnosis in 82 percent. The following observations were reported:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Across all 11 studies, the mean annual incidence of TD associated with second-generation antipsychotic drugs was 2.1 percent.",
"     </li>",
"     <li>",
"      In three studies that directly compared treatment using a second-generation antipsychotic drug with a conventional antipsychotic (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/50/32553?source=see_link\">",
"       haloperidol",
"      </a>",
"      ) in young and middle-aged adults (mean age 39 years, range 18 to 65), the mean annual incidence of TD was approximately five- to six-fold lower with second-generation antipsychotic drugs than with haloperidol (&lt;1 percent versus 5.4 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A later systematic review from the same investigators identified antipsychotic drug treatment studies of at least one year duration published or presented from 2004 to 2007 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/26/36264/abstract/43\">",
"       43",
"      </a>",
"      ]. Included were 12 studies with over 28,000 patients (mean age 40 years; dementia was the diagnosis in 92 percent) that reported TD incidence rates. The following observations were noted:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Across all studies and age groups, the annual incidence rate of TD was significantly lower with second-generation antipsychotic drugs than with conventional antipsychotic drugs (4.0 percent [95% CI 3.6-4.3] versus 5.5 percent [95% CI 5.1-6.1]).",
"     </li>",
"     <li>",
"      In six studies directly comparing second-generation antipsychotic drug treatment with conventional antipsychotics, there were 12,924 patients (mean age 51 years, range 25 to 83). The annual incidence rate of TD was again significantly lower with second-generation antipsychotic drugs than with conventional antipsychotic drugs (4.2 percent [95% CI 3.8-4.5] versus 5.5 percent [95% CI 5.0-6.1]).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, the earlier systematic review suggested that second-generation antipsychotic treatment reduced the risk of TD by up to six-fold compared with conventional agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36264/abstract/44\">",
"     44",
"    </a>",
"    ], while the later review suggests that the risk reduction is much less [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36264/abstract/43\">",
"     43",
"    </a>",
"    ]. However, these data are not definitive for the following reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most findings are based primarily on short-term studies not designed to address TD risk.",
"     </li>",
"     <li>",
"      Few of the studies included specific neurologic assessments.",
"     </li>",
"     <li>",
"      The studies included very few patients not previously exposed to conventional antipsychotic drugs that may also contribute to TD risk.",
"     </li>",
"     <li>",
"      In the earlier systematic review, the three studies with a comparator used",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/50/32553?source=see_link\">",
"       haloperidol",
"      </a>",
"      , a high-potency conventional antipsychotic drug, sometimes given in relatively high doses [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/26/36264/abstract/44\">",
"       44",
"      </a>",
"      ]. The later systematic review covering 2004 to 2007 included several studies that used moderately dosed, mid-potency conventional antipsychotics [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/26/36264/abstract/43\">",
"       43",
"      </a>",
"      ]. Furthermore, most patients in the earlier systematic review had schizophrenia, while most in the later review had dementia.",
"     </li>",
"     <li>",
"      A majority of the included studies in the 2004 to 2007 review used nonstandard definitions of TD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/26/36264/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Interpretation of such findings is further complicated by spontaneous remission of TD over time and by suppression of dyskinetic symptoms by antipsychotic drug treatment, even with second-generation agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36264/abstract/25,45-47\">",
"     25,45-47",
"    </a>",
"    ], possibly resulting in a misleadingly low incidence of TD. However, since several prospective studies excluded patients with dyskinesia at baseline, suppression of TD is unlikely to entirely account for the lower rates of new TD cases observed during treatment with second-generation antipsychotic drugs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36264/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Conclusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;While the risk of TD is probably lower with most second-generation antipsychotic drugs than with high-potency conventional antipsychotic drugs, the risk with second-generation agents is not necessarily lower than that associated with low-potency conventional antipsychotic drugs taken at moderate doses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36264/abstract/38\">",
"     38",
"    </a>",
"    ]. TD still occurs with second-generation agents other than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    , possibly most often with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36264/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Further studies of patients never treated with first-generation antipsychotic drugs and exposed to only a single second-generation antipsychotic drug are necessary to establish and quantify any hypothesized decline in the incidence of TD in association with use of particular drugs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     METOCLOPRAMIDE",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/13/216?source=see_link\">",
"     Metoclopramide",
"    </a>",
"    is a dopamine receptor antagonist that blocks both D1 and D2 receptors in the central nervous system. When given in higher doses, it also blocks serotonin receptors.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/13/216?source=see_link\">",
"     Metoclopramide",
"    </a>",
"    is used primarily as an antiemetic agent,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    as a prokinetic agent for the treatment of gastroparesis. It is approved in the US by the FDA for short-term therapy (&le;12 weeks) of gastroesophageal reflux, and for treatment of diabetic gastroparesis (&le;8 weeks). However, gastroparesis is a chronic condition, and some patients have been exposed to long-term metoclopramide use.",
"   </p>",
"   <p>",
"    Accumulating evidence, mainly retrospective, suggests that chronic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    use is a major cause of TD in adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36264/abstract/2,48-51\">",
"     2,48-51",
"    </a>",
"    ]. However, the precise incidence and prevalence of metoclopramide-induced TD is unclear.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a case-control study, patients treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/13/216?source=see_link\">",
"       metoclopramide",
"      </a>",
"      had a higher risk of developing TD than controls, but the finding did not achieve statistical significance (relative risk [RR] 1.67, 95% CI 0.93-2.97) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/26/36264/abstract/2\">",
"       2",
"      </a>",
"      ]. Metoclopramide treatment was associated with a significantly increased risk of drug-induced parkinsonism (RR 4.0, 95% CI 1.5-10.5) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/26/36264/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study that included 10 patients treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/13/216?source=see_link\">",
"       metoclopramide",
"      </a>",
"      who developed TD, the average duration of metoclopramide exposure before TD onset was approximately one year [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/26/36264/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In some referral centers,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/13/216?source=see_link\">",
"       metoclopramide",
"      </a>",
"      has replaced",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/50/32553?source=see_link\">",
"       haloperidol",
"      </a>",
"      as the medication most commonly associated with TD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/26/36264/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     RISK FACTORS FOR TD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Older age is the most robust risk factor for TD.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study found that the incidence of new cases of TD for patients exposed to conventional antipsychotic drugs was three to five times greater in patients above age 50 than in younger patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/26/36264/abstract/20\">",
"       20",
"      </a>",
"      ]. In addition, the prevalence of TD was five to six times greater in patients older than age 65 when compared with younger patients.",
"     </li>",
"     <li>",
"      In two systematic reviews evaluating second-generation antipsychotic drugs, the incidence of TD was very low in studies involving children, higher in studies involving predominantly middle-aged adults, and highest in studies involving older adults [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/26/36264/abstract/43,44\">",
"       43,44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Rates of spontaneous TD remission decrease with increasing age [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/26/36264/abstract/18,52\">",
"       18,52",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other factors that have been tentatively associated with greater prevalence of TD include female sex, brain damage, dementia, major affective disorder, diabetes, longer duration of antipsychotic drug exposure, use of anticholinergic-antiparkinson drugs, and a history of previous acute extrapyramidal reactions to antipsychotic drugs. Most of these associations are based on prevalence rather than incidence studies. Thus, their role as risk factors for TD is not firmly established.",
"   </p>",
"   <p>",
"    Drug exposure by dose is particularly difficult to evaluate as a potential risk factor. Dosing may be an important risk factor in elderly patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36264/abstract/26\">",
"     26",
"    </a>",
"    ], but several retrospective studies have reported little difference in TD prevalence between moderate and high doses of conventional antipsychotic drugs, or between the daily equivalent of 300 and 3000 mg of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/38/30312?source=see_link\">",
"     chlorpromazine",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36264/abstract/11\">",
"     11",
"    </a>",
"    ]. The risk of TD may already be maximal at chlorpromazine-equivalent doses of approximately 300 mg daily, which is in the mid-range of typical antipsychotic doses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36264/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a prospective study, 57 patients with first-episode psychotic disorders and no evidence of TD at baseline were treated with low-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    (mean 1.7 mg daily) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36264/abstract/53\">",
"     53",
"    </a>",
"    ]. At 12 months, dyskinesia developed in seven (12.3 percent). Although there was no control group, the incidence of apparent TD was similar to that in other prospective studies of TD incidence involving treatment with conventional antipsychotic drugs at standard doses.",
"   </p>",
"   <p>",
"    In a prospective study of 9000 patients with schizophrenia, the presence of extrapyramidal symptoms (dystonia, akathisia, or parkinsonism) at baseline predicted an increased risk for the development of TD over one year of treatment with several different antipsychotics (hazard ratio 2.0, 95% CI 1.6-2.6) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36264/abstract/54\">",
"     54",
"    </a>",
"    ]. In the prospective Hillside studies, patients with a history of severe, early extrapyramidal reactions to antipsychotic drugs developed TD more frequently than those without early extrapyramidal reactions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36264/abstract/20,26\">",
"     20,26",
"    </a>",
"    ]. However, the high rates of acute extrapyramidal reactions may have reflected use of more potent antipsychotic drugs at relatively high doses.",
"   </p>",
"   <p>",
"    Among older patients, a history of electroconvulsive treatment was a predictor of TD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36264/abstract/26\">",
"     26",
"    </a>",
"    ]. Female sex and African-American ethnicity were also identified as risk factors for TD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36264/abstract/21,24-26\">",
"     21,24-26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?1/10/1186?source=see_link\">",
"       \"Patient information: Tardive dyskinesia (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tardive dyskinesia (TD) is a unique complication of antipsychotic drugs and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/13/216?source=see_link\">",
"       metoclopramide",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The ability of antipsychotic drugs to block postsynaptic dopamine receptors is a potential mechanism for the development of TD. An updated version of the dopamine hypothesis suggests that an imbalance between D1 and D2 receptor-mediated effects in the basal ganglia may be responsible for TD. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients treated with conventional (first-generation) antipsychotic drugs, the annual incidence of TD is approximately 3 and 8 percent overall, and approximately 10 to 20 percent in those older than 55 years. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'First-generation antipsychotic drugs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among second-generation antipsychotic drugs, also known as atypical neuroleptics,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/21/35161?source=see_link\">",
"       clozapine",
"      </a>",
"      has a very low risk for TD or acute extrapyramidal reactions. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Second-generation antipsychotic drugs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      With increased use of second-generation antipsychotic drugs, the prevalence of TD was expected to decline, but data are conflicting. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Is the rate of tardive dyskinesia declining?'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The risk of TD is probably lower with most second-generation antipsychotic drugs than with high-potency conventional antipsychotic drugs. Nevertheless, it is not certain whether most second-generation antipsychotic drugs have a lower risk in comparison to low-potency conventional antipsychotic drugs taken at moderate doses. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Second- versus first-generation antipsychotic drugs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Accumulating evidence, mainly retrospective, suggests that chronic",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/13/216?source=see_link\">",
"       metoclopramide",
"      </a>",
"      use is a major cause of TD in adults. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Metoclopramide'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Older age is the most robust risk factor for TD. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Risk factors for TD'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36264/abstract/1\">",
"      Tarsy D, Baldessarini RJ. Tardive dyskinesia. Annu Rev Med 1984; 35:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36264/abstract/2\">",
"      Ganzini L, Casey DE, Hoffman WF, McCall AL. The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders. Arch Intern Med 1993; 153:1469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36264/abstract/3\">",
"      Harrison PJ. The neuropathological effects of antipsychotic drugs. Schizophr Res 1999; 40:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36264/abstract/4\">",
"      Tarsy D, Baldessarini RJ. Behavioural supersensitivity to apomorphine following chronic treatment with drugs which interfere with the synaptic function of catecholamines. Neuropharmacology 1974; 13:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36264/abstract/5\">",
"      Lee T, Seeman P, Tourtellotte WW, et al. Binding of 3H-neuroleptics and 3H-apomorphine in schizophrenic brains. Nature 1978; 274:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36264/abstract/6\">",
"      Gerlach J, Hansen L. Clozapine and D1/D2 antagonism in extrapyramidal functions. Br J Psychiatry Suppl 1992; :34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36264/abstract/7\">",
"      Trugman, JM. Tardive dyskinesia: Diagnosis, pathogenesis, and management. The Neurologist 1998; 4:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36264/abstract/8\">",
"      Gunne LM, H&auml;ggstr&ouml;m JE, Sj&ouml;quist B. Association with persistent neuroleptic-induced dyskinesia of regional changes in brain GABA synthesis. Nature 1984; 309:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36264/abstract/9\">",
"      De Keyser J. Excitotoxic mechanisms may be involved in the pathophysiology of tardive dyskinesia. Clin Neuropharmacol 1991; 14:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36264/abstract/10\">",
"      Lohr JB, Kuczenski R, Niculescu AB. Oxidative mechanisms and tardive dyskinesia. CNS Drugs 2003; 17:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36264/abstract/11\">",
"      Tardive dyskinesia: summary of a Task Force Report of the American Psychiatric Association. By the Task Force on Late Neurological Effects of Antipsychotic Drugs. Am J Psychiatry 1980; 137:1163.",
"     </a>",
"    </li>",
"    <li>",
"     Lohr, JB. Commentary: Is tardive dyskinesia disappearing? In: Drug Induced Movement Disorders, Factor, SA, Lang, AE, Weiner, WJ, Lang, AE (Eds), Futura-Blackwell Publishing, Malden MA 2004. p.302.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36264/abstract/13\">",
"      Kane JM. Tardive dyskinesia rates with atypical antipsychotics in adults: prevalence and incidence. J Clin Psychiatry 2004; 65 Suppl 9:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36264/abstract/14\">",
"      Fenton WS, Blyler CR, Wyatt RJ, McGlashan TH. Prevalence of spontaneous dyskinesia in schizophrenic and non-schizophrenic psychiatric patients. Br J Psychiatry 1997; 171:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36264/abstract/15\">",
"      Blanchet PJ, Abdillahi O, Beauvais C, et al. Prevalence of spontaneous oral dyskinesia in the elderly: a reappraisal. Mov Disord 2004; 19:892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36264/abstract/16\">",
"      Weiden PJ, Mann JJ, Haas G, et al. Clinical nonrecognition of neuroleptic-induced movement disorders: a cautionary study. Am J Psychiatry 1987; 144:1148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36264/abstract/17\">",
"      Jeste DV, Wyatt RJ. Changing epidemiology of tardive dyskinesia: an overview. Am J Psychiatry 1981; 138:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36264/abstract/18\">",
"      Smith JM, Baldessarini RJ. Changes in prevalence, severity, and recovery in tardive dyskinesia with age. Arch Gen Psychiatry 1980; 37:1368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36264/abstract/19\">",
"      Kane JM, Smith JM. Tardive dyskinesia: prevalence and risk factors, 1959 to 1979. Arch Gen Psychiatry 1982; 39:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36264/abstract/20\">",
"      Kane JM, Woerner M, Weinhold P, et al. A prospective study of tardive dyskinesia development: preliminary results. J Clin Psychopharmacol 1982; 2:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36264/abstract/21\">",
"      Kane JM, Woerner M, Borenstein M, et al. Integrating incidence and prevalence of tardive dyskinesia. Psychopharmacol Bull 1986; 22:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36264/abstract/22\">",
"      Glazer WM. Review of incidence studies of tardive dyskinesia associated with typical antipsychotics. J Clin Psychiatry 2000; 61 Suppl 4:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36264/abstract/23\">",
"      Tarsy D, Baldessarini RJ. Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics? Mov Disord 2006; 21:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36264/abstract/24\">",
"      Morgenstern H, Glazer WM. Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale Tardive Dyskinesia Study. Arch Gen Psychiatry 1993; 50:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36264/abstract/25\">",
"      Glazer WM, Morgenstern H, Doucette JT. Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications. J Clin Psychiatry 1993; 54:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36264/abstract/26\">",
"      Woerner MG, Alvir JM, Saltz BL, et al. Prospective study of tardive dyskinesia in the elderly: rates and risk factors. Am J Psychiatry 1998; 155:1521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36264/abstract/27\">",
"      Jeste DV, Caligiuri MP, Paulsen JS, et al. Risk of tardive dyskinesia in older patients. A prospective longitudinal study of 266 outpatients. Arch Gen Psychiatry 1995; 52:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36264/abstract/28\">",
"      Friedman JH. Historical perspective on movement disorders. J Clin Psychiatry 2004; 65 Suppl 9:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36264/abstract/29\">",
"      Jeste DV. Tardive dyskinesia rates with atypical antipsychotics in older adults. J Clin Psychiatry 2004; 65 Suppl 9:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36264/abstract/30\">",
"      Chouinard G. New nomenclature for drug-induced movement disorders including tardive dyskinesia. J Clin Psychiatry 2004; 65 Suppl 9:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36264/abstract/31\">",
"      Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353:1209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36264/abstract/32\">",
"      Leucht S, Wahlbeck K, Hamann J, Kissling W. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 2003; 361:1581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36264/abstract/33\">",
"      Kapur S, Seeman P. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis. Am J Psychiatry 2001; 158:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36264/abstract/34\">",
"      Miyamoto S, Duncan GE, Marx CE, Lieberman JA. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry 2005; 10:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36264/abstract/35\">",
"      Wahlbeck K, Cheine M, Essali A, Adams C. Evidence of clozapine's effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials. Am J Psychiatry 1999; 156:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36264/abstract/36\">",
"      Tarsy D, Baldessarini RJ, Tarazi FI. Effects of newer antipsychotics on extrapyramidal function. CNS Drugs 2002; 16:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36264/abstract/37\">",
"      Kane JM, Woerner MG, Pollack S, et al. Does clozapine cause tardive dyskinesia? J Clin Psychiatry 1993; 54:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36264/abstract/38\">",
"      Gardner DM, Baldessarini RJ, Waraich P. Modern antipsychotic drugs: a critical overview. CMAJ 2005; 172:1703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36264/abstract/39\">",
"      van Os J, Fahy T, Jones P, et al. Tardive dyskinesia: who is at risk? Acta Psychiatr Scand 1997; 96:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36264/abstract/40\">",
"      van Harten PN, Hoek HW, Matroos GE, et al. Intermittent neuroleptic treatment and risk for tardive dyskinesia: Cura&ccedil;ao Extrapyramidal Syndromes Study III. Am J Psychiatry 1998; 155:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36264/abstract/41\">",
"      Muscettola G, Barbato G, Pampallona S, et al. Extrapyramidal syndromes in neuroleptic-treated patients: prevalence, risk factors, and association with tardive dyskinesia. J Clin Psychopharmacol 1999; 19:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36264/abstract/42\">",
"      Halliday J, Farrington S, Macdonald S, et al. Nithsdale Schizophrenia Surveys 23: movement disorders. 20-year review. Br J Psychiatry 2002; 181:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36264/abstract/43\">",
"      Correll CU, Schenk EM. Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry 2008; 21:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36264/abstract/44\">",
"      Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 2004; 161:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36264/abstract/45\">",
"      Gardos G, Casey DE, Cole JO, et al. Ten-year outcome of tardive dyskinesia. Am J Psychiatry 1994; 151:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36264/abstract/46\">",
"      Fernandez HH, Krupp B, Friedman JH. The course of tardive dyskinesia and parkinsonism in psychiatric inpatients: 14-year follow-up. Neurology 2001; 56:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36264/abstract/47\">",
"      Caroff SN, Mann SC, Campbell EC, Sullivan KA. Movement disorders associated with atypical antipsychotic drugs. J Clin Psychiatry 2002; 63 Suppl 4:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36264/abstract/48\">",
"      Sewell DD, Kodsi AB, Caligiuri MP, Jeste DV. Metoclopramide and tardive dyskinesia. Biol Psychiatry 1994; 36:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36264/abstract/49\">",
"      Pasricha PJ, Pehlivanov N, Sugumar A, Jankovic J. Drug Insight: from disturbed motility to disordered movement--a review of the clinical benefits and medicolegal risks of metoclopramide. Nat Clin Pract Gastroenterol Hepatol 2006; 3:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36264/abstract/50\">",
"      Miller LG, Jankovic J. Metoclopramide-induced movement disorders. Clinical findings with a review of the literature. Arch Intern Med 1989; 149:2486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36264/abstract/51\">",
"      Kenney C, Hunter C, Davidson A, Jankovic J. Metoclopramide, an increasingly recognized cause of tardive dyskinesia. J Clin Pharmacol 2008; 48:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36264/abstract/52\">",
"      Jeste DV. Tardive dyskinesia in older patients. J Clin Psychiatry 2000; 61 Suppl 4:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36264/abstract/53\">",
"      Oosthuizen PP, Emsley RA, Maritz JS, et al. Incidence of tardive dyskinesia in first-episode psychosis patients treated with low-dose haloperidol. J Clin Psychiatry 2003; 64:1075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36264/abstract/54\">",
"      Tenback DE, van Harten PN, Slooff CJ, van Os J. Evidence that early extrapyramidal symptoms predict later tardive dyskinesia: a prospective analysis of 10,000 patients in the European Schizophrenia Outpatient Health Outcomes (SOHO) study. Am J Psychiatry 2006; 163:1438.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4905 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.96.59.103-08F48505D8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_26_36264=[""].join("\n");
var outline_f35_26_36264=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Pathophysiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      FIRST-GENERATION ANTIPSYCHOTIC DRUGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Incidence of tardive dyskinesia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Incidence in the elderly",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      SECOND-GENERATION ANTIPSYCHOTIC DRUGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Risk of tardive dyskinesia among second-generation antipsychotic drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Is the rate of tardive dyskinesia declining?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SECOND- VERSUS FIRST-GENERATION ANTIPSYCHOTIC DRUGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Conclusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      METOCLOPRAMIDE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      RISK FACTORS FOR TD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/24/7562?source=related_link\">",
"      First-generation antipsychotic medications: Pharmacology, administration, and comparative side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?1/10/1186?source=related_link\">",
"      Patient information: Tardive dyskinesia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/10/15530?source=related_link\">",
"      Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/40/27269?source=related_link\">",
"      Tardive dyskinesia: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/8/34952?source=related_link\">",
"      Tardive dyskinesia: Prevention and treatment",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_26_36265="Modifying HIV antiretroviral therapy regimens";
var content_f35_26_36265=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Modifying HIV antiretroviral therapy regimens",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/26/36265/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/26/36265/contributors\">",
"     John G Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/26/36265/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/26/36265/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/26/36265/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/26/36265/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/26/36265/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Potent antiretroviral therapy (ART) has resulted in substantial reductions in mortality, progression to AIDS, opportunistic infections (OIs), and hospitalizations, particularly among those who achieve viral suppression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36265/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Viral suppression is also associated with decreased morbidity and mortality related to other comorbidities (eg, cardiovascular disease, liver disease, and nephropathy) and decreased HIV transmission to uninfected persons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36265/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. For these reasons, the 2012 HIV treatment guidelines from the United States Department of Health and Human Services (DHHS) and the International Antiviral Society (IAS)-USA panels now recommend ART for all HIV-infected patients, regardless of CD4 cell count [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36265/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/35/9786?source=see_link\">",
"     \"When to initiate antiretroviral therapy in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, the challenges of lifelong therapy include drug toxicity, the emergence of viral drug resistance, adverse drug interactions, high cost and the inconvenience of taking medications on a daily basis.",
"   </p>",
"   <p>",
"    Clinicians need to continually assess the patient for adverse events, toxicities, and adherence while on HIV therapy. This topic will address the evaluation of the patient with indications for treatment modification. The medications discussed in this topic and their classes and abbreviations are shown in the table (",
"    <a class=\"graphic graphic_table graphicRef60927 \" href=\"mobipreview.htm?24/25/24989\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Initiation of ART regimens in naive patients, the use of ART to treat acute HIV, and major clinical trials of various regimens are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/24/36234?source=see_link\">",
"     \"Selecting antiretroviral regimens for the treatment naive HIV-infected patient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/35/9786?source=see_link\">",
"     \"When to initiate antiretroviral therapy in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/42/32424?source=see_link\">",
"     \"Drug resistance testing in the clinical management of HIV infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/61/986?source=see_link\">",
"     \"Counseling HIV-infected patients regarding potential side effects of antiretroviral therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/9/32918?source=see_link\">",
"     \"Clinical trials of HIV antiretroviral therapy: CCR5 antagonists\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/34/7720?source=see_link\">",
"     \"Clinical trials of HIV antiretroviral therapy: Integrase inhibitors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/16/17672?source=see_link\">",
"     \"Clinical trials of HIV antiretroviral therapy: Protease inhibitors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/4/9287?source=see_link\">",
"     \"Clinical trials of HIV antiretroviral therapy: Non-nucleoside reverse transcriptase inhibitors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/27/14774?source=see_link\">",
"     \"Clinical trials of HIV antiretroviral therapy: Protease inhibitors versus non-nucleoside reverse transcriptase inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR CHANGING ANTIRETROVIRAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several indications for changing the antiretroviral regimen:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Toxicity",
"     </li>",
"     <li>",
"      Virologic failure",
"     </li>",
"     <li>",
"      Difficulty adhering to the regimen",
"     </li>",
"     <li>",
"      Suboptimal regimen",
"     </li>",
"     <li>",
"      Regimen simplification",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DRUG TOXICITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug toxicity can necessitate regimen modification. In a 2010 study of 1318 treatment-naive patients initiating antiretroviral therapy (ART), switches or discontinuations because of drug toxicity occurred at a rate of 22 per 100 person-years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36265/abstract/5\">",
"     5",
"    </a>",
"    ]. The most frequent adverse effects were gastrointestinal intolerance (29 percent), hypersensitivity (18 percent), central nervous system side effects (17 percent), and hepatic events (12 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36265/abstract/5\">",
"     5",
"    </a>",
"    ]. However, several of the antiretroviral medications associated with toxicity within this retrospective study (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    ) are no longer considered first-line agents, and most current first-line agents are relatively well tolerated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36265/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Thus, drug toxicity has greatly improved since the early era of combination ART.",
"   </p>",
"   <p>",
"    Patients may experience toxicities that are specific to individual medications or that may be similar for all members of a class. It is important for clinicians to distinguish between serious adverse events that can cause significant morbidity and mortality (eg, drug hypersensitivity) and other side effects that can be easily managed (eg, mild diarrhea). Some preliminary data suggest that pharmacogenetic markers may predict risk of toxicity related to certain drugs, eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/31/506?source=see_link\">",
"     atazanavir",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36265/abstract/6\">",
"     6",
"    </a>",
"    ]. Counseling patients regarding adverse events related to antiretroviral medications is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/61/986?source=see_link\">",
"     \"Counseling HIV-infected patients regarding potential side effects of antiretroviral therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Serious toxicities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serious toxicities are contraindications to continued use of the implicated drug:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/12/18633?source=see_link\">",
"       Nevirapine",
"      </a>",
"      is considered an &ldquo;alternative&rdquo; treatment option because of its association with rash and hepatotoxicity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/26/36265/abstract/3,4\">",
"       3,4",
"      </a>",
"      ]. Stevens-Johnson syndrome and toxic epidermal necrolysis can occur uncommonly in patients taking nevirapine. Risk factors for hepatotoxicity related to nevirapine use include the patient&rsquo;s immunologic status; thus, nevirapine is not recommended as first-line therapy in treatment-naive women with a baseline CD4 count above 250",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      and in treatment-naive men with a CD4 count &gt;400",
"      <span class=\"nowrap\">",
"       cells/microL.",
"      </span>",
"      However, two studies in treatment-experienced patients have demonstrated that switching to nevirapine from another regimen appears generally safe in virologically suppressed patients, regardless of CD4 cell count [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/26/36265/abstract/7,8\">",
"       7,8",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/18/37162?source=see_link&amp;anchor=H4845324#H4845324\">",
"       \"Pharmacology of non-nucleoside reverse transcriptase inhibitors\", section on 'Hepatotoxicity'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/63/31734?source=see_link\">",
"       Abacavir",
"      </a>",
"      hypersensitivity reactions (AHR) can occur within the first six weeks of treatment. However, the risk of AHR has been dramatically reduced with genetic testing to detect HLA-B*5701 prior to abacavir exposure. In fact, there have been no reported cases of abacavir hypersensitivity in patients with a negative HLA-B*5701 screening test. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/61/986?source=see_link&amp;anchor=H7#H7\">",
"       \"Counseling HIV-infected patients regarding potential side effects of antiretroviral therapy\", section on 'Abacavir hypersensitivity reaction'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Other important or common side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some mild side effects can often be managed with symptomatic treatment since many resolve after continued drug exposure (eg, drowsiness on",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    ). However, other adverse events may become more problematic after chronic administration. Adverse events can often be managed by switching to an alternative agent. The following are illustrative examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lipid abnormalities may be seen with all protease inhibitors, but are less frequent with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/31/506?source=see_link\">",
"       atazanavir",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/39/36473?source=see_link\">",
"       darunavir",
"      </a>",
"      ; this may prompt switching from certain protease inhibitors (PIs) (eg, boosted lopinavir) to agents associated with better lipid profiles such as: a) boosted atazanavir, b) the integrase inhibitor,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/27/10678?source=see_link\">",
"       raltegravir",
"      </a>",
"      , or c) the NNRTI,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15798?source=see_link\">",
"       rilpivirine",
"      </a>",
"      . The alternative is to manage drug-associated hyperlipidemia with statins. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/3/49?source=see_link\">",
"       \"Management of dyslipidemia and cardiovascular risk in the HIV-infected patient\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Increased transaminase levels are usually asymptomatic and most elevations revert to normal levels despite continuation of the implicated drugs. However, some authorities recommend careful monitoring when aminotransferases reach five times the upper limit of normal (grade 3 toxicity) and discontinuation of medications when the aminotransferases are greater than 10 times the upper limit of normal (grade 4 toxicity) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/26/36265/abstract/9\">",
"       9",
"      </a>",
"      ]. ART should also be stopped in the event of symptomatic hepatotoxicity (eg, right upper quadrant pain, nausea, vomiting, jaundice). Clinicians should be aware that the risk of drug-induced liver injury is higher in patients with underlying chronic viral hepatitis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/32/30218?source=see_link&amp;anchor=H32#H32\">",
"       \"Epidemiology, natural history, and diagnosis of hepatitis C in the HIV-infected patient\", section on 'HCV and risk of hepatotoxicity with ART'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Although considered generally safe [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/26/36265/abstract/10\">",
"       10",
"      </a>",
"      ],",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"       tenofovir",
"      </a>",
"      has been associated with mild changes in renal function with long-term administration, particularly among patients with other risk factors for renal insufficiency (eg, diabetes, hypertension) and in those taking concomitant PIs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/26/36265/abstract/11\">",
"       11",
"      </a>",
"      ]. Tenofovir is not recommended among patients with a creatinine clearance &lt;50",
"      <span class=\"nowrap\">",
"       mL/min,",
"      </span>",
"      but can be administered once weekly to patients on hemodialysis. Tenofovir use is also rarely associated with the Fanconi syndrome, which is characterized by defects in bicarbonate and phosphate reabsorption [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/26/36265/abstract/12\">",
"       12",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/15/41209?source=see_link&amp;anchor=H11211178#H11211178\">",
"       \"Pharmacology of nucleoside reverse transcriptase inhibitors\", section on 'Use in patients with renal or hepatic insufficiency'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Rash is common with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"       efavirenz",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?13/0/13320?source=see_link\">",
"       etravirine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/12/18633?source=see_link\">",
"       nevirapine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15798?source=see_link\">",
"       rilpivirine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/31/506?source=see_link\">",
"       atazanavir",
"      </a>",
"      . Most rashes are mild and do not require medication discontinuation and most resolve quickly during continued administration. However, the implicated drug should be stopped if the rash is associated with fever, blistering, oral mucous membrane involvement, or arthralgias (eg, suspected hypersensitivity secondary to nevirapine or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/63/31734?source=see_link\">",
"       abacavir",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/18/37162?source=see_link\">",
"       \"Pharmacology of non-nucleoside reverse transcriptase inhibitors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Full-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"       ritonavir",
"      </a>",
"      (600 mg twice daily) was very poorly tolerated due to severe diarrhea and is no longer used; however, low-dose ritonavir (100 to 200 mg daily), which is given for pharmacokinetic boosting of all recommended first-line PIs (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/39/36473?source=see_link\">",
"       darunavir",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/31/506?source=see_link\">",
"       atazanavir",
"      </a>",
"      ) and alternative PIs (eg, lopinavir), is better tolerated [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/26/36265/abstract/13,14\">",
"       13,14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/31/506?source=see_link\">",
"       Atazanavir",
"      </a>",
"      is associated with hyperbilirubinemia, which can manifest as jaundice in a minority of patients. Patients at increased risk for jaundice have reduced activity of UDP-glucuronosyltransferase, consistent with Gilbert's syndrome [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/26/36265/abstract/15\">",
"       15",
"      </a>",
"      ]. The hyperbilirubinemia does not signify the presence of liver disease, but its presence may be disconcerting to the patient for cosmetic reasons. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/23/42359?source=see_link\">",
"       \"Gilbert's syndrome and unconjugated hyperbilirubinemia due to bilirubin overproduction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Abnormal dreams, insomnia and dizziness are commonly reported with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"       efavirenz",
"      </a>",
"      ; patients need to be forewarned of these potential adverse events, which usually improve after three to four weeks of use. A more serious concern is worsening of baseline depression, which is a contraindication to efavirenz administration. All of these adverse events are less common with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15798?source=see_link\">",
"       rilpivirine",
"      </a>",
"      , so switching to an alternative nonnucleoside reverse transcriptase inhibitor (NNRTI) agent may improve these symptoms [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/26/36265/abstract/16\">",
"       16",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/18/37162?source=see_link&amp;anchor=H10929706#H10929706\">",
"       \"Pharmacology of non-nucleoside reverse transcriptase inhibitors\", section on 'Rilpivirine (Edurant)'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9112542\">",
"    <span class=\"h2\">",
"     Medications to avoid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some of the toxicities noted below are related to antiretroviral medications that should be avoided because of their side effect profiles (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/38/14952?source=see_link\">",
"     didanosine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36265/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]; these medications are no longer recommended in contemporary guidelines from the United States or Europe. They are listed here for completeness; a switch of therapeutic agent to one with a more favorable toxicity profile is preferred:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Peripheral neuropathy is associated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/45/43734?source=see_link\">",
"       stavudine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/38/14952?source=see_link\">",
"       didanosine",
"      </a>",
"      . (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/56/29577?source=see_link\">",
"       \"Epidemiology, clinical manifestations, diagnosis, and treatment of HIV-associated peripheral neuropathy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Mitochondrial toxicity from",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/38/14952?source=see_link\">",
"       didanosine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/45/43734?source=see_link\">",
"       stavudine",
"      </a>",
"      exposure can lead to severe lactic acidosis with or without hepatic steatosis; this syndrome has also been described with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/28/24008?source=see_link\">",
"       zidovudine",
"      </a>",
"      use. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/40/30345?source=see_link\">",
"       \"Mitochondrial toxicity of HIV nucleoside reverse transcriptase inhibitors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pancreatitis is associated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/38/14952?source=see_link\">",
"       didanosine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/45/43734?source=see_link\">",
"       stavudine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/26/36265/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Bone marrow suppression with anemia",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      leukopenia can be seen with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/28/24008?source=see_link\">",
"       zidovudine",
"      </a>",
"      use. This can be managed by switching zidovudine to a preferred nucleoside analog, as recommended by major treatment guidelines [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/26/36265/abstract/3,4\">",
"       3,4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     VIROLOGIC FAILURE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9112561\">",
"    <span class=\"h2\">",
"     Viral failure versus viral blip",
"    </span>",
"    &nbsp;&mdash;&nbsp;Virologic failure is defined as:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The failure to achieve a viral load &lt;50",
"      <span class=\"nowrap\">",
"       copies/mL",
"      </span>",
"      by 24 weeks after initiation of antiretroviral therapy (ART)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    OR",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Any sustained recurrence of HIV RNA &gt;50",
"      <span class=\"nowrap\">",
"       copies/mL",
"      </span>",
"      after initial suppression",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are two causes of viral failure: drug resistance, or inability of the drugs to reach the target site. The latter may be related to problems adhering to the drug regimen, drug interactions, or altered pharmacokinetics. In clinical practice, a detectable plasma HIV RNA level during therapy should be confirmed within two to four weeks prior to making any new management decisions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36265/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The rationale for achieving a plasma viral load of &lt;50",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    is based to some extent on studies showing an absence of viral evolution below that level [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36265/abstract/18\">",
"     18",
"    </a>",
"    ], while sequence evolution with resistance mutations was noted in 9 of 21 patients (43 percent) with sustained viral loads between 50 and 400",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36265/abstract/19\">",
"     19",
"    </a>",
"    ]. One study of 982 patients also demonstrated that a delay in regimen modification, after the onset of virologic failure, was associated with an increased risk of mortality, which remained elevated for four years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36265/abstract/20\">",
"     20",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    In contrast to virologic failure, viral &ldquo;blips&rdquo; refer to intermittent periods of low-level detectable viremia, usually brief in duration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36265/abstract/21\">",
"     21",
"    </a>",
"    ]. Various explanations for these viral blips have been offered which include: &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bursts of HIV replication",
"     </li>",
"     <li>",
"      Laboratory methodologic issues &nbsp;",
"     </li>",
"     <li>",
"      Intermittent poor adherence",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One observational analysis in 3550 HIV-infected patients suggested that the amplitude of the blip may be important for predicting subsequent virologic failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36265/abstract/22\">",
"     22",
"    </a>",
"    ]. Because of the increased sensitivity of newer assays, the United States Department of Health and Human Services (DHHS) guidelines have defined confirmed detection of HIV RNA &gt;200",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    as representative of virologic failure since most reports of 50 to 200",
"    <span class=\"nowrap\">",
"     c/mL",
"    </span>",
"    are laboratory errors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36265/abstract/23-25\">",
"     23-25",
"    </a>",
"    ]. However, repeated values of 50 to 200",
"    <span class=\"nowrap\">",
"     c/mL",
"    </span>",
"    should raise concern regarding possible virologic failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36265/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Viral blips should prompt a discussion between the patient and provider about adherence since one study of 228 subjects showed an association between missed doses and subsequent transient increases in HIV RNA levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36265/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. The management of viral blips is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/17/38167?source=see_link&amp;anchor=H7#H7\">",
"     \"Patient monitoring during HIV antiretroviral therapy\", section on 'Viral blips'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9112583\">",
"    <span class=\"h2\">",
"     Implications of virologic failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Virologic failure secondary to drug resistance can have significant implications for other members of the same drug class. For example, a patient who develops drug resistance on",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    (eg, K103N) will have predictable drug resistance to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    , also known as &ldquo;cross-resistance&rdquo;. Thus, virologic failure on efavirenz due to drug resistance would preclude nevirapine use. Other examples of cross-resistance are found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/26/34218?source=see_link&amp;anchor=H6#H6\">",
"     \"Primer on interpretation of HIV drug resistance testing\", section on 'Cross-resistance'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9113184\">",
"    <span class=\"h1\">",
"     SUBOPTIMAL ADHERENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Low levels of adherence are associated with drug resistance to medications, particularly those with low barriers to genetic resistance (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/27/10678?source=see_link\">",
"     raltegravir",
"    </a>",
"    ). The risk of the emergence of drug resistance with suboptimal adherence is generally greater in patients taking nonnucleoside reverse transcriptase inhibitors (NNRTIs) compared with most protease inhibitors (PIs) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36265/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/24/36234?source=see_link&amp;anchor=H13#H13\">",
"     \"Selecting antiretroviral regimens for the treatment naive HIV-infected patient\", section on 'NNRTI-based ART versus PI-based ART'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the patient with virologic failure, the following steps may be helpful in determining a patient&rsquo;s level of adherence:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients should be asked to describe how they are taking their antiretroviral therapy (ART) regimen so as to detect errors in prescribing, dispensing, or patient comprehension.",
"     </li>",
"     <li>",
"      Patients should be asked in a nonjudgmental manner how many doses they are missing.",
"     </li>",
"     <li>",
"      Among the most successful methods for tracking adherence are pharmacy records; pill counts at the clinic are often done but may be notoriously misleading [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/26/36265/abstract/31,32\">",
"       31,32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Virologic failure in the absence of resistance is probably one of the best indicators of poor adherence.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1115408\">",
"    <span class=\"h1\">",
"     IMMUNOLOGIC FAILURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there are no specific definitions, some experts have suggested that immunologic failure should be considered in a patient who does not attain an increase of CD4 cell counts above a specific clinical threshold (eg, &gt;350",
"    <span class=\"nowrap\">",
"     cells/mL)",
"    </span>",
"    over a specific period of time (eg, four to seven years) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36265/abstract/13\">",
"     13",
"    </a>",
"    ]. Interventions for immunologic failure, such as &ldquo;treatment intensification&rdquo; with the addition of antiretroviral medications to an existing antiretroviral therapy (ART) regimen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36265/abstract/33-35\">",
"     33-35",
"    </a>",
"    ] or the use of IL-2 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36265/abstract/36\">",
"     36",
"    </a>",
"    ] have been investigated; neither therapeutic strategy has been associated with clinical benefit. Furthermore, a persistently low CD4 cell count while on suppressive ART is associated with a low risk of AIDS and non-AIDS-related morbidity and mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36265/abstract/37,38\">",
"     37,38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Factors associated with a poor CD4 cell count response, despite viral suppression on ART, include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A CD4 count &lt;200",
"      <span class=\"nowrap\">",
"       cells/mL",
"      </span>",
"      when starting ART [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/26/36265/abstract/39\">",
"       39",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Older age &gt;50 years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/26/36265/abstract/40\">",
"       40",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Advanced liver disease in HIV patients coinfected with hepatitis C virus (HCV) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/26/36265/abstract/41,42\">",
"       41,42",
"      </a>",
"      ] &nbsp;",
"     </li>",
"     <li>",
"      Persistent immune activation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/26/36265/abstract/43,44\">",
"       43,44",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Poor thymic function [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/26/36265/abstract/45,46\">",
"       45,46",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In summary, the primary goal of ART is HIV viral suppression. In a minority of patients, CD4 cell counts fail to increase significantly despite achievement of viral suppression. Although there are no proven interventions to boost CD4 cell counts in this clinical scenario, the risk of opportunistic infections (OIs) is markedly reduced. However, the standard recommendations for prophylaxis of OIs still apply. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/42/33450?source=see_link\">",
"     \"Primary prevention of opportunistic infections in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     GENERAL APPROACHES TO MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The various approaches listed below may be helpful in the evaluation and management of the patient who requires treatment modification.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25842460\">",
"    <span class=\"h2\">",
"     Managing toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of toxicity may require replacement of one agent or discontinuation of the entire regimen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25842488\">",
"    <span class=\"h3\">",
"     Switching an individual agent",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a previously treatment-naive patient is having intolerance to a particular antiretroviral agent and viral suppression has been recently documented, substituting another agent for the offending drug is generally satisfactory. &nbsp;",
"   </p>",
"   <p>",
"    Some HIV treatment studies have evaluated switching to a drug from the same class or to a drug from an alternate class. As an example, patients who switched from",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    -",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    -",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/38/44646?source=see_link\">",
"     rilpivirine-emtricitabine-tenofovir",
"    </a>",
"    maintained viral suppression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36265/abstract/47\">",
"     47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/34/7720?source=see_link&amp;anchor=H27660883#H27660883\">",
"     \"Clinical trials of HIV antiretroviral therapy: Integrase inhibitors\", section on 'Switching from a protease inhibitor to raltegravir'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Intolerance can frequently be managed by single drug substitutions within the same class (assuming drug susceptibility). Examples include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/63/31734?source=see_link\">",
"       abacavir",
"      </a>",
"      hypersensitivity can be switched to another nucleoside reverse transcriptase inhibitor (NRTI), like",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"       tenofovir",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Patients who cannot tolerate the neurocognitive side effects of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"       efavirenz",
"      </a>",
"      can be switched to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15798?source=see_link\">",
"       rilpivirine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/12/18633?source=see_link\">",
"       nevirapine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?13/0/13320?source=see_link\">",
"       etravirine",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Patients who have diarrhea or gastrointestinal side effects with agents such as lopinavir or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/11/44217?source=see_link\">",
"       fosamprenavir",
"      </a>",
"      may tolerate",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"       ritonavir",
"      </a>",
"      -boosted",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/31/506?source=see_link\">",
"       atazanavir",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/39/36473?source=see_link\">",
"       darunavir",
"      </a>",
"      . This observation may be related to the lower dosing of ritonavir that is used for pharmacokinetic boosting with medications such as atazanavir and darunavir (ie, 100 mg) compared with lopinavir (ie, 200 mg).",
"     </li>",
"     <li>",
"      Patients who develop lipid abnormalities on lopinavir may benefit with a change to boosted",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/31/506?source=see_link\">",
"       atazanavir",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/27/10678?source=see_link\">",
"       raltegravir",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25842440\">",
"    <span class=\"h3\">",
"     Interrupting therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;As a general rule, whenever an antiretroviral agent needs to be interrupted or discontinued, all agents should be stopped simultaneously to avoid the risk of resistance during exposure to a suboptimal regimen. In the patient who attained viral suppression on antiretroviral therapy (ART), virologic rebound will occur at two to three weeks and the viral load will usually rise quickly to pretreatment levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36265/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. The CD4 cell count will also typically fall rapidly in the first four weeks following discontinuation and then decline more slowly toward pretreatment levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36265/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are a few exceptions to this general rule:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When one medication has a longer half-life than others, stopping combination ART at the same time can result in functional monotherapy. Whether drug resistance occurs will depend on the drug's genetic barrier to resistance and the magnitude of viral replication present when the drug's concentration is high enough to exert an antiviral effect [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/26/36265/abstract/51\">",
"       51",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      For example, the nonnucleoside reverse transcriptase inhibitors (NNRTIs)",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/12/18633?source=see_link\">",
"       nevirapine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"       efavirenz",
"      </a>",
"      have long half-lives. Discontinuing either of these medications at the same time as the NRTI backbone may lead to functional monotherapy for a period of days or weeks, which could promote NNRTI resistance [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/26/36265/abstract/13,52,53\">",
"       13,52,53",
"      </a>",
"      ]. To address this, some experts recommend continuing the NRTI backbone for five to seven days after stopping the NNRTI [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/26/36265/abstract/13,52,54\">",
"       13,52,54",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      One potential problem with this tactic is that efavirenz, for example, may provide therapeutic blood levels for two to four weeks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/26/36265/abstract/55\">",
"       55",
"      </a>",
"      ]. Also, there is great individual patient variation that is partly based on the genetics of efavirenz metabolism [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/26/36265/abstract/55\">",
"       55",
"      </a>",
"      ]. The result is that the clinician dealing with an individual patient cannot know if efavirenz will be present therapeutically for one week or four weeks. An alternative strategy is to substitute a protease inhibitor (PI) with the two NRTIs for one month after discontinuation of efavirenz.",
"     </li>",
"     <li>",
"      In patients coinfected with hepatitis B, discontinuing",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"       tenofovir",
"      </a>",
"      can lead to a flare of hepatitis, even if the patient is taking",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/15/5366?source=see_link\">",
"       emtricitabine",
"      </a>",
"      . To address this, some experts recommend initiating",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/55/29557?source=see_link\">",
"       entecavir",
"      </a>",
"      in selected patients with HIV suppression [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/26/36265/abstract/13\">",
"       13",
"      </a>",
"      ]. Entecavir is not a treatment option if the patient has ongoing HIV viremia. The alternative is to monitor patients closely for evidence of a hepatitis flare, but this may be dangerous in patients with marginal hepatic reserve. Treatment strategies are discussed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/51/16185?source=see_link\">",
"       \"Treatment of hepatitis B in the HIV-infected patient\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In general, interruption of therapy is best avoided whenever feasible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1116171\">",
"    <span class=\"h2\">",
"     Managing virologic failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cause of virologic failure despite adherence to an appropriate ART regimen is usually a result of transmitted drug resistance or to the development of HIV resistance while on therapy.",
"   </p>",
"   <p>",
"    The standard approach to virologic failure is to:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Evaluate adherence and potential interactions with other drugs or food",
"     </li>",
"     <li>",
"      Perform drug resistance testing (which requires HIV RNA levels of &gt;500 to 1000",
"      <span class=\"nowrap\">",
"       c/mL)",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1116198\">",
"    <span class=\"h3\">",
"     Pharmacokinetic causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pharmacokinetic causes of virologic failure should be explored, particularly in patients with low-level virologic failure (viral load &lt;1000 to 2000",
"    <span class=\"nowrap\">",
"     copies/mL).",
"    </span>",
"    The following steps are appropriate:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Review the patient's medications to make sure that there are no deleterious drug-drug interactions either within the ART regimen or with other medications the patient is currently taking (eg, proton pump inhibitors)",
"     </li>",
"     <li>",
"      Review whether the patient is taking antiretroviral medications at the appropriate times, particularly with regard to requirements for taking certain medications with food (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15798?source=see_link\">",
"       rilpivirine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/31/506?source=see_link\">",
"       atazanavir",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/39/36473?source=see_link\">",
"       darunavir",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/33/19992?source=see_link\">",
"       tipranavir",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?13/0/13320?source=see_link\">",
"       etravirine",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Review whether the current ART regimen may be associated with inadequate trough drug levels (eg, unboosted",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/31/506?source=see_link\">",
"       atazanavir",
"      </a>",
"      with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"       tenofovir",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Review the patient&rsquo;s clinical history to evaluate whether there is any suggestion of an underlying malabsorption problem. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/41/38551?source=see_link\">",
"       \"Evaluation of the HIV-infected patient with diarrhea\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1116205\">",
"    <span class=\"h3\">",
"     Switching regimens for resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV resistance testing is the standard method for demonstrating that HIV resistance is responsible for virologic failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36265/abstract/56\">",
"     56",
"    </a>",
"    ]. Commercially available resistance tests generally require a viral load of at least 500 to 1000",
"    <span class=\"nowrap\">",
"     copies/mL.",
"    </span>",
"    Changes in the ART regimen should take into account the patient&rsquo;s full history of drug resistance testing (current and prior results) and the patient&rsquo;s prior treatment history. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/48/4873?source=see_link\">",
"     \"Overview of HIV drug resistance testing assays\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/26/34218?source=see_link\">",
"     \"Primer on interpretation of HIV drug resistance testing\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/42/32424?source=see_link\">",
"     \"Drug resistance testing in the clinical management of HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients who are experiencing failure of an ART regimen because of viral resistance, the goal is to select a regimen with preferably three, or minimally two, active antiretroviral medications. Use of a single active agent usually leads to resistance to that particular drug and is not recommended. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/21/27994?source=see_link&amp;anchor=H7365500#H7365500\">",
"     \"Selection of antiretroviral therapy for the treatment-experienced patient with drug-resistant HIV infection\", section on 'Selecting a regimen'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1116232\">",
"    <span class=\"h3\">",
"     Drug levels and therapeutic drug monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapeutic drug monitoring (TDM) is generally not recommended since the reproducibility of these methods is highly variable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36265/abstract/23\">",
"     23",
"    </a>",
"    ]. Monitoring of PI or NNRTI levels may be useful if done with well-validated methods in pregnant women, patients with renal or liver impairment, and in the management of drug-drug interactions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36265/abstract/3,13\">",
"     3,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Managing adherence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who are having difficulty with adherence to an ART regimen may be able to be managed without a change of the ART regimen. Strategies should be individualized to deal with patient-specific barriers to adherence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36265/abstract/57\">",
"     57",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/24/36234?source=see_link\">",
"     \"Selecting antiretroviral regimens for the treatment naive HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1115948\">",
"    <span class=\"h3\">",
"     Psychosocial supports",
"    </span>",
"    &nbsp;&mdash;&nbsp;Assistance from family and friends or support groups, the use of timers, medication boxes, and many other methods may be helpful in reminding patients to take their medications. In patients who have significant but potentially reversible causes of poor adherence (eg, depression, substance abuse, homelessness, dementia, drug toxicity), it may be appropriate to stop ART for a period of time while attempting to ameliorate the underlying barriers to adherence. However, clinicians need to be aware that discontinuation of a \"failing\" regimen is followed by a prompt increase in viral load and a rapid decrease in CD4 count. Drug discontinuation is not recommended in patients who have advanced HIV disease. Strategies for improving adherence are presented in the tables (",
"    <a class=\"graphic graphic_table graphicRef57486 graphicRef78917 graphicRef68684 \" href=\"mobipreview.htm?12/61/13277\">",
"     table 2A-C",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Changing ART regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adherence to an ART regimen is associated with a greater likelihood of viral suppression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36265/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. The goal in changing ART regimens in patients with inadequate adherence is generally to improve tolerance or simplify the regimen in terms of dosing frequency, number of pills, or food requirements. Even in patients who have adequate adherence, it is reasonable to consider simplifying an ART regimen that is burdensome.",
"   </p>",
"   <p>",
"    Fortunately, the increased availability of once-daily three-drug coformulations have led to improved patient adherence and overall improved virologic outcomes. These coformulations include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"       Efavirenz",
"      </a>",
"      -",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/15/5366?source=see_link\">",
"       emtricitabine",
"      </a>",
"      -",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"       tenofovir",
"      </a>",
"      , coformulated as Atripla",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/38/44646?source=see_link\">",
"       Rilpivirine-emtricitabine-tenofovir",
"      </a>",
"      , coformulated as Complera",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/54/8041?source=see_link\">",
"       Elvitegravir-cobicistat-tenofovir-emtricitabine",
"      </a>",
"      (for pharmacokinetic boosting), coformulated as Stribild",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other coformulations, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/52/1863?source=see_link\">",
"     tenofovir-emtricitabine",
"    </a>",
"    (coformulated as Truvada) and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/4/3141?source=see_link\">",
"     abacavir-lamivudine",
"    </a>",
"    (coformulated as Epzicom) require an additional third agent to serve as a complete ART regimen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     General approach",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Indications for changing antiretroviral therapy (ART) regimens include: toxicity, virologic failure, convenience, difficulty adhering to the regimen, and suboptimal therapy. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Indications for changing antiretroviral therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Toxicity",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intolerance of ART because of toxicity can frequently be managed by drug substitutions. (See",
"      <a class=\"local\" href=\"#H25842460\">",
"       'Managing toxicity'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Virologic failure issues",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Virologic failure is generally defined as the failure to achieve a viral load &lt;50",
"      <span class=\"nowrap\">",
"       copies/mL",
"      </span>",
"      or recurrence of viremia after initial suppression. Sporadic HIV RNA levels of 50 to 100",
"      <span class=\"nowrap\">",
"       c/mL",
"      </span>",
"      usually indicate laboratory errors, but sustained levels in that range may suggest virologic failure. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Virologic failure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the adherent patient with confirmed detectable viremia on recommended therapeutic regimens, consideration should be given to drug-drug interactions, malabsorption, and attention to food-medication requirements. In the absence of these considerations, HIV resistance is a possible explanation for virologic failure in patients with appropriate adherence. (See",
"      <a class=\"local\" href=\"#H1116171\">",
"       'Managing virologic failure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with virologic failure should undergo HIV resistance testing for guidance in subsequent regimen selection. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/42/32424?source=see_link\">",
"       \"Drug resistance testing in the clinical management of HIV infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients who are experiencing failure of an ART regimen because of viral resistance, the goal is to select a regimen with at least three active antiretroviral medications. Such therapeutic regimens usually include a dual &ldquo;nucleoside backbone&rdquo; combined with either a nonnucleoside reverse transcriptase inhibitor (NNRTI), a boosted protease inhibitor (PI), or an integrase inhibitor. (See",
"      <a class=\"local\" href=\"#H1116205\">",
"       'Switching regimens for resistance'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1116359\">",
"    <span class=\"h2\">",
"     Adherence issues",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients who are unable to adhere to their current HIV regimen, treatment simplification with regard to dosing frequency, number of pills, and the need to take medications with regard to meals is one priority. Another consideration is to use a boosted PI-containing regimen, which is associated with a lower risk of drug resistance than a NNRTI-containing regimen. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Changing ART regimens'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Intolerance to medications can also contribute to lack of adherence; this possibility should be explored through discussion with the patient before switching to a new antiretroviral regimen. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Changing ART regimens'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36265/abstract/1\">",
"      Marschner IC, Collier AC, Coombs RW, et al. Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy. J Infect Dis 1998; 177:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36265/abstract/2\">",
"      Sterne JA, Hern&aacute;n MA, Ledergerber B, et al. Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet 2005; 366:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36265/abstract/3\">",
"      Thompson MA, Aberg JA, Hoy JF, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 2012; 308:387.",
"     </a>",
"    </li>",
"    <li>",
"     US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available at: file://aidsinfo.nih.gov/Guidelines/GuidelineDetail.aspx?MenuItem=Guidelines&amp;Search=Off&amp;GuidelineID=7&amp;ClassID=1 (Accessed on April 06, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36265/abstract/5\">",
"      Elzi L, Marzolini C, Furrer H, et al. Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008. Arch Intern Med 2010; 170:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36265/abstract/6\">",
"      Lubomirov R, Colombo S, di Iulio J, et al. Association of pharmacogenetic markers with premature discontinuation of first-line anti-HIV therapy: an observational cohort study. J Infect Dis 2011; 203:246.",
"     </a>",
"    </li>",
"    <li>",
"     Mocroft A, Lacombe K, Rockstroh J, et al. Risk of discontinuation of nevirapine due to toxicity in antiretroviral naive and experienced patients with high and low CD4 counts. IAS Toronto 2006 Abstract #THAB0104.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36265/abstract/8\">",
"      Kumarasamy N, Venkatesh KK, Devaleenal B, et al. Safety of switching to nevirapine-based highly active antiretroviral therapy at elevated CD4 cell counts in a resource-constrained setting. J Acquir Immune Defic Syndr 2007; 45:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36265/abstract/9\">",
"      Kottilil S, Polis MA, Kovacs JA. HIV Infection, hepatitis C infection, and HAART: hard clinical choices. JAMA 2004; 292:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36265/abstract/10\">",
"      Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004; 292:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36265/abstract/11\">",
"      Young J, Sch&auml;fer J, Fux CA, et al. Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir. AIDS 2012; 26:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36265/abstract/12\">",
"      Peyri&egrave;re H, Reynes J, Rouanet I, et al. Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases. J Acquir Immune Defic Syndr 2004; 35:269.",
"     </a>",
"    </li>",
"    <li>",
"     file://aidsinfo.nih.gov/Guidelines/GuidelineDetail.aspx?MenuItem=Guidelines&amp;Search=Off&amp;GuidelineID=7&amp;ClassID=1 (Accessed on January 21, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36265/abstract/14\">",
"      O'Brien ME, Clark RA, Besch CL, et al. Patterns and correlates of discontinuation of the initial HAART regimen in an urban outpatient cohort. J Acquir Immune Defic Syndr 2003; 34:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36265/abstract/15\">",
"      Rotger M, Taffe P, Bleiber G, et al. Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia. J Infect Dis 2005; 192:1381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36265/abstract/16\">",
"      Nguyen A, Calmy A, Delhumeau C, et al. A randomized crossover study to compare efavirenz and etravirine treatment. AIDS 2011; 25:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36265/abstract/17\">",
"      Reisler RB, Murphy RL, Redfield RR, Parker RA. Incidence of pancreatitis in HIV-1-infected individuals enrolled in 20 adult AIDS clinical trials group studies: lessons learned. J Acquir Immune Defic Syndr 2005; 39:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36265/abstract/18\">",
"      Kieffer TL, Finucane MM, Nettles RE, et al. Genotypic analysis of HIV-1 drug resistance at the limit of detection: virus production without evolution in treated adults with undetectable HIV loads. J Infect Dis 2004; 189:1452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36265/abstract/19\">",
"      Nettles RE, Kieffer TL, Simmons RP, et al. Genotypic resistance in HIV-1-infected patients with persistently detectable low-level viremia while receiving highly active antiretroviral therapy. Clin Infect Dis 2004; 39:1030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36265/abstract/20\">",
"      Petersen ML, van der Laan MJ, Napravnik S, et al. Long-term consequences of the delay between virologic failure of highly active antiretroviral therapy and regimen modification. AIDS 2008; 22:2097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36265/abstract/21\">",
"      Nettles RE, Kieffer TL, Kwon P, et al. Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART. JAMA 2005; 293:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36265/abstract/22\">",
"      Grennan JT, Loutfy MR, Su D, et al. Magnitude of virologic blips is associated with a higher risk for virologic rebound in HIV-infected individuals: a recurrent events analysis. J Infect Dis 2012; 205:1230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36265/abstract/23\">",
"      Nettles RE, Kieffer TL, Parsons T, et al. Marked intraindividual variability in antiretroviral concentrations may limit the utility of therapeutic drug monitoring. Clin Infect Dis 2006; 42:1189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36265/abstract/24\">",
"      Willig JH, Nevin CR, Raper JL, et al. Cost ramifications of increased reporting of detectable plasma HIV-1 RNA levels by the Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 version 1.0 viral load test. J Acquir Immune Defic Syndr 2010; 54:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36265/abstract/25\">",
"      Charpentier C, Landman R, Laou&eacute;nan C, et al. Persistent low-level HIV-1 RNA between 20 and 50 copies/mL in antiretroviral-treated patients: associated factors and virological outcome. J Antimicrob Chemother 2012; 67:2231.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.aidsinfo.nih.gov/guidelines/ (Accessed on May 07, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36265/abstract/27\">",
"      Sungkanuparph S, Groger RK, Overton ET, et al. Persistent low-level viraemia and virological failure in HIV-1-infected patients treated with highly active antiretroviral therapy. HIV Med 2006; 7:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36265/abstract/28\">",
"      Podsadecki TJ, Vrijens BC, Tousset EP, et al. Decreased adherence to antiretroviral therapy observed prior to transient human immunodeficiency virus type 1 viremia. J Infect Dis 2007; 196:1773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36265/abstract/29\">",
"      Gallant JE. Making sense of blips. J Infect Dis 2007; 196:1729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36265/abstract/30\">",
"      Bangsberg DR, Acosta EP, Gupta R, et al. Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness. AIDS 2006; 20:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36265/abstract/31\">",
"      Celum C, Baeten JM. Tenofovir-based pre-exposure prophylaxis for HIV prevention: evolving evidence. Curr Opin Infect Dis 2012; 25:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36265/abstract/32\">",
"      Thompson MA, Mugavero MJ, Amico KR, et al. Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: evidence-based recommendations from an International Association of Physicians in AIDS Care panel. Ann Intern Med 2012; 156:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36265/abstract/33\">",
"      Holodniy M, Brown ST, Cameron DW, et al. Results of antiretroviral treatment interruption and intensification in advanced multi-drug resistant HIV infection from the OPTIMA trial. PLoS One 2011; 6:e14764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36265/abstract/34\">",
"      Wilkin TJ, Lalama CM, McKinnon J, et al. A pilot trial of adding maraviroc to suppressive antiretroviral therapy for suboptimal CD4��� T-cell recovery despite sustained virologic suppression: ACTG A5256. J Infect Dis 2012; 206:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36265/abstract/35\">",
"      Byakwaga H, Kelly M, Purcell DF, et al. Intensification of antiretroviral therapy with raltegravir or addition of hyperimmune bovine colostrum in HIV-infected patients with suboptimal CD4+ T-cell response: a randomized controlled trial. J Infect Dis 2011; 204:1532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36265/abstract/36\">",
"      INSIGHT-ESPRIT Study Group, SILCAAT Scientific Committee, Abrams D, et al. Interleukin-2 therapy in patients with HIV infection. N Engl J Med 2009; 361:1548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36265/abstract/37\">",
"      Moore DM, Hogg RS, Chan K, et al. Disease progression in patients with virological suppression in response to HAART is associated with the degree of immunological response. AIDS 2006; 20:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36265/abstract/38\">",
"      Zoufaly A, an der Heiden M, Kollan C, et al. Clinical outcome of HIV-infected patients with discordant virological and immunological response to antiretroviral therapy. J Infect Dis 2011; 203:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36265/abstract/39\">",
"      Kelley CF, Kitchen CM, Hunt PW, et al. Incomplete peripheral CD4+ cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment. Clin Infect Dis 2009; 48:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36265/abstract/40\">",
"      Cao W, Jamieson BD, Hultin LE, et al. Premature aging of T cells is associated with faster HIV-1 disease progression. J Acquir Immune Defic Syndr 2009; 50:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36265/abstract/41\">",
"      Hull MW, Rollet K, Odueyungbo A, et al. Factors associated with discordance between absolute CD4 cell count and CD4 cell percentage in patients coinfected with HIV and hepatitis C virus. Clin Infect Dis 2012; 54:1798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36265/abstract/42\">",
"      McGovern BH, Golan Y, Lopez M, et al. The impact of cirrhosis on CD4+ T cell counts in HIV-seronegative patients. Clin Infect Dis 2007; 44:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36265/abstract/43\">",
"      Lederman MM, Calabrese L, Funderburg NT, et al. Immunologic failure despite suppressive antiretroviral therapy is related to activation and turnover of memory CD4 cells. J Infect Dis 2011; 204:1217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36265/abstract/44\">",
"      Fernandez S, Tanaskovic S, Helbig K, et al. CD4+ T-cell deficiency in HIV patients responding to antiretroviral therapy is associated with increased expression of interferon-stimulated genes in CD4+ T cells. J Infect Dis 2011; 204:1927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36265/abstract/45\">",
"      Teixeira L, Valdez H, McCune JM, et al. Poor CD4 T cell restoration after suppression of HIV-1 replication may reflect lower thymic function. AIDS 2001; 15:1749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36265/abstract/46\">",
"      Dion ML, Bordi R, Zeidan J, et al. Slow disease progression and robust therapy-mediated CD4+ T-cell recovery are associated with efficient thymopoiesis during HIV-1 infection. Blood 2007; 109:2912.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.retroconference.org/2011/Abstracts/41838.htm (Accessed on September 27, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36265/abstract/48\">",
"      Deeks SG, Wrin T, Liegler T, et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med 2001; 344:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36265/abstract/49\">",
"      Markowitz M, Jin X, Hurley A, et al. Discontinuation of antiretroviral therapy commenced early during the course of human immunodeficiency virus type 1 infection, with or without adjunctive vaccination. J Infect Dis 2002; 186:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36265/abstract/50\">",
"      Wit FW, Blanckenberg DH, Brinkman K, et al. Safety of long-term interruption of successful antiretroviral therapy: the ATHENA cohort study. AIDS 2005; 19:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36265/abstract/51\">",
"      Taylor S, Boffito M, Khoo S, et al. Stopping antiretroviral therapy. AIDS 2007; 21:1673.",
"     </a>",
"    </li>",
"    <li>",
"     British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. www.bhiva.org/guidelines/2003/hiv/index.html (Accessed on July 08, 2005).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36265/abstract/53\">",
"      Kikaire B, Khoo S, Walker AS, et al. Nevirapine clearance from plasma in African adults stopping therapy: a pharmacokinetic substudy. AIDS 2007; 21:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36265/abstract/54\">",
"      Fox Z, Phillips A, Cohen C, et al. Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimen. AIDS 2008; 22:2279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36265/abstract/55\">",
"      Ribaudo HJ, Haas DW, Tierney C, et al. Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study. Clin Infect Dis 2006; 42:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36265/abstract/56\">",
"      Hirsch MS, G&uuml;nthard HF, Schapiro JM, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis 2008; 47:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36265/abstract/57\">",
"      Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36265/abstract/58\">",
"      Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36265/abstract/59\">",
"      Harrigan PR, Hogg RS, Dong WW, et al. Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J Infect Dis 2005; 191:339.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3766 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-91.202.164.29-5B3EA195B2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_26_36265=[""].join("\n");
var outline_f35_26_36265=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H33\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INDICATIONS FOR CHANGING ANTIRETROVIRAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DRUG TOXICITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Serious toxicities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Other important or common side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9112542\">",
"      Medications to avoid",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      VIROLOGIC FAILURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9112561\">",
"      Viral failure versus viral blip",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9112583\">",
"      Implications of virologic failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9113184\">",
"      SUBOPTIMAL ADHERENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1115408\">",
"      IMMUNOLOGIC FAILURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      GENERAL APPROACHES TO MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25842460\">",
"      Managing toxicity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25842488\">",
"      - Switching an individual agent",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25842440\">",
"      - Interrupting therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1116171\">",
"      Managing virologic failure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1116198\">",
"      - Pharmacokinetic causes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1116205\">",
"      - Switching regimens for resistance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1116232\">",
"      - Drug levels and therapeutic drug monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Managing adherence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1115948\">",
"      - Psychosocial supports",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Changing ART regimens",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      General approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Virologic failure issues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1116359\">",
"      Adherence issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/3766\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3766|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?24/25/24989\" title=\"table 1\">",
"      Antiretroviral drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?35/57/36763\" title=\"table 2A\">",
"      Adherence improvement patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?29/61/30683\" title=\"table 2B\">",
"      Adherence improvement HCW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?1/13/1243\" title=\"table 2C\">",
"      Adherence improvement actions",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/9/32918?source=related_link\">",
"      Clinical trials of HIV antiretroviral therapy: CCR5 antagonists",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/34/7720?source=related_link\">",
"      Clinical trials of HIV antiretroviral therapy: Integrase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/4/9287?source=related_link\">",
"      Clinical trials of HIV antiretroviral therapy: Non-nucleoside reverse transcriptase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/16/17672?source=related_link\">",
"      Clinical trials of HIV antiretroviral therapy: Protease inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/27/14774?source=related_link\">",
"      Clinical trials of HIV antiretroviral therapy: Protease inhibitors versus non-nucleoside reverse transcriptase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/61/986?source=related_link\">",
"      Counseling HIV-infected patients regarding potential side effects of antiretroviral therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/42/32424?source=related_link\">",
"      Drug resistance testing in the clinical management of HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/56/29577?source=related_link\">",
"      Epidemiology, clinical manifestations, diagnosis, and treatment of HIV-associated peripheral neuropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/32/30218?source=related_link\">",
"      Epidemiology, natural history, and diagnosis of hepatitis C in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/41/38551?source=related_link\">",
"      Evaluation of the HIV-infected patient with diarrhea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/23/42359?source=related_link\">",
"      Gilbert's syndrome and unconjugated hyperbilirubinemia due to bilirubin overproduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/3/49?source=related_link\">",
"      Management of dyslipidemia and cardiovascular risk in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/40/30345?source=related_link\">",
"      Mitochondrial toxicity of HIV nucleoside reverse transcriptase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/48/4873?source=related_link\">",
"      Overview of HIV drug resistance testing assays",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/17/38167?source=related_link\">",
"      Patient monitoring during HIV antiretroviral therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/18/37162?source=related_link\">",
"      Pharmacology of non-nucleoside reverse transcriptase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/15/41209?source=related_link\">",
"      Pharmacology of nucleoside reverse transcriptase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/42/33450?source=related_link\">",
"      Primary prevention of opportunistic infections in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/26/34218?source=related_link\">",
"      Primer on interpretation of HIV drug resistance testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/24/36234?source=related_link\">",
"      Selecting antiretroviral regimens for the treatment naive HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/21/27994?source=related_link\">",
"      Selection of antiretroviral therapy for the treatment-experienced patient with drug-resistant HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/51/16185?source=related_link\">",
"      Treatment of hepatitis B in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/35/9786?source=related_link\">",
"      When to initiate antiretroviral therapy in HIV-infected patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_26_36266="Prevention of recurrent gout";
var content_f35_26_36266=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prevention of recurrent gout",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/26/36266/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/26/36266/contributors\">",
"     Michael A Becker, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/26/36266/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/26/36266/contributors\">",
"     H Ralph Schumacher, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/26/36266/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/26/36266/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/26/36266/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pharmacologic modalities employed in the treatment of gout can be classified as antiinflammatory, prophylactic, and antihyperuricemic. These designations reflect the three distinctive aims of treatment:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antiinflammatory therapy for prompt and safe termination of the acute arthritic attack",
"     </li>",
"     <li>",
"      Antiinflammatory prophylaxis for prevention of recurrences of acute gouty arthritis",
"     </li>",
"     <li>",
"      Antihyperuricemic (urate-lowering) therapy for prevention and reversal of the consequences of urate crystal deposition in joints (gouty arthropathy), urinary tract (nephrolithiasis), renal interstitium (rarely producing renal failure due to urate nephropathy), and tissues and parenchymal organs (tophi)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Upon resolution of an acute gouty attack, the patient is said to have entered an intercritical (between attacks) period. Intervals between attacks of acute gouty arthritis are of variable duration. Most untreated patients with gout will experience a second episode within two years. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/49/4890?source=see_link&amp;anchor=H18#H18\">",
"     \"Clinical manifestations and diagnosis of gout\", section on 'Intercritical gout and recurrent gouty arthritis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following preventive issues should be addressed during the intercritical period:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lifestyle modification and agents for risk reduction",
"     </li>",
"     <li>",
"      Comorbid disease management",
"     </li>",
"     <li>",
"      The need for pharmacologic urate-lowering therapy",
"     </li>",
"     <li>",
"      Prophylactic nonsteroidal antiinflammatory drug or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/13/32983?source=see_link\">",
"       colchicine",
"      </a>",
"      therapy, primarily to reduce the recurrence of acute attacks of gout during initiation of urate-lowering therapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In patients presenting with gouty arthritis and normal renal function but without visible or palpable tophaceous deposits or radiographic evidence of joint destruction or bony erosions, it should be possible to manage their disease successfully with life-style modifications, combined when necessary with pharmacologic therapy. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Pharmacologic urate-lowering therapy'",
"    </a>",
"    below.). Pharmacologic urate-lowering measures are also effective in most patients with tophaceous gout. In a few patients with complications due to tophaceous disease, surgical intervention may be an adjunct to medical management.",
"   </p>",
"   <p>",
"    A number of articles have, however, documented sub-optimal clinical outcomes in gout patients, both in terms of recurrences of acute flares and of progression to chronic tophaceous gout and chronic gouty arthropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36266/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Impediments to successful management have been identified and discussed, including [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36266/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Inaccurate diagnosis",
"     </li>",
"     <li>",
"      Few management guidelines for primary care practitioners",
"     </li>",
"     <li>",
"      Incomplete patient education about gout",
"     </li>",
"     <li>",
"      Suboptimal patient adherence to treatment recommendations",
"     </li>",
"     <li>",
"      Comorbidities and deleterious drug-drug interactions",
"     </li>",
"     <li>",
"      Patient groups at high risk for progression to tophaceous gout",
"     </li>",
"     <li>",
"      Limited urate-lowering treatment alternatives",
"     </li>",
"     <li>",
"      Suboptimal treatment recommendations by clinicians",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The prevention of recurrent gout and of disease progression will be reviewed here. The clinical manifestations and diagnosis of gout, the treatment of episodes of acute gouty arthritis, and issues related to asymptomatic hyperuricemia are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/49/4890?source=see_link\">",
"     \"Clinical manifestations and diagnosis of gout\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/24/17800?source=see_link\">",
"     \"Treatment of acute gout\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/24/1416?source=see_link\">",
"     \"Asymptomatic hyperuricemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RISK REDUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperuricemia and gout are often associated with one or more major disorders such as hypertension, obesity, diabetes, hyperlipidemia, atherosclerosis, and ethanol abuse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36266/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Nutritional and lifestyle strategies (eg, achievement of ideal body weight and limitation of ethanol consumption) can favorably affect both the associated conditions and hyperuricemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36266/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. In some cases, however, treatment of the accompanying disorder, particularly the use of diuretics to treat hypertension, may adversely affect gout.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Obesity and diet",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased adiposity and weight gain appear to be risk factors for incident gout, while weight loss reduces risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36266/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. This was best illustrated in a 12 year prospective Health Professionals Follow-up Study that monitored 47,150 men with no history of gout at baseline [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36266/abstract/8\">",
"     8",
"    </a>",
"    ]. The risk of gout was significantly higher in men with a body mass index (BMI) of 25",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    or greater, and the magnitude of the association became larger with increasing BMI. Men who had gained 13.6 kg or more had a twofold increased risk of gout compared with men who maintained their weight, while weight loss greater than 4.5 kg was associated with a significantly reduced risk of gout.",
"   </p>",
"   <p>",
"    These findings suggest that one method of reducing recurrent gouty attacks is for obese individuals to lose weight. A separate issue is the dietary components that may be best for reducing serum urate. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/9/8345?source=see_link\">",
"     \"Dietary therapy for obesity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A severely purine-restricted diet has traditionally been recommended for patients with gout. Such a diet can reduce urinary uric acid excretion by 200 to 400",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    However, mean serum urate concentrations decrease only about 1",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (59",
"    <span class=\"nowrap\">",
"     micromol/L),",
"    </span>",
"    and diets with restricted purine and protein contents are unpalatable and often are neither practical nor effective in the management of hyperuricemia and gout in patients with normal dietary habits. Furthermore, with the availability of potent antihyperuricemic drugs, this dietary approach is rarely employed except in individuals with severe renal insufficiency or intolerance to pharmacologic therapy.",
"   </p>",
"   <p>",
"    On the other hand, a more palatable diet, which emphasizes caloric restriction but allows an increased proportion of protein, the replacement of refined with complex carbohydrates, and a decrease in saturated fat can produce a substantial reduction in serum urate. Such a diet resulted in a 1.7",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (100",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    decrease in serum urate and a reduced frequency of gouty attacks (0.6 versus 2.1 attacks per month at baseline) in a group of 13 men who lost an average of 7.7 kg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36266/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If a diet containing an increased proportion of protein is recommended, the type of protein consumed is important. In an analysis from the Health Professionals Follow-up Study, the risk of developing gout increased with dietary meat and fish intake [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36266/abstract/10\">",
"     10",
"    </a>",
"    ]. In contrast, consumption of dairy products, particularly low fat dairy products, was associated with a substantially reduced risk of gout. Thus, if dietary changes are employed to manage gout, it may be preferable to recommend increasing dietary protein intake from low fat dairy products and decreasing the intake of red meat and fish.",
"   </p>",
"   <p>",
"    Frequent consumption of sugar-sweetened beverages or foods or beverages that contain fructose enhances the risk of having gout; drinking diet soft drinks is not associated with an increased risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36266/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Finally, there are some patients with dietary habits that influence the occurrence of gouty attacks. Fatty meals have been implicated in precipitating flares [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36266/abstract/13\">",
"     13",
"    </a>",
"    ]. In some patients, benefit may be derived from avoidance of specific dietary components that raise serum urate levels, such as organ-rich foods (eg, liver, sweetbreads), beer, or distilled spirits.",
"   </p>",
"   <p>",
"    In addition, patients with cystic fibrosis may develop dysuria, crystalluria, hyperuricemia, hyperuricosuria, and, in some cases, gouty arthritis during the course of high-dose treatment with purine-rich pancreatic extract therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36266/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Such patients may benefit from dose reduction, with a return to more normal serum urate concentrations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Alcohol",
"    </span>",
"    &nbsp;&mdash;&nbsp;Observational studies have varied in the estimate of the effect that consumption of alcohol has on the risk of gout. In the largest prospective study, drinking two or more beers per day increased the risk of gout 2.5-fold compared with no beer intake among men without a previous history of gout [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36266/abstract/16\">",
"     16",
"    </a>",
"    ]. The risk of gout was also increased in men who drank a similar amount of spirits per day, although the risk was lower than with beer (1.6-fold compared with no spirits). In contrast, two 4 ounce glasses of wine or more per day were not associated with an increased risk of gout.",
"   </p>",
"   <p>",
"    These findings suggest that moderate wine intake does not increase the risk of gout. On the other hand, patients with a history of gout may benefit from a reduction in intake of other alcoholic beverages, particularly beer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Hypertension and diuretics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both essential hypertension alone and diuretic use are associated with hyperuricemia and gout [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36266/abstract/8,17\">",
"     8,17",
"    </a>",
"    ]. In the Health Professionals Follow-up Study, for example, the relative risk of gout among men with hypertension compared with men without hypertension was 2.31 (95% CI 1.96-2.72), after adjusting for diuretic use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36266/abstract/8\">",
"     8",
"    </a>",
"    ]. Similarly, after adjusting for the presence of hypertension, the relative risk of gout among men taking versus not taking a diuretic was 1.77 (95% CI 1.60-8.14). Thiazide and loop diuretics appear to confer similar risks.",
"   </p>",
"   <p>",
"    The rise in serum urate with the most common diuretic used to treat hypertension,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/4/8263?source=see_link\">",
"     hydrochlorothiazide",
"    </a>",
"    , is relatively small at low doses (",
"    <a class=\"graphic graphic_figure graphicRef69912 \" href=\"mobipreview.htm?37/49/38685\">",
"     figure 1",
"    </a>",
"    ) and can be minimized by concurrent therapy with an angiotensin converting enzyme (ACE) inhibitor or an angiotensin II receptor blocker (ARB). In addition, the ARB",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/35/26168?source=see_link\">",
"     losartan",
"    </a>",
"    reduces serum urate via a uricosuric effect that is not seen or is less pronounced with other ARBs and with ACE inhibitors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36266/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/63/15350?source=see_link\">",
"     \"Use of thiazide diuretics in patients with primary hypertension\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/26/29094?source=see_link&amp;anchor=H3#H3\">",
"     \"Diuretic-induced hyperuricemia and gout\", section on 'Benefits of angiotensin inhibition and losartan'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The implications of these findings for patient care need to be individualized. Thiazide diuretics are often recommended for the initial therapy of essential hypertension because they have proven cardiovascular benefits and are inexpensive. However, if hypertension can be easily controlled by another drug and if cost is not a limiting issue, it may be reasonable to choose an ARB (particularly",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/35/26168?source=see_link\">",
"     losartan",
"    </a>",
"    ) or ACE inhibitor in patients with a history of gout. In patients who are also taking a urate-lowering agent as described in the next section, the additional benefit of stopping diuretics or adding losartan is likely to be minimal. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/29/36314?source=see_link\">",
"     \"Choice of therapy in primary (essential) hypertension: Recommendations\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PHARMACOLOGIC URATE-LOWERING THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preventing recurrent and progressive gouty arthritis and tophi requires, in many patients, the long-term use of drugs that reduce the serum urate concentration either by enhancing renal excretion of uric acid (uricosuric agents) or by decreasing urate synthesis (xanthine oxidase inhibitors). While prolonged use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    and NSAIDs may prevent recurrent episodes of gouty arthritis, they do not prevent the development of silent bony erosions and tophaceous deposits.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/38/41572?source=see_link\">",
"     Pegloticase",
"    </a>",
"    , a polyethylene glycol-modified mammalian recombinant uricase (urate oxidase), which converts urate to the more soluble purine end product allantoin, is now available in the US as a treatment for refractory tophaceous gout.",
"   </p>",
"   <p>",
"    Increasingly robust data confirm the view that lowering serum urate prevents recurrent episodes of gouty arthritis. In contrast, an effect of antihyperuricemic drugs in preventing functionally significant renal impairment in patients with gout has been considered but has not been established [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36266/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. This may reflect uncertainty about whether hyperuricemia alone or hyperuricemia in patients with gout produces functionally significant renal disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/57/27541?source=see_link\">",
"     \"Uric acid renal diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main indications for pharmacologic urate-lowering therapy in patients with a history of gout are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Frequent and disabling attacks of gouty arthritis",
"     </li>",
"     <li>",
"      Clinical or radiographic signs of chronic gouty joint disease",
"     </li>",
"     <li>",
"      Tophaceous deposits in soft tissues or subchondral bone",
"     </li>",
"     <li>",
"      Gout with renal insufficiency",
"     </li>",
"     <li>",
"      Recurrent nephrolithiasis",
"     </li>",
"     <li>",
"      Urinary uric acid excretion exceeding 1100",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      (6.5 mmol), when determined in men less than 25 years of age or in premenopausal women",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Precise definitions of frequent or disabling attacks are not strictly established. More than two or three attacks annually are often quoted as an indication for urate-lowering treatment. However, a lower threshold for treatment may be considered after discussion with the patient if attacks are especially prolonged, interfere with vocational or avocational activities,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    continue to recur over several years.",
"   </p>",
"   <p>",
"    Urinary uric acid excretion of &gt;1100 mg (&gt;6.5 mmol) per day in patients with gout is associated with an almost 50 percent incidence of urolithiasis, which provides a relative indication for treatment. In clinical practice, accurate determination of daily urinary uric acid excretion is often difficult or impractical to obtain. Nevertheless, it is important to make this measurement in selected patients, such as when uricosuric drug therapy is considered and when gout occurs in young men (&lt;25 years old) or premenopausal women, which are patient groups that are enriched for familial forms of hyperuricemia.",
"   </p>",
"   <p>",
"    Measurement of daily uric acid excretion may identify patients who have either an X chromosome-linked enzyme defect associated with uric acid overproduction and overexcretion (hypoxanthine phosphoribosyltransferase deficiency or phosphoribosyl pyrophosphate [PRPP] synthetase overactivity) or an underlying autosomal dominant renal disorder in which renal uric acid clearance is impaired [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36266/abstract/5\">",
"     5",
"    </a>",
"    ]. The latter disorder is suggested by the presence of hyperuricemia with a normal 24-hour excretion of uric acid, especially when accompanied by a marked reduction in the fractional clearance of uric acid.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Goals",
"    </span>",
"    &nbsp;&mdash;&nbsp;The general goal of antihyperuricemic therapy is a serum urate concentration of &lt;6",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (&lt;357",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36266/abstract/21\">",
"     21",
"    </a>",
"    ], which is substantially below the urate concentration (6.8",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    at which monosodium urate is saturating in extracellular fluids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36266/abstract/22\">",
"     22",
"    </a>",
"    ]. Lowering the serum uric acid slowly (no more than 1 to 2",
"    <span class=\"nowrap\">",
"     mg/dL/month)",
"    </span>",
"    is suggested. A goal serum urate of &lt;5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    <span class=\"nowrap\">",
"     (&lt;297micromol/L)",
"    </span>",
"    may be appropriate in patients with tophi.",
"   </p>",
"   <p>",
"    The efficacy of pharmacologic lowering of serum urate to this degree was illustrated by a retrospective study of Japanese patients with newly diagnosed gout [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36266/abstract/23\">",
"     23",
"    </a>",
"    ]. Lowering mean serum urate to less than 6",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (&lt;357",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    resulted in elimination of recurrent attacks in 71 of 81 patients (86 percent) after the first year of treatment and during the years (up to three) of urate-lowering therapy. Another retrospective review found that the optimal range of serum urate concentrations on therapy was 4.6 to 6.6",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (273 to 392",
"    <span class=\"nowrap\">",
"     micromol/L),",
"    </span>",
"    and lowering serum urate slowly (no more than 0.6",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [36",
"    <span class=\"nowrap\">",
"     micromol/L]",
"    </span>",
"    per month during the first six months) was associated with the lowest rate of recurrent acute attacks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36266/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Initiation and duration of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is generally recommended that urate-lowering therapy not be initiated until the acute inflammatory event has resolved. Acute urate-lowering can precipitate an attack, and initiation of therapy during an acute attack can theoretically worsen the arthritis, although the absolute risks of these complications are not clear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36266/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. Based upon clinical experience and given these concerns, we generally wait until at least two weeks after an acute flare subsides to obtain baseline serum uric acid testing and to begin urate-lowering therapy. Urate lowering has been successfully initiated during a flare while under",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    treatment in patients with very difficult to manage recurrent flares. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Prophylaxis during initiation of antihyperuricemic therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Once the decision is made to begin therapy to lower serum urate, the duration of therapy is indefinite and should be continuous to remain effective. One study looked at the value of intermittent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/40/25223?source=see_link\">",
"     allopurinol",
"    </a>",
"    (two months per year) compared with continuous therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36266/abstract/27\">",
"     27",
"    </a>",
"    ]. Acute gouty arthritis occurred with similar frequency in both groups during the first year, but, after one year, the continuous allopurinol group experienced fewer attacks.",
"   </p>",
"   <p>",
"    The majority of patients who achieve control of gout with long-term urate-lowering therapy will have recurrent symptoms",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    tophi if treatment is stopped [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36266/abstract/28-31\">",
"     28-31",
"    </a>",
"    ]. In addition, lower serum urate concentrations during treatment correlate with a longer delay before acute attacks resume or tophi reappear. In one study, for example, patients with average serum urate concentrations less than 5.05",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (&lt;300",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    during continuous treatment for at least six years had the longest time to recurrence (mean of three to four years) after the cessation of urate-lowering therapy, probably due to a greater reduction in the urate pool [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36266/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Nonadherence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonadherence to recommended treatment is an important issue in patients with gout. Treatment is prolonged (perhaps lifelong), and the patient is asymptomatic for the vast majority of the time. The extent of patient nonadherence was illustrated in a study that tracked use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/40/25223?source=see_link\">",
"     allopurinol",
"    </a>",
"    over two years in a managed care setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36266/abstract/32\">",
"     32",
"    </a>",
"    ]. Less than 20 percent of patients who initiated treatment complied well with therapy (defined as using the drug on 80 percent or more of the days during the study). Perhaps better compliance can be achieved if patients are provided an understandable rationale for taking medication daily over the long term and without symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Uricosuric drugs",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Decreased efficiency of renal uric acid excretion is responsible for at least 85 to 90 percent of cases of primary or secondary hyperuricemia (",
"    <a class=\"graphic graphic_table graphicRef66799 \" href=\"mobipreview.htm?43/14/44267\">",
"     table 1",
"    </a>",
"    ). Patients with relative renal underexcretion of uric acid (ie, normal values for uric acid excretion in the presence of hyperuricemia) are candidates for a uricosuric drug (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/18/37157?source=see_link\">",
"     probenecid",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/42/24230?source=see_link\">",
"     \"Uric acid balance\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Uricosuric treatment has been used rather uncommonly in the US since the introduction of the xanthine oxidase inhibitor,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/40/25223?source=see_link\">",
"     allopurinol",
"    </a>",
"    , in 1966, although a substantial proportion of gout patients with indications for urate-lowering could be candidates for a uricosuric agent. Reasons for this discrepancy include the smaller range of gout patients for whom uricosuric agents are appropriate, in comparison with xanthine oxidase inhibitors, and the requirement for multiple daily dosing of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/18/37157?source=see_link\">",
"     probenecid",
"    </a>",
"    , the only potent uricosuric agent currently available in the US. The use of uricosuric therapy is more common in countries where benzbromarone is available; this uricosuric agent is highly effective and can be administered in a single daily dose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36266/abstract/21,33\">",
"     21,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Uricosuric agents should be avoided in those in whom nephrolithiasis or uric acid nephropathy might occur. Thus, relative to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/40/25223?source=see_link\">",
"     allopurinol",
"    </a>",
"    (see below), uricosuric drugs are second-line agents in patients with tophaceous disease or urate overproduction. In addition,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/18/37157?source=see_link\">",
"     probenecid",
"    </a>",
"    should not be used in hyperuricemic patients who also have cystinuria because of increased urinary cystine and, in those treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/6/4200?source=see_link\">",
"     penicillamine",
"    </a>",
"    , decreased cysteine-penicillamine mixed disulfide and penicillamine disulfide metabolites [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36266/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/62/25577?source=see_link&amp;anchor=H18#H18\">",
"     \"Cystine stones\", section on 'Penicillamine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/18/37157?source=see_link\">",
"     Probenecid",
"    </a>",
"    and sulfinpyrazone are effective for most patients but are likely to be ineffective in those with impaired renal function. Benzbromarone, where available, may be more effective for patients with mild to moderate renal insufficiency (creatinine clearance 30 to 59 mL per minute) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36266/abstract/35,36\">",
"     35,36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Agents and dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The uricosuric drugs are weak organic acids that promote renal clearance of uric acid by inhibiting urate-anion exchangers in the proximal tubule that mediates urate reabsorption [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36266/abstract/37,38\">",
"     37,38",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/18/37157?source=see_link\">",
"     Probenecid",
"    </a>",
"    , although infrequently used, is the most widely used of the uricosuric drugs in the United States, where sulfinpyrazone has been withdrawn from the market. Other uricosuric agents, such as benzbromarone, have gained use elsewhere [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36266/abstract/21,33\">",
"     21,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/18/37157?source=see_link\">",
"     Probenecid",
"    </a>",
"    is started at a dose of 250 mg twice daily; increments in dose are titrated according to the serum urate concentration. The dose is typically raised every several weeks to a usual maintenance dose of 500 to 1000 mg two or three times daily, aiming for the usual target for urate lowering in gout of a serum urate &lt;6",
"    <span class=\"nowrap\">",
"     mg/dL.",
"    </span>",
"    The maximal effective dose is 3",
"    <span class=\"nowrap\">",
"     g/day.",
"    </span>",
"   </p>",
"   <p>",
"    Sulfinpyrazone, where available, is started at a dose of 50 mg twice daily, with increments over several weeks to 100 to 200 mg three or four times daily as needed. The maximum effective dose of sulfinpyrazone is 800",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Side effects and interactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major side effects of uricosuric drugs are rash, precipitation of acute gouty arthritis (see",
"    <a class=\"local\" href=\"#H24\">",
"     'Prophylaxis during initiation of antihyperuricemic therapy'",
"    </a>",
"    below), gastrointestinal intolerance, and uric acid stone formation. A scheme for monitoring the course of uricosuric therapy to reduce the risk of excessive uric acid crystal deposition and stones or obstructive uropathy emphasizes adequate fluid intake and serial measurements of urinary uric acid and pH, as well as the serum urate concentration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36266/abstract/36\">",
"     36",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/18/37157?source=see_link\">",
"     Probenecid",
"    </a>",
"    also increases urinary calcium excretion in gouty patients, reinforcing the contraindication for its use in patients with prior nephrolithiasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36266/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Interference with the transport of other organic anions across cell membranes by uricosuric drugs is the basis of numerous drug interactions. As an example, urinary excretion of penicillin and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    are decreased by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/18/37157?source=see_link\">",
"     probenecid",
"    </a>",
"    , resulting in prolongation of the half-lives of these antibiotics.",
"   </p>",
"   <p>",
"    The uricosuric effect of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/18/37157?source=see_link\">",
"     probenecid",
"    </a>",
"    may be reduced by relatively large doses of salicylates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36266/abstract/40\">",
"     40",
"    </a>",
"    ]. However, low dose daily",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , as used to prevent cardiovascular disease, may not have such an effect. In a crossover trial of 11 patients, the addition of low dose aspirin (325",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    to an ongoing regimen of probenecid did not change the serum urate concentration or daily uric acid excretion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36266/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Other drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, the angiotensin II receptor antagonist,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/35/26168?source=see_link\">",
"     losartan",
"    </a>",
"    , has a modest uricosuric effect that appears to plateau at a dose of 50",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36266/abstract/18\">",
"     18",
"    </a>",
"    ]. Losartan may be an option for patients who need an antihypertensive agent and in whom the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/18/37157?source=see_link\">",
"     probenecid",
"    </a>",
"    is not feasible due, for example, to allergy or intolerance. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/26/29094?source=see_link&amp;anchor=H3#H3\">",
"     \"Diuretic-induced hyperuricemia and gout\", section on 'Benefits of angiotensin inhibition and losartan'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/23/17784?source=see_link\">",
"     Fenofibrate",
"    </a>",
"    , a fibric acid derivative used for the treatment of hyperlipidemia, also has uricosuric activity. In a short-term unblinded study of 10 patients with gout who were already being treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/40/25223?source=see_link\">",
"     allopurinol",
"    </a>",
"    , the addition of fenofibrate (200",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    resulted in a 19 percent reduction in serum urate and a mean increase in uric acid renal clearance of 36 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36266/abstract/42\">",
"     42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/39/7800?source=see_link\">",
"     \"Lipid lowering with fibric acid derivatives\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Vitamin C may have a mild but persistent urate-lowering effect. This was illustrated in a trial that randomly assigned nonsmoking adults to 500 mg of vitamin C or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36266/abstract/43\">",
"     43",
"    </a>",
"    ]. Vitamin C significantly reduced serum urate levels by 0.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (30",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    compared with no change with placebo. Evaluation of vitamin C in patients with gout is warranted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Xanthine oxidase inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/40/25223?source=see_link\">",
"     Allopurinol",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29668?source=see_link\">",
"     febuxostat",
"    </a>",
"    are the only readily available xanthine oxidase inhibitors. Oxypurinol, an active metabolite of allopurinol, was formerly available on a \"compassionate use\" basis for patients intolerant of allopurinol. Some patients treated with oxypurinol tolerated this agent with satisfactory urate-lowering and clinical benefit, but other allopurinol-intolerant individuals showed adverse reactions similar to those expressed while previously receiving allopurinol [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36266/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/18/37157?source=see_link\">",
"     probenecid",
"    </a>",
"    , which is primarily indicated only in patients who have impaired renal excretion of uric acid, xanthine oxidase inhibitors are likely to be effective in virtually all circumstances warranting urate-lowering therapy for gout. However, safety considerations limit their use in some patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Allopurinol",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Mechanism",
"      </strong>",
"      &mdash;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/40/25223?source=see_link\">",
"       Allopurinol",
"      </a>",
"      inhibition of uric acid production is in large part due to inhibition of xanthine oxidase (xanthine dehydrogenase) by both the native drug and the active metabolite oxypurinol. Allopurinol and oxypurinol are pyrazolo-pyrimidine analogs of the purine bases hypoxanthine and xanthine, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/26/36266/abstract/45,46\">",
"       45,46",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Allopurinol has multiple effects on human purine and pyrimidine metabolism:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      It is a competitive inhibitor of xanthine oxidase and, along with oxypurinol, produces pseudo-irreversible inactivation of the enzyme. As a result, urate production falls, but hypoxanthine and xanthine accumulate in body fluids, producing a state of pharmacologic xanthinuria.",
"     </li>",
"     <li>",
"      It substantially reduces total urinary purine (uric acid plus hypoxanthine plus xanthine) excretion in most patients. This effect is due to inhibition of purine synthesis by drug-derived and endogenous nucleotide products of enhanced purine base reutilization. This effect requires activity of the enzyme HPRT and potentiates the fall in serum urate levels.",
"     </li>",
"     <li>",
"      Through nucleotide derivatives of oxypurinol, it induces a state of orotic aciduria and orotidinuria, due to inhibition of the enzyme orotidylate decarboxylase in the pathway of pyrimidine nucleotide synthesis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/26/36266/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Dose",
"      </strong>",
"      &mdash; The most commonly used daily dose of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/40/25223?source=see_link\">",
"       allopurinol",
"      </a>",
"      is 300 mg, despite approval in the US and Europe of daily doses up to 800 mg and 900 mg, respectively. There is considerable interpatient variation in the daily dose required to achieve control of the serum urate concentration, ranging from 100 to 800 mg or even more. Some studies suggest that baseline serum urate concentrations may have increased among gout patients compared with values encountered several decades ago when allopurinol was in clinical development [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/26/36266/abstract/48,49\">",
"       48,49",
"      </a>",
"      ]. As a result, a majority of gout patients may require doses of allopurinol exceeding 300",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      in order to achieve a serum urate &lt;6.0",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (&lt;357",
"      <span class=\"nowrap\">",
"       micromol/L).",
"       <br/>",
"       <br/>",
"       We",
"      </span>",
"      usually initiate allopurinol treatment at 100 mg daily in patients with weight-adjusted creatinine clearances &gt;40",
"      <span class=\"nowrap\">",
"       ml/min",
"      </span>",
"      and titrate the dose according to the antihyperuricemic effect achieved. The half-life of oxypurinol is prolonged in renal functional impairment. This fact and the belief that metabolites of oxypurinol may play a role in severe allopurinol toxic reactions led to the publication of recommendations for reducing the starting allopurinol dose for patients with more severe renal functional impairment, as discussed below. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Prophylaxis in advanced chronic kidney disease'",
"      </a>",
"      below.)",
"      <br/>",
"      <br/>",
"      Serum urate levels begin to fall within two days of allopurinol administration and reach stable levels in one to two weeks. Thus, when titrating allopurinol dosage, the urate-lowering effect of the current dose can be assessed after two or three weeks of treatment. Allopurinol may not induce goal serum urate levels early in the course of therapy of patients with extensive tophaceous deposits. However, true refractoriness to the drug is rare and most often reflects a failure of patient adherence or of clinician-patient communication [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/26/36266/abstract/4,22\">",
"       4,22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Side effects",
"      </strong>",
"      &mdash; The therapeutic effectiveness of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/40/25223?source=see_link\">",
"       allopurinol",
"      </a>",
"      has been documented for more than 40 years, but side effects and adverse reactions, sometimes severe, have been encountered [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/26/36266/abstract/22\">",
"       22",
"      </a>",
"      ]. (See",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/40/25223?source=see_link\">",
"       \"Allopurinol: Drug information\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      As with uricosuric agents,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/40/25223?source=see_link\">",
"       allopurinol",
"      </a>",
"      administration can precipitate acute gouty arthritis, especially if",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/13/32983?source=see_link\">",
"       colchicine",
"      </a>",
"      prophylaxis has been omitted. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Prophylaxis during initiation of antihyperuricemic therapy'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Among adverse reactions occurring in 3 to 5 percent of patients are rash, leukopenia or thrombocytopenia, diarrhea, and drug fever. Many types of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/40/25223?source=see_link\">",
"       allopurinol",
"      </a>",
"      rashes have been described. Some rashes are mild and remit with reduction in allopurinol dose. However, even a mild rash may be a harbinger of allopurinol hypersensitivity and should demand attention. Severe cutaneous reactions have included toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome. In one report from Taiwan, each of 51 patients with severe cutaneous reactions to allopurinol were found to carry the histocompatibility haplotype HLA- B*5801 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/26/36266/abstract/50\">",
"       50",
"      </a>",
"      ]. A study in Thailand confirmed the association of this haplotype with severe cutaneous reactions to allopurinol in each of 27 patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/26/36266/abstract/51\">",
"       51",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      A study of drug-induced severe cutaneous reactions in six European and Middle Eastern countries identified allopurinol as the most common drug cause of such reactions. These findings confirm a problem of significant extent and severity but also suggest that a means may soon become available for risk management or prevention of at least severe allopurinol complications, particularly if the haplotype association is confirmed in other population groups.",
"      <br/>",
"      <br/>",
"      Desensitization to allopurinol has been successfully accomplished in some patients with adverse reactions [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/26/36266/abstract/52-56\">",
"       52-56",
"      </a>",
"      ]. However, desensitization protocols are cumbersome, and recurrence of hypersensitivity reactions has been reported [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/26/36266/abstract/57\">",
"       57",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/40/25223?source=see_link\">",
"       allopurinol",
"      </a>",
"      hypersensitivity syndrome (AHS), consisting of an erythematous rash, fever, hepatitis, eosinophilia, and acute renal failure, is an unusual but potentially life-threatening reaction, with a mortality rate approaching 25 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/26/36266/abstract/58,59\">",
"       58,59",
"      </a>",
"      ]. Although the incidence of AHS is unlikely to exceed 0.1 percent of treated patients, this dramatic side effect has, in our opinion, influenced allopurinol prescribing patterns toward use of lower and often inadequate doses of this agent. The AHS may be more likely to occur in patients with renal insufficiency who are treated with allopurinol and a diuretic. As a result, administration of allopurinol should be limited to patients with appropriate indications for its use and used only at the minimum dose necessary to achieve an adequate antihyperuricemic effect.",
"     </li>",
"     <li>",
"      Among additional adverse reactions to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/40/25223?source=see_link\">",
"       allopurinol",
"      </a>",
"      are gastrointestinal intolerance, vasculitis, and interstitial nephritis.",
"     </li>",
"     <li>",
"      Urolithiasis or crystalluria composed of xanthine or oxypurinol crystals is rare and is more likely to occur in patients with significant uric acid overproduction, resulting either from an inherited defect in an enzyme of purine nucleotide synthesis or cytolytic cancer chemotherapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Drug interactions",
"      </strong>",
"      &mdash; The following important drug interactions with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/40/25223?source=see_link\">",
"       allopurinol",
"      </a>",
"      have been reported (see",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/40/25223?source=see_link\">",
"       \"Allopurinol: Drug information\"",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Potentiation of the immunosuppressive and cytolytic effects of 6-",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/43/37559?source=see_link\">",
"       mercaptopurine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      , which are metabolized in part by xanthine oxidase [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/26/36266/abstract/2,60\">",
"       2,60",
"      </a>",
"      ]. Thus,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/40/25223?source=see_link\">",
"       allopurinol",
"      </a>",
"      should generally be avoided in patients treated with these drugs. If, however, the patient has severe gout and allopurinol must be used, we have reduced the azathioprine dose (by at least 50 percent) and carefully monitored the white blood cell count. Azathioprine eventually has to be discontinued in many such patients. A possible alternative in some disorders is switching from azathioprine to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      , which does not interact with allopurinol. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/14/3303?source=see_link\">",
"       \"Hyperuricemia and gout in renal transplant recipients\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Bone marrow suppression in patients receiving alkylating agents, such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/26/36266/abstract/61\">",
"       61",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      A marked increase in the likelihood of an",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/51/13112?source=see_link\">",
"       ampicillin",
"      </a>",
"      -induced rash [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/26/36266/abstract/1\">",
"       1",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Febuxostat",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Mechanism",
"      </strong>",
"      &mdash;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29668?source=see_link\">",
"       Febuxostat",
"      </a>",
"      is a xanthine oxidase inhibitor. It is a thiazolecarboxylic acid derivative that, unlike",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/40/25223?source=see_link\">",
"       allopurinol",
"      </a>",
"      , is not a purine base analogue.",
"     </li>",
"     <li>",
"      <strong>",
"       Efficacy",
"      </strong>",
"      &mdash;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29668?source=see_link\">",
"       Febuxostat",
"      </a>",
"      produces a dose-dependent decrease in serum urate levels [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/26/36266/abstract/62\">",
"       62",
"      </a>",
"      ]. A daily dose of 40 mg produces a reduction that is roughly equivalent to that seen in patients who are treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/40/25223?source=see_link\">",
"       allopurinol",
"      </a>",
"      at a dose of 300 mg per day [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/26/36266/abstract/49,63\">",
"       49,63",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      A phase III 52-week trial involved 760 patients with gout and serum urate &ge;8",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (&ge;476",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      who were assigned to febuxostat at daily doses of 80 or 120 mg or to allopurinol at 300 mg daily [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/26/36266/abstract/49\">",
"       49",
"      </a>",
"      ]. Although serum urate levels were significantly reduced in all three study groups, the primary efficacy end point of the study, reduction of serum urate to a target level &lt;6",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (&lt;357",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      on each of the last three study visits, was achieved by a significantly greater proportion of those in the 80 and 120 mg febuxostat groups than those in the allopurinol 300 mg group (53 and 62 versus 21 percent, respectively).",
"      <br/>",
"      <br/>",
"      Trends toward reductions in gout flare incidence and in tophus areas over time were observed in all three treatment groups, but these end points were not significantly different among the groups over the year-long trial. The incidence of adverse events did not differ across the groups, but withdrawal from the study due to gout flares and abnormal liver function studies was more common in both febuxostat groups than the allopurinol group.",
"      <br/>",
"      <br/>",
"      In a second phase III safety and efficacy trial of six months' duration [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/26/36266/abstract/64\">",
"       64",
"      </a>",
"      ], febuxostat (at daily doses of 80 mg or 120 mg) was compared with allopurinol (300 mg or, in the case of subjects with renal functional impairment, 100 mg) and placebo. This study confirmed the superiority in urate-lowering efficacy of febuxostat at both doses relative to allopurinol and placebo, both in subjects with normal renal function and in a small subgroup of subjects with mild to moderate CKD. No dose reduction in febuxostat appeared necessary in subjects with these levels of CKD.",
"      <br/>",
"      <br/>",
"      The use of febuxostat in patients with mild or moderate renal functional impairment (defined, respectively, as estimated creatinine clearance of 60 to 89",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      and 30 to 59",
"      <span class=\"nowrap\">",
"       mL/min)",
"      </span>",
"      was assessed as part of a six-month study that randomly assigned 2268 subjects with gout and baseline sUA &ge;8",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (476",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      to receive febuxostat 40 mg or 80 mg daily or allopurinol (300 mg daily in subjects with normal or mildly impaired renal function or 200 mg daily if baseline renal function was moderately impaired) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/26/36266/abstract/63\">",
"       63",
"      </a>",
"      ]. Approximately 65 percent of subjects in each treatment group had either mild or moderate renal impairment, and, in this subset of patients, urate-lowering with febuxostat at either 40 mg with 50 percent and 80 mg with 72 percent was more likely to achieve the serum urate goal. Safety was comparable across all treatment groups.",
"     </li>",
"     <li>",
"      <strong>",
"       Dose",
"      </strong>",
"      &mdash;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29668?source=see_link\">",
"       Febuxostat",
"      </a>",
"      received approval from the US Food and Drug Administration for treatment of hyperuricemia in gout at daily doses of 40 mg and 80 mg [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/26/36266/abstract/65\">",
"       65",
"      </a>",
"      ]. The American manufacturers recommended that the starting dose is 40 mg once daily. An increase in dose to 80 mg daily is suggested for patients whose serum urate level does not fall to &lt;6",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (&lt;357",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      after two weeks of treatment on the lower (40 mg daily) dose. In Europe, higher doses have received regulatory approval (80 to 120",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/26/36266/abstract/66\">",
"       66",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Important drug interactions",
"      </strong>",
"      &mdash; Decreased metabolism of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/43/37559?source=see_link\">",
"       mercaptopurine",
"      </a>",
"      is an expected result of administration of a xanthine oxidase inhibitor, and a need for continued use of any of these three drugs is considered by the manufacturer to be a contraindication to the use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29668?source=see_link\">",
"       febuxostat",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/26/36266/abstract/67\">",
"       67",
"      </a>",
"      ]. As noted above, we and others have used reduced doses of azathioprine or mercaptopurine with the xanthine oxidase inhibitor",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/40/25223?source=see_link\">",
"       allopurinol",
"      </a>",
"      while carefully monitoring for bone marrow toxicity (ie, development of cytopenias). It is uncertain at present whether such a strategy can safely be pursued with febuxostat.",
"     </li>",
"     <li>",
"      <strong>",
"       Side effects",
"      </strong>",
"      &mdash; A greater incidence of liver function test abnormalities, nausea, arthralgia, and rash has been noted in",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29668?source=see_link\">",
"       febuxostat",
"      </a>",
"      -treated patients than in placebo controls, but not in",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/40/25223?source=see_link\">",
"       allopurinol",
"      </a>",
"      -treated subjects, during clinical trials. Periodic monitoring of liver function, principally hepatic transaminase enzyme levels, is suggested by the manufacturer of febuxostat [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/26/36266/abstract/67\">",
"       67",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      During clinical trials, patients treated with febuxostat had a higher incidence of cardiovascular events than comparators who received allopurinol (0.74 [95% CI 0.36-1.37] versus 0.60 [95% CI 0.16-1.53] events per 100 patient years, respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/26/36266/abstract/67\">",
"       67",
"      </a>",
"      ]. However, such an imbalance was not confirmed in a subsequent randomized trial [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/26/36266/abstract/63\">",
"       63",
"      </a>",
"      ], and a postmarketing study relevant to this finding is in progress.",
"      <br/>",
"      <br/>",
"      As with any urate lowering treatment, the risk of acute gout attacks is increased when febuxostat is initiated. Prophylaxis for acute attacks is recommended. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Prophylaxis during initiation of antihyperuricemic therapy'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      <strong>",
"       Cost",
"      </strong>",
"      &mdash; The cost of treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29668?source=see_link\">",
"       febuxostat",
"      </a>",
"      is substantially higher than with either generic",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/40/25223?source=see_link\">",
"       allopurinol",
"      </a>",
"      or its brand name equivalent. The average retail cost of a 30-day supply of febuxostat in retail pharmacies in the United States is reported to be 161.4 dollars, more than 10 times the cost of the generic allopurinol (300",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      and four times as much as one pharmaceutical brand of allopurinol.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Combination therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of combined therapy with a uricosuric drug and a xanthine oxidase inhibitor has not been well studied in a randomized manner and with controls. Pharmacologic interactions between",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/40/25223?source=see_link\">",
"     allopurinol",
"    </a>",
"    and uricosuric agents have been documented, including increased excretion of oxypurinol during uricosuric therapy. Despite these concerns, combined therapy with both classes of antihyperuricemic drugs has, when occasionally required for adequate serum urate lowering, usually proven to be safe and effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36266/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Choice of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both uricosuric drugs and xanthine oxidase inhibitors have comparable efficacy in establishing normouricemia and ultimately in decreasing or abolishing attacks of gouty arthritis and preventing tophi.",
"   </p>",
"   <p>",
"    The majority of patients with gout underexcrete uric acid (ie, they require a higher serum urate concentration to excrete the daily uric acid load) and are candidates for uricosuric therapy. However,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/40/25223?source=see_link\">",
"     allopurinol",
"    </a>",
"    is the most frequently prescribed antihyperuricemic drug, in part because of its ease of use (once daily versus two to three times daily for uricosuric agents) and because it is effective regardless of the cause of hyperuricemia.",
"   </p>",
"   <p>",
"    Nevertheless, safety considerations with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/40/25223?source=see_link\">",
"     allopurinol",
"    </a>",
"    and the demonstrated long-term efficacy of uricosuric drugs make use of uricosuric agents an alternative that merits strong consideration in many patients with interval gout, with the following exceptions (",
"    <a class=\"graphic graphic_figure graphicRef78555 \" href=\"mobipreview.htm?32/13/32978\">",
"     algorithm 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients who are overproducers of uric acid or who have a history of urolithiasis",
"     </li>",
"     <li>",
"      Patients with chronic kidney disease (CKD; creatinine clearance &lt;80",
"      <span class=\"nowrap\">",
"       mL/min),",
"      </span>",
"      in whom uricosuric agents show diminished efficacy with increasing renal functional impairment. An exception to this statement may be benzbromarone, a uricosuric drug that is effective in patients with mild to moderate renal insufficiency [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/26/36266/abstract/69\">",
"       69",
"      </a>",
"      ]. However, benzbromarone is unavailable in many countries, including the United States.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It has been suggested that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/40/25223?source=see_link\">",
"     allopurinol",
"    </a>",
"    is preferable to uricosuric drugs in patients over the age of 60 and in those who have already developed tophi [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36266/abstract/70\">",
"     70",
"    </a>",
"    ]. The former recommendation stems from an assumption that the loss of renal function with age limits the usefulness of uricosuric agents in older adults, and the latter stems from a theoretical concern about inducing uric acid renal stones or sludge due to excretion of large amounts of preformed urate.",
"   </p>",
"   <p>",
"    There is no evidence that tailoring antihyperuricemic therapy to the results of 24-hour urine testing for uric acid excretion improves outcomes. Nevertheless, such an approach is suggested if uricosuric therapy is being considered [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36266/abstract/36\">",
"     36",
"    </a>",
"    ]. Patients with gout who excrete less than 800 mg (4.76 mmol) of uric acid per day on a standard diet are potential candidates for uricosuric drug therapy in the absence of the contraindications listed above.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Colchicine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    is effective for the treatment of acute gouty arthritis, particularly when administered early after the onset of symptoms. This agent does not affect serum urate levels and is thus not a urate-lowering agent. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/24/17800?source=see_link\">",
"     \"Treatment of acute gout\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    is, however, also of value in reducing the frequency of recurrent episodes of acute gouty arthritis early in the course of urate-lowering with uricosuric agents or xanthine oxidase inhibitors (",
"    <a class=\"graphic graphic_figure graphicRef78555 \" href=\"mobipreview.htm?32/13/32978\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36266/abstract/71,72\">",
"     71,72",
"    </a>",
"    ]. Because of potential toxicity (eg, myopathy or neuromyopathy) and because of the fact that it does not prevent urate accumulation, colchicine is now infrequently used for long-term prophylaxis (ie, for periods exceeding six months' duration) compared with uricosuric drugs and xanthine oxidase inhibitors, but it is given as short-term therapy to prevent acute attacks during the initiation of antihyperuricemic therapy. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Prophylaxis during initiation of antihyperuricemic therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Resources for patients who need assistance paying for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    or other medications are reviewed separately. (See",
"    <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/61/32726?source=see_link&amp;anchor=H18537225#H18537225\">",
"     \"Patient information: Reducing the costs of medicines (Beyond the Basics)\", section on 'Help paying for your medicine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Uricase",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uricase (urate oxidase) is the enzyme that catalyzes conversion of urate to a more soluble purine degradation product, allantoin. Uricase is present in most mammals but is absent in humans and some primate species due to mutational inactivation of the uricase gene.",
"   </p>",
"   <p>",
"    Urate-lowering therapy for gout with uricase is aimed at supplying the absent enzyme activity safely and for a sufficient period of time to promote depletion of body urate pools, thus resulting in clinical benefits such as gout flare reduction and tophus resolution. Pursuit of these aims has resulted in the development of recombinant uricases, modified by covalent linkage to polyethylene-glycol (PEG) in order to prolong enzyme activity and potentially reduce immunogenicity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H402899\">",
"    <span class=\"h3\">",
"     Pegloticase",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/38/41572?source=see_link\">",
"     Pegloticase",
"    </a>",
"    is a porcine uricase linked to methoxy polyethylene-glycol; we use pegloticase as an option for patients whose gout is advanced, actively symptomatic, and uncontrolled by other urate-lowering therapies or for whom such therapies are contraindicated. An important criterion in support of the candidacy of such patients for pegloticase treatment is the need for rapid improvement in clinical outcomes, such as flare and tophus reduction, function, and quality of life, outcomes that take several years to achieve with oral agents and only months in some pegloticase-treated patients.",
"   </p>",
"   <p>",
"    Regulatory approval in the United States was based upon the results of two replicate randomized trials, which showed efficacy for patients with chronic gout reported to be refractory to conventional treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36266/abstract/73,74\">",
"     73,74",
"    </a>",
"    ]. The two phase-3 trials enrolled a total of 225 patients with treatment resistant gout and serum urate levels &ge;8",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (475",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    who were randomly assigned (in a 2:2:1 ratio) to receive infusions of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/38/41572?source=see_link\">",
"     pegloticase",
"    </a>",
"    (8 mg every two weeks or 8 mg every four weeks) or placebo for six months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36266/abstract/74\">",
"     74",
"    </a>",
"    ]. A total of 212 patients received at least one infusion. All patients received prophylaxis for gout attacks with either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    or an NSAID and a proton pump inhibitor. They also received prophylaxis for infusion reactions with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/33/35350?source=see_link\">",
"     fexofenadine",
"    </a>",
"    the night before the infusion, fexofenadine and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    on the morning of the infusion, and 200 mg of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    administered intravenously immediately before each infusion.",
"   </p>",
"   <p>",
"    The primary outcome measure was a reduction of plasma urate to less than 6",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (357",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    for 80 percent of the time during months three and six of the trial. The results included the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients were predominantly white men with a mean age of about 55 years. Tophi, frequent gout flares, and a contraindication to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/40/25223?source=see_link\">",
"       allopurinol",
"      </a>",
"      use were frequent characteristics of the patients in these studies. Hypertension, obesity, dyslipidemia, diabetes, and atherosclerotic vascular disease were common comorbidities. Patients excluded from the trials included those with unstable angina, uncontrolled hypertension",
"      <span class=\"nowrap\">",
"       (&gt;150/95",
"      </span>",
"      mm Hg) or cardiac arrhythmia, uncompensated heart failure, renal dialysis, or solid organ transplant.",
"     </li>",
"     <li>",
"      Persistent lowering of plasma urate to less than 6",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      was achieved in a substantially higher proportion of subjects receiving",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/38/41572?source=see_link\">",
"       pegloticase",
"      </a>",
"      than those receiving placebo (42, 35, and 0 percent, in the two-week, four-week, and placebo groups, respectively).",
"     </li>",
"     <li>",
"      Complete resolution of at least one tophus by the final visit was more frequent in those receiving",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/38/41572?source=see_link\">",
"       pegloticase",
"      </a>",
"      every two weeks than placebo (40 versus 7 percent). There was a similar trend for those receiving pegloticase every four weeks, but this did not achieve statistical significance (21 versus 7 percent).",
"     </li>",
"     <li>",
"      The urate-lowering effect of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/38/41572?source=see_link\">",
"       pegloticase",
"      </a>",
"      infusions was attenuated or lost in some patients, usually as a result of the development of high titer pegloticase-antibody.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/38/41572?source=see_link\">",
"       Pegloticase",
"      </a>",
"      -antibody developed in nearly 90 percent of those receiving the active drug. High titers of the antibody were associated with loss of the urate-lowering effect of pegloticase and with increased risk for infusion reactions. Loss of urate-lowering efficacy among patients with infusion reactions preceded the first infusion reaction in 91 percent of patients (20 of 22) on every two week pegloticase and 71 percent of those (24 of 34) receiving pegloticase every four weeks.",
"     </li>",
"     <li>",
"      Five patients on",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/38/41572?source=see_link\">",
"       pegloticase",
"      </a>",
"      , but none on placebo, had mild to moderately severe infusion reactions consistent with anaphylaxis, although three of these patients continued in the trial without further incident.",
"     </li>",
"     <li>",
"      Acute gout attacks and infusion reactions were the most common causes for patient withdrawal from the trials, despite prophylaxis for gout flares and infusion reactions; withdrawals due to adverse events were more frequent in the two- and four-week",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/38/41572?source=see_link\">",
"       pegloticase",
"      </a>",
"      groups than in the placebo group (18 and 19 versus 2 percent, respectively).",
"      <br/>",
"      <br/>",
"      As with the initiation of other urate lowering therapies, gout flares were more frequent in those receiving pegloticase than placebo during the first three months of study, but they were significantly less frequent in the group receiving pegloticase every other week than in the placebo group during months four to six. Serious cardiovascular (CV) adverse events were numerically more common during the trial in patients treated with pegloticase versus those treated with placebo (12 versus 0 percent). This difference was not statistically significant, and the CV adverse events were not related to treatment duration. Deaths due to any cause occurred in 4 of 169 pegloticase-treated subjects and 3 of 43 subjects in the placebo group.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/38/41572?source=see_link\">",
"     pegloticase",
"    </a>",
"    , with appropriate prophylaxis for acute gout attacks and for infusion reactions, represents a novel therapy that can be expected to be effective in approximately 40 percent of patients with gout that has not responded to other treatments or for those patients with contraindications to other uric acid lowering therapies.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/38/41572?source=see_link\">",
"     Pegloticase",
"    </a>",
"    treatment should be discontinued if there is loss of urate-lowering effectiveness as indicated (during monitoring of each pre-infusion serum uric acid concentration) by serum urate values &gt;6",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (&gt;357",
"    <span class=\"nowrap\">",
"     micromol/L).",
"    </span>",
"    Other urate-lowering therapies should not be given to patients receiving pegloticase, because they may mask recognition of the increasing serum urate levels associated with an increased risk for infusion-related reactions and loss of effectiveness resulting from the effects of high titer anti-pegloticase antibodies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36266/abstract/74,75\">",
"     74,75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Use should also be discontinued following a moderate to severe infusion reaction with features suggestive of hypersensitivity (eg, stridor,",
"    <span class=\"nowrap\">",
"     oral/lingual/pharyngeal",
"    </span>",
"    edema, wheezing, or hemodynamic instability).",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/38/41572?source=see_link\">",
"     Pegloticase",
"    </a>",
"    is contraindicated in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H402906\">",
"    <span class=\"h3\">",
"     Rasburicase",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of brief courses of nonpegylated recombinant uricase (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/54/34661?source=see_link\">",
"     rasburicase",
"    </a>",
"    , Elitek&trade;) for the prevention of acute uric acid nephropathy due to tumor lysis syndrome in patients with high risk lymphoma and leukemia is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/20/3402?source=see_link&amp;anchor=H21712072#H21712072\">",
"     \"Tumor lysis syndrome: Prevention and treatment\", section on 'Rasburicase'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Experience with this agent for the treatment of gout is limited [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36266/abstract/76\">",
"     76",
"    </a>",
"    ], largely by the expectation that this unmodified foreign protein is likely to be more immunogenic than pegylated uricases over the longer term of treatment needed for achieving the aims of gout management. However, repeated infusions of modified or unmodified uricase can reduce the size of tophi in patients with tophaceous disease, including those with solid organ transplants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36266/abstract/77-79\">",
"     77-79",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     PROPHYLAXIS DURING INITIATION OF ANTIHYPERURICEMIC THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The increase in uric acid excretion early in the course of treatment with uricosuric agents can promote urinary stone or gravel formation. The risk of precipitating urinary stone formation and acute gouty arthritis can be minimized by starting with low doses of antihyperuricemic therapy and by hydration (two or more liters of fluid daily). Alkalinization of the urine is, in most patients, unnecessary. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/62/3047?source=see_link\">",
"     \"Uric acid nephrolithiasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, an acute fall in serum urate concentration often precipitates acute gouty arthritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36266/abstract/49,80\">",
"     49,80",
"    </a>",
"    ]. Although unproven to date, a tenable explanation for the mechanism of this effect is that urate-lowering disrupts the physical state",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    surface chemical composition of preformed crystal deposits and thus makes the component crystals interactive with local cells competent in initiating IL-1- mediated acute inflammatory responses emanating from activation of toll-like receptors and the formation of NALP3 inflammasomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36266/abstract/81,82\">",
"     81,82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risk of precipitating acute gouty arthritis may be minimized by starting with low doses of antihyperuricemic therapy. It is a widely recommended practice to administer low doses of oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    or, less commonly, a nonsteroidal antiinflammatory drug in patients who are beginning antihyperuricemic therapy to decrease or prevent recurrent episodes of acute gouty arthritis. Identification of interleukin (IL)-1 as a major cytokine in the initiation of acute gouty flares [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36266/abstract/82\">",
"     82",
"    </a>",
"    ] has prompted interest in potential roles for IL-1 inhibitory agents (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/18/294?source=see_link\">",
"     anakinra",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/52/41796?source=see_link\">",
"     canakinumab",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/21/16724?source=see_link\">",
"     rilonacept",
"    </a>",
"    ) both in treatment of on-going flares [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36266/abstract/83,84\">",
"     83,84",
"    </a>",
"    ] and as prophylaxis of flares during the initiation of antihyperuricemic therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/43/28344?source=see_link&amp;anchor=H6#H6\">",
"     \"Pathophysiology of gouty arthritis\", section on 'Inflammation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Colchicine prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of prophylactic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    in patients beginning antihyperuricemic therapy was demonstrated in a randomized trial in which 43 patients were assigned to treatment with colchicine or placebo prior to initiation of urate-lowering therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36266/abstract/85\">",
"     85",
"    </a>",
"    ]. The patients were then followed for at least three months beyond the time their serum urate levels were reduced to a level of less than 6.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (&lt;387",
"    <span class=\"nowrap\">",
"     micromol/L).",
"    </span>",
"    At six months, there were significantly fewer acute attacks in those who received colchicine (mean number of flares 0.1 versus 1.8 with placebo).",
"   </p>",
"   <p>",
"    A typical",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    regimen at the initiation of antihyperuricemic therapy is 0.6 mg orally once or twice daily for patients with normal renal function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36266/abstract/25\">",
"     25",
"    </a>",
"    ]. Many patients, particularly older individuals, develop loose or diarrheal stools that preclude use of the recommended colchicine dose. Satisfactory prophylaxis in such patients is often attained with the lower colchicine doses of 0.6 mg once daily or even every other day. The dose of colchicine should also be reduced to 0.6 mg per day in patients with a creatinine clearance of 35 to 49",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    and to 0.6 mg every two to three days in patients with a creatinine clearance of 10 to 34",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"    Colchicine should not be used in patients with a creatinine clearance &lt;10",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    or in patients undergoing dialysis for end stage renal disease.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/13/32983?source=see_link\">",
"     Colchicine",
"    </a>",
"    -induced neuromyopathy is a potential complication of chronic therapy, particularly in patients with a reduced creatinine clearance. It should be suspected in patients who complain of paresthesias, numbness,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    weakness. Most cases occur in patients treated with daily low dose colchicine for months to years. Patients taking HMG-CoA reductase inhibitors (statins) may be at increased risk for colchicine-induced myopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36266/abstract/86\">",
"     86",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/44/6856?source=see_link&amp;anchor=H12#H12\">",
"     \"Drug-induced myopathies\", section on 'Colchicine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Organ transplant recipients who develop gout and are treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    while receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    are at increased risk for colchicine myopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36266/abstract/87\">",
"     87",
"    </a>",
"    ]. Such patients should be treated, if at all, with low doses of colchicine and for as brief a period of time as possible. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/14/3303?source=see_link\">",
"     \"Hyperuricemia and gout in renal transplant recipients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The cost of prophylactic use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    may be an issue for many patients and their clinicians. In the United States, only one manufacturer's brand is approved for use, and the cost of the FDA approved product is reportedly 4.30 US dollars per tablet [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36266/abstract/88\">",
"     88",
"    </a>",
"    ]. The manufacturer offers a program to defray the cost for eligible patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36266/abstract/89\">",
"     89",
"    </a>",
"    ]. Resources for patients who need assistance paying for colchicine or other medications are reviewed separately. (See",
"    <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/61/32726?source=see_link&amp;anchor=H18537225#H18537225\">",
"     \"Patient information: Reducing the costs of medicines (Beyond the Basics)\", section on 'Help paying for your medicine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     NSAID prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/50/36649?source=see_link\">",
"     Indomethacin",
"    </a>",
"    (25 mg twice daily) appears to be effective for prophylaxis in patients who do not tolerate low dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    , although the data are very limited [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36266/abstract/90\">",
"     90",
"    </a>",
"    ]. Nonsteroidal antiinflammatory drugs (NSAIDs) other than indomethacin may also be effective and may be associated with a lower frequency of side effects. Gastrointestinal toxicity is a potential complication of all NSAIDs. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/49/17177?source=see_link\">",
"     \"Nonselective NSAIDs: Overview of adverse effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/31/38393?source=see_link\">",
"     \"NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Duration of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of potential toxicity, the continued use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    or NSAIDs is not recommended after persistent normouricemia has been achieved with antihyperuricemic drugs. The recommended duration of prophylactic colchicine or NSAIDs during the initiation of uric acid lowering therapy varies with the clinical setting:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients without evident tophi, prophylaxis can often be safely discontinued six months after normal serum urate values have been obtained.",
"     </li>",
"     <li>",
"      The optimal duration of prophylactic therapy for patients with tophi is uncertain. Our practice for such patients is to continue",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/13/32983?source=see_link\">",
"       colchicine",
"      </a>",
"      for six months after resolution of these lesions, or it is clear that tophaceous deposits will not resolve despite persistent normouricemia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     PROPHYLAXIS IN ADVANCED CHRONIC KIDNEY DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment designed to prevent acute attacks of gout and to reduce the size of tophi is challenging in patients with advanced chronic kidney disease. Pharmacologic antihyperuricemic therapy and use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    are limited for the following reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Uricosuric drugs are relatively ineffective when the glomerular filtration rate is substantially reduced.",
"     </li>",
"     <li>",
"      The half-lives of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/40/25223?source=see_link\">",
"       allopurinol",
"      </a>",
"      and its active metabolite oxypurinol are prolonged in renal failure. A reduction in the starting dose, depending upon the severity of the reduction in glomerular filtration rate (",
"      <a class=\"graphic graphic_table graphicRef81066 \" href=\"mobipreview.htm?0/2/34\">",
"       table 2",
"      </a>",
"      ), is recommended. If limiting treatment to the listed starting dose, however, the desired serum urate concentration is often not achieved [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/26/36266/abstract/91\">",
"       91",
"      </a>",
"      ]. In such patients, cautious up-titration of the dose is warranted and has been successful without increased toxicity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/26/36266/abstract/92\">",
"       92",
"      </a>",
"      ], with careful observation for adverse effects.",
"     </li>",
"     <li>",
"      The clearance of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/13/32983?source=see_link\">",
"       colchicine",
"      </a>",
"      is reduced in patients with chronic kidney disease, increasing the risk of neuromyopathy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/26/36266/abstract/93\">",
"       93",
"      </a>",
"      ]. If given for prophylaxis, the recommended colchicine dose is 0.6 mg once daily at a creatinine clearance of 35 to 49",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      and 0.6 mg every two to three days at a creatinine clearance of 10 to 34",
"      <span class=\"nowrap\">",
"       mL/min.",
"      </span>",
"      Colchicine is not dialyzable and is contraindicated at a creatinine clearance below 10",
"      <span class=\"nowrap\">",
"       mL/min.",
"      </span>",
"     </li>",
"     <li>",
"      Among patients with chronic kidney disease, drugs that inhibit CYP3A4 or P-glycoprotein, including some commonly used antibiotics such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/57/10138?source=see_link\">",
"       clarithromycin",
"      </a>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/34/33312?source=see_link\">",
"       ketoconazole",
"      </a>",
"      ; antiretroviral drugs; and antihypertensive agents, including",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/16/12554?source=see_link\">",
"       diltiazem",
"      </a>",
"      ; further reduce clearance of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/13/32983?source=see_link\">",
"       colchicine",
"      </a>",
"      by interfering with colchicine metabolism. Concurrent use of these medications with colchicine may thus increase the risk of myelosuppression, and fatal pancytopenia may ensue [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/26/36266/abstract/93\">",
"       93",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Low doses of glucocorticoids may reduce the frequency of acute gout attacks, but a prophylactic benefit for glucocorticoids is not supported by adequate evidence. Adverse effects of chronic glucocorticoid use should be anticipated with long-term therapy. If used for prophylaxis, the glucocorticoid dose should be the minimum necessary to prevent recurrent attacks. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with gout and impaired renal function due to organ transplantation have additional issues including interactions between urate-lowering therapy with xanthine oxidase inhibitors (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/40/25223?source=see_link\">",
"     allopurinol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29668?source=see_link\">",
"     febuxostat",
"    </a>",
"    ) and immunosuppressive agents, particularly",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/43/37559?source=see_link\">",
"     mercaptopurine",
"    </a>",
"    . Treatment of gout in patients following renal transplantation is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/14/3303?source=see_link\">",
"     \"Hyperuricemia and gout in renal transplant recipients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A modest lowering of serum urate is a potentially beneficial side effect of treatment of hyperphosphatemic patients with phosphate binding agents (eg, calcium-containing antacids or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/44/40645?source=see_link\">",
"     sevelamer",
"    </a>",
"    ). This was illustrated in a study that randomly assigned 200 dialysis-dependent hyperphosphatemic patients to sevelamer or a calcium containing agent (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/32/42504?source=see_link\">",
"     calcium carbonate",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/48/39685?source=see_link\">",
"     calcium acetate",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36266/abstract/94\">",
"     94",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The mean decrease in serum urate concentration was greater with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/44/40645?source=see_link\">",
"       sevelamer",
"      </a>",
"      than with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/32/42504?source=see_link\">",
"       calcium carbonate",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/48/39685?source=see_link\">",
"       calcium acetate",
"      </a>",
"      (0.64 versus 0.26",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [38 versus 15",
"      <span class=\"nowrap\">",
"       micromol/L],",
"      </span>",
"      respectively).",
"     </li>",
"     <li>",
"      The urate-lowering effect was most evident in those whose baseline serum level was &ge;8",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (&ge;476",
"      <span class=\"nowrap\">",
"       micromol/L).",
"      </span>",
"      The mean reduction in serum urate was again greater with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/44/40645?source=see_link\">",
"       sevelamer",
"      </a>",
"      than with the calcium-containing agents (2.5 versus 1.0",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [149 versus 59",
"      <span class=\"nowrap\">",
"       micromol/L]).",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is uncertain if serum urate lowering with these drugs results in fewer episodes of gout or reduction in the size of tophi. Phosphate lowering therapy should not be used in patients with normal serum phosphate since hypophosphatemia may ensue.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/44/40645?source=see_link\">",
"     Sevelamer",
"    </a>",
"    has only received regulatory approval for use in patients with end-stage renal disease on maintenance hemodialysis; calcium supplementation should be closely monitored as it may lead to hypercalcemia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/57/33690?source=see_link\">",
"     \"Treatment of hyperphosphatemia in chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of surgery in the management of gout is generally limited to the complications of tophaceous disease, which include infection, compression due to the mass effect of a tophus, joint deformity, and intractable pain. Although pharmacologic antihyperuricemic therapy can slowly reduce the size of tophi, some patients desire surgical excision for cosmetic reasons. Similarly, deformities due to joint damage may require arthroplasty. Such surgery may be safely performed in the absence of skin attenuation, ulceration, or soft tissue infection.",
"   </p>",
"   <p>",
"    It is the author's opinion that, whenever possible, institution of urate-lowering therapy should precede surgery in order to increase the likelihood of prompt postoperative healing. Exceptions to this recommendation are nerve compression and active infection.",
"   </p>",
"   <p>",
"    Tophaceous deposits may compress peripheral nerves, the cauda equina, or the spinal cord [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36266/abstract/95-97\">",
"     95-97",
"    </a>",
"    ]. In these instances, prompt surgical decompression is essential to prevent permanent neurologic impairment.",
"   </p>",
"   <p>",
"    Tophi may erode through the skin producing chronic ulcers. With the loss of skin integrity, infection of the adjacent soft tissues, joint space, and bone is more likely. In one report of 45 patients with tophaceous gout who required surgery, the most frequent indications were infection (51 percent) and mechanical problems caused by foot, elbow, and hand tophi (27 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/26/36266/abstract/98\">",
"     98",
"    </a>",
"    ]. Delayed wound healing was seen in 24 patients, 16 of whom had infected or ulcerated tophi prior to surgery.",
"   </p>",
"   <p>",
"    Less often, surgical excision of a soft tissue mass leads to the initial diagnosis of tophaceous gout. In addition, permeative or erosive bone lesions have been mistaken for osteomyelitis and have led to excisions or amputations prior to establishing a diagnosis of gout. In some cases, it may be impossible to distinguish soft tissue or bone involvement due to gout from that due to infection using noninvasive studies; in this setting, needle aspiration or a surgeon's assistance in obtaining an excisional or needle biopsy may be invaluable. Biopsies should be examined for crystals fresh, frozen, or fixed in alcohol as formalin dissolves MSU crystals. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/34/4649?source=see_link\">",
"     \"Overview of osteomyelitis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/3/11314?source=see_link\">",
"       \"Patient information: Gout (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?23/57/24467?source=see_link\">",
"       \"Patient information: Gout (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute gout is an intensely painful inflammatory arthritis; the goal of treatment during an acute episode is prompt and safe termination of pain and disability. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/24/17800?source=see_link\">",
"     \"Treatment of acute gout\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Upon resolution of an acute gouty attack, the patient is said to have entered an intercritical (between attacks) period. Intervals between attacks of acute gouty arthritis are of variable duration. Most untreated patients with gout will experience a recurrent episode within two years.",
"   </p>",
"   <p>",
"    The suggested approach to the treatment during this interval or chronic stage is shown in the figure (",
"    <a class=\"graphic graphic_figure graphicRef78555 \" href=\"mobipreview.htm?32/13/32978\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest that patients with gout, particularly if they are overweight, be instructed in a diet that emphasizes caloric restriction, allowing an increased proportion of protein, replacement of refined with complex carbohydrates, and a decrease in saturated fat (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The increased dietary protein should come from low-fat dairy products, not red meat or fish (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Obesity and diet'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that patients with gout limit intake of beer and spirits (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Alcohol'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Both essential hypertension and diuretic use are independently associated with hyperuricemia and gout. However, given the benefits of thiazide diuretics in patients with hypertension and low cost, we suggest switching to another antihypertensive drug only if hypertension can be easily controlled by another agent and if cost is not a significant issue (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/35/26168?source=see_link\">",
"       Losartan",
"      </a>",
"      in particular has uricosuric effects and may be a good alternative agent, although, in patients who are also taking a uric acid lowering agent, the additional benefit of stopping diuretics or adding losartan is likely to be minimal. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Hypertension and diuretics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend antihyperuricemic therapy in patients with a history of gout who have frequent and disabling attacks of gouty arthritis, clinical or radiographic signs of chronic gouty joint disease, tophi, otherwise unexplained renal insufficiency, recurrent nephrolithiasis, or urinary uric acid excretion &gt;1100",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that, if a uricosuric agent is being considered, the choice of urate-lowering therapy be based on results of 24-hour urine uric acid testing (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Uricosuric drugs are suggested as possible initial therapy for patients under the age of 60 who excrete &lt;800 mg (4.76 mmol) of uric acid per day on a standard diet, as long as they do not have renal insufficiency, a history of urolithiasis, or tophi (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Patients with mild to moderate renal insufficiency may take the uricosuric drug benzbromarone, where available. Other factors that should be considered for individual patients when deciding on antihyperuricemic therapy include difficulties with adherence associated with taking a drug multiple times daily (uricosuric drugs) compared with once daily (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/40/25223?source=see_link\">",
"       allopurinol",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29668?source=see_link\">",
"       febuxostat",
"      </a>",
"      ). Repeated active encouragement by the clinician may improve adherence to the recommended regimen. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Choice of therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that antihyperuricemic therapy be titrated to a dose that results in a serum urate range &lt;6",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (&lt;357",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Lowering the serum uric acid slowly (no more than 1 to 2",
"      <span class=\"nowrap\">",
"       mg/dL/month)",
"      </span>",
"      is suggested (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). A goal &lt;5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (&lt;297",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      may speed resolution of tophi. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Goals'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend low-dose prophylactic",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/13/32983?source=see_link\">",
"       colchicine",
"      </a>",
"      (0.6 mg once or twice daily for patients with normal renal and hepatic function) during the initiation of antihyperuricemic therapy (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). A nonsteroidal antiinflammatory drug is an alternative, although to date unvalidated, approach to flare prophylaxis in patients who cannot tolerate colchicine (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      We suggest that",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/13/32983?source=see_link\">",
"       colchicine",
"      </a>",
"      be continued for six months after normal serum urate values have been obtained in patients without tophi (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The duration of prophylactic therapy is uncertain in patients with tophi. We suggest continuing colchicine until resolution of the tophi or it is clear that tophaceous deposits will not resolve despite persistent normouricemia (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Duration of therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest a reduced starting dose of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/40/25223?source=see_link\">",
"       allopurinol",
"      </a>",
"      and smaller increments when titrating allopurinol doses for patients with chronic kidney disease (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The suggested dose and titration schedule is summarized in the table (",
"      <a class=\"graphic graphic_table graphicRef81066 \" href=\"mobipreview.htm?0/2/34\">",
"       table 2",
"      </a>",
"      ). The target serum uric acid level is &lt;6",
"      <span class=\"nowrap\">",
"       mg/dL,",
"      </span>",
"      as in patients without kidney disease. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Prophylaxis in advanced chronic kidney disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest using",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29668?source=see_link\">",
"       febuxostat",
"      </a>",
"      as urate-lowering therapy for patients for whom uricosuric therapy is either contraindicated or ineffective when they are also intolerant of or allergic to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/40/25223?source=see_link\">",
"       allopurinol",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Febuxostat might also be appropriate initial pharmacologic urate-lowering therapy for patients with mild to moderate CKD if the cost is not prohibitive. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Febuxostat'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If available,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/38/41572?source=see_link\">",
"       pegloticase",
"      </a>",
"      is an option for patients whose gout is advanced, actively symptomatic, and uncontrolled by other urate-lowering therapies or for whom such therapies are contraindicated. An important criterion in support of the candidacy of such patients for pegloticase treatment is the need for rapid improvement in clinical outcomes, such as flare and tophus reduction, function, and quality of life, outcomes that take several years to achieve with oral agents and only months in some pegloticase-treated patients. (See",
"      <a class=\"local\" href=\"#H402899\">",
"       'Pegloticase'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Surgery for gout is appropriate for patients with complications of tophaceous disease, including infection, nerve compression, joint deformity, and intractable pain. Some patients also desire surgery for cosmetic reasons. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Surgery'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36266/abstract/1\">",
"      Singh JA, Strand V. Gout is associated with more comorbidities, poorer health-related quality of life and higher healthcare utilisation in US veterans. Ann Rheum Dis 2008; 67:1310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36266/abstract/2\">",
"      Sarawate CA, Patel PA, Schumacher HR, et al. Serum urate levels and gout flares: analysis from managed care data. J Clin Rheumatol 2006; 12:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36266/abstract/3\">",
"      Becker MA, Chohan S. We can make gout management more successful now. Curr Opin Rheumatol 2008; 20:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36266/abstract/4\">",
"      Emmerson B. Hyperlipidaemia in hyperuricaemia and gout. Ann Rheum Dis 1998; 57:509.",
"     </a>",
"    </li>",
"    <li>",
"     Becker MA, Jolly M. Clinical gout and the pathogenesis of hyperuricemia. In: Arthritis and Allied Conditions, 15th Edition, Koopman WJ, Moreland LW (Eds), Lippincott, Williams &amp; Wilkins, Philadelphia 2005. p.2303.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36266/abstract/6\">",
"      Snaith ML. Gout: diet and uric acid revisited. Lancet 2001; 358:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36266/abstract/7\">",
"      Dessein PH, Shipton EA, Stanwix AE, et al. Beneficial effects of weight loss associated with moderate calorie/carbohydrate restriction, and increased proportional intake of protein and unsaturated fat on serum urate and lipoprotein levels in gout: a pilot study. Ann Rheum Dis 2000; 59:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36266/abstract/8\">",
"      Choi HK, Atkinson K, Karlson EW, Curhan G. Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the health professionals follow-up study. Arch Intern Med 2005; 165:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36266/abstract/9\">",
"      Roubenoff R, Klag MJ, Mead LA, et al. Incidence and risk factors for gout in white men. JAMA 1991; 266:3004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36266/abstract/10\">",
"      Choi HK, Atkinson K, Karlson EW, et al. Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med 2004; 350:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36266/abstract/11\">",
"      Choi HK, Curhan G. Soft drinks, fructose consumption, and the risk of gout in men: prospective cohort study. BMJ 2008; 336:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36266/abstract/12\">",
"      Choi HK, Willett W, Curhan G. Fructose-rich beverages and risk of gout in women. JAMA 2010; 304:2270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36266/abstract/13\">",
"      Joosten LA, Netea MG, Mylona E, et al. Engagement of fatty acids with Toll-like receptor 2 drives interleukin-1&beta; production via the ASC/caspase 1 pathway in monosodium urate monohydrate crystal-induced gouty arthritis. Arthritis Rheum 2010; 62:3237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36266/abstract/14\">",
"      Sack J, Blau H, Goldfarb D, et al. Hyperuricosuria in cystic fibrosis patients treated with pancreatic enzyme supplements. A study of 16 patients in Israel. Isr J Med Sci 1980; 16:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36266/abstract/15\">",
"      Stapleton FB, Kennedy J, Nousia-Arvanitakis S, Linshaw MA. Hyperuricosuria due to high-dose pancreatic extract therapy in cystic fibrosis. N Engl J Med 1976; 295:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36266/abstract/16\">",
"      Choi HK, Atkinson K, Karlson EW, et al. Alcohol intake and risk of incident gout in men: a prospective study. Lancet 2004; 363:1277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36266/abstract/17\">",
"      Tykarski A. Evaluation of renal handling of uric acid in essential hypertension: hyperuricemia related to decreased urate secretion. Nephron 1991; 59:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36266/abstract/18\">",
"      W&uuml;rzner G, Gerster JC, Chiolero A, et al. Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout. J Hypertens 2001; 19:1855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36266/abstract/19\">",
"      Whelton A, Macdonald PA, Zhao L, et al. Renal function in gout: long-term treatment effects of febuxostat. J Clin Rheumatol 2011; 17:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36266/abstract/20\">",
"      Goicoechea M, de Vinuesa SG, Verdalles U, et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol 2010; 5:1388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36266/abstract/21\">",
"      Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006; 65:1312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36266/abstract/22\">",
"      Wallace SL, Singer JZ. Therapy in gout. Rheum Dis Clin North Am 1988; 14:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36266/abstract/23\">",
"      Shoji A, Yamanaka H, Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum 2004; 51:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36266/abstract/24\">",
"      Yamanaka H, Togashi R, Hakoda M, et al. Optimal range of serum urate concentrations to minimize risk of gouty attacks during anti-hyperuricemic treatment. Adv Exp Med Biol 1998; 431:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36266/abstract/25\">",
"      Terkeltaub RA. Clinical practice. Gout. N Engl J Med 2003; 349:1647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36266/abstract/26\">",
"      Chen LX, Schumacher HR. Gout: can we create an evidence-based systematic approach to diagnosis and management? Best Pract Res Clin Rheumatol 2006; 20:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36266/abstract/27\">",
"      Bull PW, Scott JT. Intermittent control of hyperuricemia in the treatment of gout. J Rheumatol 1989; 16:1246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36266/abstract/28\">",
"      Loebl WY, Scott JT. Withdrawal of allopurinol in patients with gout. Ann Rheum Dis 1974; 33:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36266/abstract/29\">",
"      Gast LF. Withdrawal of longterm antihyperuricemic therapy in tophaceous gout. Clin Rheumatol 1987; 6:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36266/abstract/30\">",
"      van Lieshout-Zuidema MF, Breedveld FC. Withdrawal of longterm antihyperuricemic therapy in tophaceous gout. J Rheumatol 1993; 20:1383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36266/abstract/31\">",
"      Perez-Ruiz F, Atxotegi J, Hernando I, et al. Using serum urate levels to determine the period free of gouty symptoms after withdrawal of long-term urate-lowering therapy: a prospective study. Arthritis Rheum 2006; 55:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36266/abstract/32\">",
"      Riedel AA, Nelson M, Joseph-Ridge N, et al. Compliance with allopurinol therapy among managed care enrollees with gout: a retrospective analysis of administrative claims. J Rheumatol 2004; 31:1575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36266/abstract/33\">",
"      Perez-Ruiz F, Gomez-Ullate P, Amenabar JJ, et al. Long-term efficacy of hyperuricaemia treatment in renal transplant patients. Nephrol Dial Transplant 2003; 18:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36266/abstract/34\">",
"      Yu TF, Roboz J, Johnson S, Kaung C. Studies on the metabolism of D-penicillamine and its interaction with probenecid in cystinuria and rheumatoid arthritis. J Rheumatol 1984; 11:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36266/abstract/35\">",
"      Fam AG. Difficult gout and new approaches for control of hyperuricemia in the allopurinol-allergic patient. Curr Rheumatol Rep 2001; 3:29.",
"     </a>",
"    </li>",
"    <li>",
"     Perez-Ruiz F, Inaki H, Herrero-Beites AM. Uricosuric therapy. In: Crystal-induced arthropathies. Gout, pseudogout and apatite-associated syndromes, Wortmann RL, Schumacher HR Jr, Becker MA, Ryan LM (Eds), Taylor &amp; Francis, New York 2006. p.369.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36266/abstract/37\">",
"      Enomoto A, Kimura H, Chairoungdua A, et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 2002; 417:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36266/abstract/38\">",
"      Anzai N, Ichida K, Jutabha P, et al. Plasma urate level is directly regulated by a voltage-driven urate efflux transporter URATv1 (SLC2A9) in humans. J Biol Chem 2008; 283:26834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36266/abstract/39\">",
"      Weinberger A, Schindel B, Liberman UA, et al. Calciuric effect of probenecid in gouty patients. Isr J Med Sci 1983; 19:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36266/abstract/40\">",
"      PASCALE LR, DUBIN A, BRONSKY D, HOFFMAN WS. Inhibition of the uricosuric action of benemid by salicylate. J Lab Clin Med 1955; 45:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36266/abstract/41\">",
"      Harris M, Bryant LR, Danaher P, Alloway J. Effect of low dose daily aspirin on serum urate levels and urinary excretion in patients receiving probenecid for gouty arthritis. J Rheumatol 2000; 27:2873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36266/abstract/42\">",
"      Feher MD, Hepburn AL, Hogarth MB, et al. Fenofibrate enhances urate reduction in men treated with allopurinol for hyperuricaemia and gout. Rheumatology (Oxford) 2003; 42:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36266/abstract/43\">",
"      Huang HY, Appel LJ, Choi MJ, et al. The effects of vitamin C supplementation on serum concentrations of uric acid: results of a randomized controlled trial. Arthritis Rheum 2005; 52:1843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36266/abstract/44\">",
"      Lockard O Jr, Harmon C, Nolph K, Irvin W. Allergic reaction to allopurinol with cross-reactivity to oxypurinol. Ann Intern Med 1976; 85:333.",
"     </a>",
"    </li>",
"    <li>",
"     Elion GB. Allopurinol and other inhibitors of urate synthesis. In: Uric acid. Handbook of Experimental Pharmacology, Kelley WN, Weiner IM (Eds), Springer-Verlag, New York 1978. p.485.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36266/abstract/46\">",
"      Rundles RW. The development of allopurinol. Arch Intern Med 1985; 145:1492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36266/abstract/47\">",
"      Beardmore TD, Kelley WN. Mechanism of allopurinol-mediated inhibition of pyrimidine biosynthesis. J Lab Clin Med 1971; 78:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36266/abstract/48\">",
"      Perez-Ruiz F, Alonso-Ruiz A, Calabozo M, et al. Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout. Ann Rheum Dis 1998; 57:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36266/abstract/49\">",
"      Becker MA, Schumacher HR Jr, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005; 353:2450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36266/abstract/50\">",
"      Hung SI, Chung WH, Liou LB, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A 2005; 102:4134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36266/abstract/51\">",
"      Tassaneeyakul W, Jantararoungtong T, Chen P, et al. Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population. Pharmacogenet Genomics 2009; 19:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36266/abstract/52\">",
"      Fam AG, Lewtas J, Stein J, Paton TW. Desensitization to allopurinol in patients with gout and cutaneous reactions. Am J Med 1992; 93:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36266/abstract/53\">",
"      Fam AG, Paton TW, Chaiton A. Reinstitution of allopurinol therapy for gouty arthritis after cutaneous reactions. Can Med Assoc J 1980; 123:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36266/abstract/54\">",
"      Webster E, Panush RS. Allopurinol hypersensitivity in a patient with severe, chronic, tophaceous gout. Arthritis Rheum 1985; 28:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36266/abstract/55\">",
"      Kelsey SM, Struthers GR, Beswick T, Blake DR. Desensitisation to allopurinol. Ann Rheum Dis 1987; 46:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36266/abstract/56\">",
"      Fam AG, Dunne SM, Iazzetta J, Paton TW. Efficacy and safety of desensitization to allopurinol following cutaneous reactions. Arthritis Rheum 2001; 44:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36266/abstract/57\">",
"      Unsworth J, Blake DR, d'Assis Fonseca AE, Beswick DT. Desensitisation to allopurinol: a cautionary tale. Ann Rheum Dis 1987; 46:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36266/abstract/58\">",
"      Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984; 76:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36266/abstract/59\">",
"      Singer JZ, Wallace SL. The allopurinol hypersensitivity syndrome. Unnecessary morbidity and mortality. Arthritis Rheum 1986; 29:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36266/abstract/60\">",
"      Ragab AH, Gilkerson E, Myers M. The effect of 6-mercaptopurine and allopurinol on granulopoiesis. Cancer Res 1974; 34:2246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36266/abstract/61\">",
"      Allopurinol and cytotoxic drugs. Interaction in relation to bone marrow depression. Boston Collaborative Drug Surveillance Program. JAMA 1974; 227:1036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36266/abstract/62\">",
"      Becker MA, Schumacher HR Jr, Wortmann RL, et al. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum 2005; 52:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36266/abstract/63\">",
"      Becker MA, Schumacher HR, Espinoza LR, et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther 2010; 12:R63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36266/abstract/64\">",
"      Schumacher HR Jr, Becker MA, Wortmann RL, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum 2008; 59:1540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36266/abstract/65\">",
"      Avena-Woods C, Hilas O. Febuxostat (Uloric), A New Treatment Option for Gout. Pharmacy &amp; Therapeutics 2010; 35:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36266/abstract/66\">",
"      Febuxostat (Uloric) for chronic treatment of gout. Med Lett Drugs Ther 2009; 51:37.",
"     </a>",
"    </li>",
"    <li>",
"     Uloric (febuxostat): Complete prescribing information www.uloric.com (Accessed on June 08, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36266/abstract/68\">",
"      Hisatome I, Kosaka H, Ohtahara K, et al. Renal handling of urate in a patient with familial juvenile gouty nephropathy. Intern Med 1996; 35:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36266/abstract/69\">",
"      Perez-Ruiz F, Calabozo M, Fernandez-Lopez MJ, et al. Treatment of chronic gout in patients with renal function impairment: an open, randomized, actively controlled study. J Clin Rheumatol 1999; 5:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36266/abstract/70\">",
"      Fam AG. Gout in the elderly. Clinical presentation and treatment. Drugs Aging 1998; 13:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36266/abstract/71\">",
"      YU TF, GUTMAN AB. Efficacy of colchicine prophylaxis in gout. Prevention of recurrent gouty arthritis over a mean period of five years in 208 gouty subjects. Ann Intern Med 1961; 55:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36266/abstract/72\">",
"      Y&uuml; T. The efficacy of colchicine prophylaxis in articular gout--a reappraisal after 20 years. Semin Arthritis Rheum 1982; 12:256.",
"     </a>",
"    </li>",
"    <li>",
"     Pegloticase (Krystexxa) IV infusion. Arthritis Advisory Committee Meeting. June 16, 2009. file://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ArthritisDrugsAdvisoryCommittee/UCM167777.pdf (Accessed on October 05, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36266/abstract/74\">",
"      Sundy JS, Baraf HS, Yood RA, et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA 2011; 306:711.",
"     </a>",
"    </li>",
"    <li>",
"     American College of Rheumatology Hotline: Pegloticase and concomitant urate-lowering therapies. file://www.rheumatology.org/publications/hotline/2012_01_18_pegloticase.asp (Accessed on January 23, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36266/abstract/76\">",
"      Richette P, Bri&egrave;re C, Hoenen-Clavert V, et al. Rasburicase for tophaceous gout not treatable with allopurinol: an exploratory study. J Rheumatol 2007; 34:2093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36266/abstract/77\">",
"      Rozenberg S, Roche B, Dorent R, et al. Urate-oxidase for the treatment of tophaceous gout in heart transplant recipients. A report of three cases. Rev Rhum Engl Ed 1995; 62:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36266/abstract/78\">",
"      Phillips M, Hunt RF, Shergy WJ, Hernandez J. Urate-oxidase in the treatment of severe tophaceous gout with hyperuricemia refractory to high-dose allopurinol: case report and review. Arthritis Rheum 2000; 43:S401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36266/abstract/79\">",
"      Vogt B. Urate oxidase (rasburicase) for treatment of severe tophaceous gout. Nephrol Dial Transplant 2005; 20:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36266/abstract/80\">",
"      Sundy JS, Becker MA, Baraf HS, et al. Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study. Arthritis Rheum 2008; 58:2882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36266/abstract/81\">",
"      Liu-Bryan R, Scott P, Sydlaske A, et al. Innate immunity conferred by Toll-like receptors 2 and 4 and myeloid differentiation factor 88 expression is pivotal to monosodium urate monohydrate crystal-induced inflammation. Arthritis Rheum 2005; 52:2936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36266/abstract/82\">",
"      Martinon F, P&eacute;trilli V, Mayor A, et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006; 440:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36266/abstract/83\">",
"      So A, De Smedt T, Revaz S, Tschopp J. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 2007; 9:R28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36266/abstract/84\">",
"      Terkeltaub R, Sundy JS, Schumacher HR, et al. The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study. Ann Rheum Dis 2009; 68:1613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36266/abstract/85\">",
"      Borstad GC, Bryant LR, Abel MP, et al. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol 2004; 31:2429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36266/abstract/86\">",
"      Justiniano M, Dold S, Espinoza LR. Rapid onset of muscle weakness (rhabdomyolysis) associated with the combined use of simvastatin and colchicine. J Clin Rheumatol 2007; 13:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36266/abstract/87\">",
"      Simkin PA, Gardner GC. Colchicine use in cyclosporine treated transplant recipients: how little is too much? J Rheumatol 2000; 27:1334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36266/abstract/88\">",
"      Colchicine and other drugs for gout. Med Lett Drugs Ther 2009; 51:93.",
"     </a>",
"    </li>",
"    <li>",
"     URL Pharma launches Colcrys patient assistance program www.colcrys.com/assets/pdf/Colcrys PAP Release 122309.pdf (Accessed on February 08, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36266/abstract/90\">",
"      Ferraz MB. An evidence based appraisal of the management of nontophaceous interval gout. J Rheumatol 1995; 22:1618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36266/abstract/91\">",
"      Dalbeth N, Kumar S, Stamp L, Gow P. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. J Rheumatol 2006; 33:1646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36266/abstract/92\">",
"      Stamp LK, O'Donnell JL, Zhang M, et al. Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. Arthritis Rheum 2011; 63:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36266/abstract/93\">",
"      Hung IF, Wu AK, Cheng VC, et al. Fatal interaction between clarithromycin and colchicine in patients with renal insufficiency: a retrospective study. Clin Infect Dis 2005; 41:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36266/abstract/94\">",
"      Garg JP, Chasan-Taber S, Blair A, et al. Effects of sevelamer and calcium-based phosphate binders on uric acid concentrations in patients undergoing hemodialysis: a randomized clinical trial. Arthritis Rheum 2005; 52:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36266/abstract/95\">",
"      Nakamichi K, Tachibana S. Cubital tunnel syndrome caused by tophaceous gout. J Hand Surg Br 1996; 21:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36266/abstract/96\">",
"      Vervaeck M, De Keyser J, Pauwels P, et al. Sudden hypotonic paraparesis caused by tophaceous gout of the lumbar spine. Clin Neurol Neurosurg 1991; 93:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36266/abstract/97\">",
"      Murshid WR, Moss TH, Ettles DF, Cummins BH. Tophaceous gout of the spine causing spinal cord compression. Br J Neurosurg 1994; 8:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/26/36266/abstract/98\">",
"      Kumar S, Gow P. A survey of indications, results and complications of surgery for tophaceous gout. N Z Med J 2002; 115:U109.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1672 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.195.65.244-820E8C5BBF-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_26_36266=[""].join("\n");
var outline_f35_26_36266=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H31\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RISK REDUCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Obesity and diet",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Alcohol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Hypertension and diuretics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PHARMACOLOGIC URATE-LOWERING THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Goals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Initiation and duration of therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Nonadherence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Uricosuric drugs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Indications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Agents and dosing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Side effects and interactions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Other drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Xanthine oxidase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Indications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Allopurinol",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Febuxostat",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Combination therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Choice of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Colchicine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Uricase",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H402899\">",
"      - Pegloticase",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H402906\">",
"      - Rasburicase",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      PROPHYLAXIS DURING INITIATION OF ANTIHYPERURICEMIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Colchicine prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      NSAID prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Duration of therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      PROPHYLAXIS IN ADVANCED CHRONIC KIDNEY DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SURGERY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/1672\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/1672|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?32/13/32978\" title=\"algorithm 1\">",
"      Treatment of interval gout",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?37/49/38685\" title=\"figure 1\">",
"      Thiazide side effects and dose",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/1672|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?43/14/44267\" title=\"table 1\">",
"      Secondary uricemia excretion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?0/2/34\" title=\"table 2\">",
"      Allopurinol dosing in CRF",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?24/40/25223?source=related_link\">",
"      Allopurinol: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/24/1416?source=related_link\">",
"      Asymptomatic hyperuricemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/29/36314?source=related_link\">",
"      Choice of therapy in primary (essential) hypertension: Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/49/4890?source=related_link\">",
"      Clinical manifestations and diagnosis of gout",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/62/25577?source=related_link\">",
"      Cystine stones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/9/8345?source=related_link\">",
"      Dietary therapy for obesity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/26/29094?source=related_link\">",
"      Diuretic-induced hyperuricemia and gout",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/44/6856?source=related_link\">",
"      Drug-induced myopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/14/3303?source=related_link\">",
"      Hyperuricemia and gout in renal transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/39/7800?source=related_link\">",
"      Lipid lowering with fibric acid derivatives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/31/38393?source=related_link\">",
"      NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/49/17177?source=related_link\">",
"      Nonselective NSAIDs: Overview of adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/34/4649?source=related_link\">",
"      Overview of osteomyelitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/43/28344?source=related_link\">",
"      Pathophysiology of gouty arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?23/57/24467?source=related_link\">",
"      Patient information: Gout (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/3/11314?source=related_link\">",
"      Patient information: Gout (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/61/32726?source=related_link\">",
"      Patient information: Reducing the costs of medicines (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/24/17800?source=related_link\">",
"      Treatment of acute gout",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/57/33690?source=related_link\">",
"      Treatment of hyperphosphatemia in chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/20/3402?source=related_link\">",
"      Tumor lysis syndrome: Prevention and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/42/24230?source=related_link\">",
"      Uric acid balance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/62/3047?source=related_link\">",
"      Uric acid nephrolithiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/57/27541?source=related_link\">",
"      Uric acid renal diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/63/15350?source=related_link\">",
"      Use of thiazide diuretics in patients with primary hypertension",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_26_36267="Diagnosis diabetic diarrhea";
var content_f35_26_36267=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F69401&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F69401&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Sequential evaluation of chronic diarrhea in patients with diabetes mellitus",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        First line",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        History and physical examination",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Blood chemistry",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stool analysis - weight, fat, chymotrypsin, elastase, leukocytes, parasites",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Barium studies - looking for gastric retention, malabsorption pattern, small intestinal and colonic wall thickness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Second line",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Upper GI endoscopy with duodenal biopsy - histology, bacteriology",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Colonoscopy with biopsy - histology",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        [13]C-acetate or -octanoic acid breath test",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Glucose hydrogen breath test - consider bacterial overgrowth",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anorectal manometry and sensory testing if fecal incontinence is present",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Third line",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ambulatory small intestinal manometry - to rule out intestinal pseudo-obstruction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        [75]Se-HCAT test or empiric cholestyramine - to rule out bile acid malabsorption",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Push-enteroscopy with biopsy and enteroclysis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Secretin-pancreazyme test - to exclude exocrine pancreatic insufficiency",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_26_36267=[""].join("\n");
var outline_f35_26_36267=null;
var title_f35_26_36268="Dietary composition children";
var content_f35_26_36268=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F68420&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F68420&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommended daily amount from each food group, by calorie level",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup width=\"15%\">",
"     </colgroup>",
"     <colgroup span=\"7\" width=\"12%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Food group",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"7\">",
"        Calorie level",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        1200",
"       </td>",
"       <td class=\"subtitle2\">",
"        1400",
"       </td>",
"       <td class=\"subtitle2\">",
"        1600",
"       </td>",
"       <td class=\"subtitle2\">",
"        1800",
"       </td>",
"       <td class=\"subtitle2\">",
"        2000",
"       </td>",
"       <td class=\"subtitle2\">",
"        2200",
"       </td>",
"       <td class=\"subtitle2\">",
"        3000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Grains*",
"       </td>",
"       <td>",
"        4 ounces",
"       </td>",
"       <td>",
"        5 ounces",
"       </td>",
"       <td>",
"        5 ounces",
"       </td>",
"       <td>",
"        6 ounces",
"       </td>",
"       <td>",
"        6 ounces",
"       </td>",
"       <td>",
"        7 ounces",
"       </td>",
"       <td>",
"        10 ounces",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vegetables",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        1.5 cups",
"       </td>",
"       <td>",
"        1.5 cups",
"       </td>",
"       <td>",
"        2 cups",
"       </td>",
"       <td>",
"        2.5 cups",
"       </td>",
"       <td>",
"        2.5 cups",
"       </td>",
"       <td>",
"        3 cups",
"       </td>",
"       <td>",
"        4 cups",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fruits",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        1 cup",
"       </td>",
"       <td>",
"        1.5 cups",
"       </td>",
"       <td>",
"        1.5 cups",
"       </td>",
"       <td>",
"        1.5 cups",
"       </td>",
"       <td>",
"        2 cups",
"       </td>",
"       <td>",
"        2 cups",
"       </td>",
"       <td>",
"        2.5 cups",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dairy",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        2.5 cups",
"       </td>",
"       <td>",
"        2.5 cups",
"       </td>",
"       <td>",
"        3 cups",
"       </td>",
"       <td>",
"        3 cups",
"       </td>",
"       <td>",
"        3 cups",
"       </td>",
"       <td>",
"        3 cups",
"       </td>",
"       <td>",
"        3 cups",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Protein foods",
"       </td>",
"       <td>",
"        3 ounces",
"       </td>",
"       <td>",
"        4 ounces",
"       </td>",
"       <td>",
"        5 ounces",
"       </td>",
"       <td>",
"        5 ounces",
"       </td>",
"       <td>",
"        5.5 ounces",
"       </td>",
"       <td>",
"        6 ounces",
"       </td>",
"       <td>",
"        7 ounces",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * In general, 1 slice of bread, 1 cup of ready-to-eat cereal, or &frac12; cup of cooked rice, cooked pasta, or cooked cereal can be considered as 1 ounce equivalent from the Grains Group. At least half of these servings should be whole grains.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     1 cup vegetables is approximately equal to 12 baby carrots, or one large tomato. Because of high water content, a serving of lettuce must be twice as large (1 cup of lettuce = 1/2 cup of other vegetables).",
"     <br/>",
"     &Delta; 1 cup of fruit is approximately equal to one apple or banana, 2 plums, 1/8th melon, or eight strawberries.",
"     <br/>",
"     <span class=\"lozenge\">",
"      &loz;",
"     </span>",
"     Milk should be fat-free or low-fat after two years of age.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: the United States Department of Agriculture \"Choose My Plate\" website, available at:",
"     <a href=\"file://www.choosemyplate.gov\" target=\"_blank\">",
"      www.choosemyplate.gov",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_26_36268=[""].join("\n");
var outline_f35_26_36268=null;
var title_f35_26_36269="Sodium glucose cotransport";
var content_f35_26_36269=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F70371&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F70371&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 475px\">",
"   <div class=\"ttl\">",
"    Sodium-glucose cotransport",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 455px; height: 272px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Time course of D-glucose uptake in proximal brush border membrane vesicles. Vesicles were initially incubated so that the glucose, sodium, and potassium concentrations were the same as the medium (eg, sodium concentration outside and inside the vesicle were the same, [Na]o/i = 1]). In this setting, there was little glucose uptake (dashed line). In comparison, bathing the vesicles in a medium in which the sodium concentration was 10 times higher than the vesicles (solid line) led to a marked stimulation of glucose uptake despite the absence of any transvesicle glucose gradient. Although not shown, creation of a favorable glucose gradient is able to stimulate the uptake of sodium. These findings indicate the presence of a sodium-glucose cotransporter.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Beck, JC, Sacktor, B, J Biol Chem 1978; 253:5531.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_26_36269=[""].join("\n");
var outline_f35_26_36269=null;
var title_f35_26_36270="Treatment algorithm for defecating disorders";
var content_f35_26_36270=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F88134&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F88134&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Treatment algorithm for defecating disorders",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 444px; height: 510px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     MR: magnetic resonance; p.r.n.: as needed.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Bharucha AE, Dorn SD, Lembo A, Pressman A. American Gastroenterological Association Medical Position Statement on Constipation. Gastroenterology 2013; 144:211. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_26_36270=[""].join("\n");
var outline_f35_26_36270=null;
var title_f35_26_36271="Gelhorn pessaries";
var content_f35_26_36271=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F81272&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F81272&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gelhorn vaginal pessaries",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 214px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The short stem Gelhorn pessary can be useful for women with a short vagina.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Leah Moynihan, RNC, MSN.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_26_36271=[""].join("\n");
var outline_f35_26_36271=null;
